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Abstract 
Glioblastoma is the most common and most biologically aggressive primary brain 
tumour in adults. In spite of tremendous investment into research which has led to 
the development and application of novel diagnostic and therapeutic measures in the 
management of glioblastoma, the prognosis is still dismal with median survival time 
of about 12 – 15 months. Also, the success of most cytotoxic drugs clinically 
employed in the treatment of glioblastoma is greatly limited by their dose-limiting 
toxicity which typically manifests as clinically significant reduction in blood cell 
counts. The aim of this study is to demonstrate that a high dose nanoparticle 
formulation of the cytotoxic drug lomustine using a self-assembling chitosan 
amphiphile, quaternary ammonium palmitoyl glycol chitosan would lead to 
improved survival outcomes without a commensurate increase in toxic effects. 
The novel nanoparticle based lomustine formulation employed in this study enabled 
the administration of a lomustine dose (13 mg kg
-1
) 10 times higher than the dose 
(1.2 mg kg
-1
) achievable with an ethanolic formulation of lomustine. Human 
glioblastoma tumour bearing mice treated with the high dose formulation had a mean 
survival time of 33.1 days while the mice treated with the low dose formulation had a 
mean survival time of 22.5 days after intravenous administration of the drug once 
daily for 10 consecutive days. The increased (1.5 times longer) survival time 
resulting from treatment with the nanoparticle based high dose formulation was not 
accompanied by an increase in gross toxic effects. Thus, the nanoparticle based 
formulation afforded the administration of lomustine in a continuous high dose 
schedule which led to beneficial therapeutic outcomes.  
In addition, three self-assembling peptide amphiphiles were synthesised and 
characterised for potential application in the transport and delivery of therapeutic 
molecules to the brain for the treatment of intracranial tumours.  
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Nanoparticle based strategies for the treatment of Glioblastoma 
Chapter 1 Introduction   
1.1 Glioblastoma 
Glioblastoma, previously named glioblastoma multiforme is a highly malignant glial 
tumour of astrocytic origin, occurring most commonly in the cerebral hemispheres, 
although glioblastoma may involve any neuroanatomical structure. Glioblastoma is a 
Grade IV astrocytoma (DeAngelis 2001; Furnari et al. 2007; Khasraw and Lassman 
2010; Allard et al. 2009; Kesari 2011; Lima et al. 2012) and is still classified as such 
in the current World Health Organisation (WHO) classification of tumours of the 
central nervous system (CNS) (Louis et al. 2007). 
Glioblastoma is the most frequently occurring (constituting at least 50 % of 
malignant gliomas) primary brain tumour in adults, and is the most biologically 
aggressive malignancy of the CNS (Furnari et al. 2007; Stark et al. 2005; Louis et al. 
2007 Olar and Adalpe 2014). Glioblastoma is a leading cause of morbidity and 
mortality (Fine 1994; Yust-Katz et al. 2013) and together with other astrocytomas 
accounts for most of the deaths due to primary tumours (Fine 1994). At least 3 new 
cases of the disease are diagnosed per 100,000 people per year (Laperriere et al. 
2002; Ohgaki and Kleihues 2005; Dolecek et al. 2012).   
The current Central Brain Tumour Registry of the United States (CBTRUS) 
statistical reports of primary brain and CNS tumours diagnosed in the United States 
in the period 2005 – 2009 revealed that glioblastoma is uncommon in children but 
more common in older adults with peak incidence in the 75 – 84 years age range. 
The results showed that incidence was higher in white males compared to other races 
like African Americans, American Indian / Alaskan Natives and Asian Pacific 
Islanders (Dolecek et al. 2012).  
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The results also showed that to some extent, five year survival rates were better in 
children of less than 20 years of age (12 %) compared to those in adults (5 %). In 
most glioblastoma cases, tumours occur without pre-existing genetic predisposition 
and there is no clear-cut association of tumour occurrence with identifiable 
underlying causes or risk factors (Krex et al. 2007; Wen and Kesari 2008). 
            Characteristics of Glioblastoma 1.1.1
Glioblastoma, like most other neoplasia is characterised by unrestrained cell 
proliferation, vigorous angiogenesis, a tendency for necrosis, profound resistance to 
apoptosis, a high degree of genomic instability and diffuse invasion of surrounding 
healthy tissue (Furnari et al. 2007; Bokstein et al. 2008; Allard et al. 2009; Agarwal 
et al. 2011a; Florio and Barbieri 2012; Agarwal et al. 2013; Juratli et al. 2013; Olar 
and Aldape 2014) [Figure 1-1]. 
Also, in glioblastoma there is significant tumour heterogeneity such that 
cytogenetically similar and dissimilar clones could occur in different portions of the 
same glioblastoma tumour sample. This poses a challenge in understanding and 
treatment of the disease (Burger and Green 1987; Harada et al. 1998; Walker et al. 
2003; Zhou et al. 2003; Furnari et al. 2007; Huse et al. 2011; Kesari 2011; Florio and 
Barbieri 2012; Jafri et al. 2013; Olar and Aldape 2014). The term multiforme used in 
the previous nomenclature of the disease is a reflection of the heterogenous nature of 
the tumours (Furnari et al. 2007; Agarwal et al. 2011a). 
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Figure 1-1: Schematic depicting glioblastoma a diffusely infiltrating disease 
 
 
 
 
 
 
 
 
26 
 
Nanoparticle based strategies for the treatment of Glioblastoma 
1.2 Diagnosis of Glioblastoma 
Glioblastoma diagnosis is made only at clinical presentation as there is currently no 
other means of detecting or screening for the disease (Kesari 2011). Tomographic 
techniques are used for diagnosis because they provide high spatial resolution and 
techniques such as computed tomography (CT) can be used in initial diagnosis 
(Jarzabek et al. 2013). However, magnetic resonance imaging (MRI), which is the 
only test required for a brain tumour diagnosis (DeAngelis 2001), remains the gold 
standard for establishing diagnosis (DeAngelis 2001; Jenkinson et al. 2007; Kesari 
2011). High resolution brain images generated by conventional MRI yield 
information to determine tumour size, location, and the presence and extent of 
necrosis and associated oedema. However, such images provide limited information 
on the physiological characteristics of the tumour (Jenkinson et al. 2007).  
Recent advances in MRI have led to the development of newer MR techniques such 
as diffusion-weighted MRI (DW-MRI), perfusion-weighted MRI (PMR), functional 
MRI (fMRI), and proton magnetic resonance (proton MR) spectroscopy, which can 
be used for monitoring tumour vasculature, study tumour drug response and also 
distinguish high-grade gliomas from brain metastasis, thus providing more pertinent 
information (Law et al. 2002; Young 2007; Jenkinson et al. 2007; Server et al. 2010). 
Conventional MRI and clinical history can be used to differentiate between brain 
metastasis and high-grade gliomas in many cases (Law et al. 2002; Cha 2004). 
However, in some other cases especially those in which the lesion is solitary and the 
clinical data are non-contributory, conventional MRI has limited capacity to 
differentiate brain metastasis and high-grade gliomas as their neuroimaging 
appearance is frequently similar and may be ambiguous or indistinguishable (Law et 
al. 2002; Cha 2004; Server et al. 2010).  
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Proton MR spectroscopy (spectroscopic MR imaging) which permits simultaneous 
spectra acquisition from the enhancing portion, the peritumoural region, and normal 
contralateral brain tissue, and perfusion-weighted MRI (PMR) measurements in the 
peritumoural region have been shown to be useful in revealing the differences in 
solitary brain metastasis and high-grade gliomas (Law et al. 2002; Cha et al. 2007; 
Server et al. 2010). These two different types of intracranial lesions can be 
differentiated based on the metabolic and physiologic information obtained from the 
advanced MRI techniques which complement the anatomic images furnished by 
conventional MRI (Law et al. 2002). Moreover, tumour types have been shown to 
exhibit distinctive metabolic patterns (Meyerand et al. 1999) characteristic of each 
tumour type with histologically similar tumours exhibiting similar spectra patterns 
while histologically dissimilar tumours exhibit different spectral patterns (Bruhn et 
al. 1989).  
The metabolites usually monitored by MR spectroscopy for distinguishing brain 
lesions include: choline, creatinine and N-acetyl-aspartate. Increased choline levels 
are associated with processes where there is increased cell proliferation or growth 
stimulation such as in tumours (Go et al. 1995; Herminghaus et al. 2002). The 
choline signal also yields information about the malignancy of tumours which is 
useful in the grading of gliomas (Möller-Hartmann et al. 2002). Creatinine is taken to 
be indicative of energy metabolism and is frequently employed as the internal 
standard (denominator) for semi-quantitative assessment of other brain metabolites 
since creatinine is assumed to be constant in a variety of metabolic conditions 
(Möller-Hartmann et al. 2002; Hattingen et al. 2008). N-acetyl-aspartate is 
commonly identified as a neuronal marker and the level is greatly reduced anytime 
brain tissue is damaged or replaced by any destructive, degenerative or infiltrative 
process (Möller-Hartmann et al. 2002).  
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In addition, lactate and lipid levels are also assessed in MR spectroscopy of brain 
lesions (Server et al. 2010). Some studies have employed MR spectroscopy in 
differentiation of brain lesions by comparing the ratios of the different metabolites 
(usually with creatinine as denominator) obtained for the different lesions evaluated. 
The spectra information obtained for the ratios of the different metabolites has 
permitted the differentiation of different brain lesions including the differentiation of 
brain metastasis of systemic tumours from high-grade gliomas (Law et al. 2002; 
Möller-Hartmann et al. 2002; Server et al. 2010).  
 
Furthermore, PMR may provide a means of differentiating solitary brain metastasis 
from primary gliomas on the basis of the differences in peritumoural relative cerebral 
blood volume (rCBV) (Law et al. 2002), as well as the peak height of the non-
enhancing T2 region and the percentage of signal intensity recovery of the contrast-
enhancing region derived from dynamic susceptibility-weighted contrast-enhanced 
(DSC) PMR (Cha et al. 2007). These studies demonstrated markedly increased rCBV 
and the peak height of the non-enhancing T2 region as well as the percentage of 
signal intensity recovery of the contrast-enhancing region in glioblastoma (a high-
grade glioma) compared to solitary brain metastasis (Law et al. 2002; Cha et al. 
2007). Pathologic examination of peritumoural abnormality shows that there is a 
tumour induced increase in interstitial water due to alterations in capillary 
permeability and blood-brain barrier breakdown. In high-grade gliomas, the 
peritumoural areas manifest altered capillary morphologic findings and interstitial 
water as well as scattered tumour cells infiltrating along newly formed or pre-
existing but dilated vascular channels. The enhancing portion of the tumour shows 
breakdown of the blood brain barrier, whereas the neural vasculature remains 
relatively impervious in the peritumoural region and the T2 hyper-intensity in the 
peritumoural region is partly the result of tumour infiltration.  
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Contrariwise, in solitary brain metastasis, the capillary endothelium of the metastatic 
tumour demonstrates increased permeability (Long 1979; Bertossi et al. 1997; Law et 
al. 2002). Moreover, the capillaries of solitary brain metastases typically resemble 
capillaries from the tissue of origin and do not possess the characteristics of brain 
capillaries (Long 1979). Thus, the increased rCBV, peak height of the non-enhancing 
T2 region and the percentage of signal intensity recovery of the contrast-enhancing 
region in glioblastoma compared to solitary brain metastasis shows that for 
metastatic tumors the peritumoural oedema observed represents pure vasogenic 
oedema resulting from increased interstitial water due to leaky capillaries, that is 
there is no histologic evidence of tumour beyond the outer contrast-enhancing 
margin of the tumour. In high-grade glioma, on the other hand, the peritumoural 
region depicts a variable combination of vasogenic oedema and infiltrating tumour 
cells (Long 1979; Bertossi et al. 1997; Law et al. 2002; Cha et al. 2007). Taken 
together, the spectra information obtained made it possible to differentiate brain 
metastasis from high-grade glioma (Law et al. 2002; Cha et al. 2007). 
1.3 Prognosis for Glioblastoma 
Glioblastoma continues to have a poor prognosis in spite of recent advances in 
diagnosis and therapeutic management of the disease. The mean survival time is 
about 12 – 15 months, 5 year survival rate is less than 5% and 75 % of patients die 
within 18 months of diagnosis (Stark et al. 2005; Mineo et al. 2007; Wen and Kesari 
2008; Brandes et al. 2008; Mangiola et al. 2010; Chamberlain 2010; Dolecek 2012; 
Jafri et al. 2013) or within shorter periods as demonstrated in population based 
studies (Ohgaki et al. 2004). Although a small number of patients, called long-term 
survivors, survive for more than 3 years (Simpson et al. 1993; Krex et al. 2007; 
Bokstein et al. 2008; Dolecek 2012), the disease is consistently fatal (Rainov et al. 
1997; Verhaak et al. 2010; Olar and Aldape 2014). 
 
 
30 
 
Nanoparticle based strategies for the treatment of Glioblastoma 
Some variables have been considered in determining prognosis in glioblastoma. 
These include treatment independent variables such as patient age, Karnofsky 
performance scale (KPS) score, tumour histology at diagnosis and treatment related 
variables such as the extent of surgery (Curran et al. 1993; Wong et al. 1999) [Figure 
1-2; Table 1-1]. 
 
 
Figure 1-2: Schematic representation of survival with glioblastoma 
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Group Prognostic factors 
A Long-term survivors: clinical and molecular 
factors largely unknown (Krex et al. 2007); 
favourable clinical factors such as younger 
patient age, high KPS. 
B Younger patient age at diagnosis, high KPS, 
absence of necrosis, maximal surgical 
resection (≥ 98 %), combined post-surgical 
radiotherapy plus concomitant chemotherapy, 
followed by adjuvant chemotherapy  
C Surgery plus post-surgical radiotherapy with 
adjuvant chemotherapy 
D Surgery plus post-surgical radiotherapy 
E Surgery alone 
F Older age at diagnosis, low KPS, no surgery, 
best supportive care 
 
Table 1-1: Genenral survival trends in glioblastoma patients 
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Younger patient age at diagnosis, better KPS score at diagnosis (Burger and Green 
1987; Franklin 1992; Lacroix et al. 2001; Filippini et al. 2008) as well as maximal 
surgical resection with minimal residual disease (Wood et al. 1988; Simpson et al. 
1993; Wong et al. 1999; Lacroix et al. 2001) are favourable prognostic variables that 
lead to better survival outcomes. 
 Tumour histology also impacts significantly on survival as the presence of necrosis 
negatively impacts on survival as it is associated with unfavourable outcomes 
(Burger and Green 1987; Hammoud et al. 1996; Lacroix et al. 2001) as well as 
increased enhancement on preoperative MRI (Hammoud et al. 1996; Lacroix et al. 
2001). More recently, information obtained from more advanced MR imaging 
techniques such as diffusion weighted (DW) MRI (DW-MRI) about the apparent 
diffusion coefficient (ADC) is also predictive of survival. Areas with minimum 
ADCs within heterogeneous tumours (such as glioblastoma) correspond to areas of 
highest cellularity and aggressiveness. Therefore patients with tumours showing low 
minimum ADC on pre-treatment DWMRI would likely have a poor outcome with 
post-surgical radio-chemotherapy (Yamasaki et al. 2010; Nakamura et al. 2013). 
Furthermore, the use of post-surgical radio and chemotherapy has been shown to 
significantly impact survival, with patients treated with regimens containing a 
combination of post-surgical radiotherapy with chemotherapy showing significantly 
pronounced survival times (Stupp et al. 2005; Filippini et al. 2008). 
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1.4 Subtypes of Glioblastoma  
Glioblastoma may be subdivided into two subtypes; namely primary and secondary 
glioblastomas, a concept first advanced by Hans-Joachim Scherer, a German 
neuropathologist (Scherer 1940). Primary and secondary glioblastomas are 
morphologically and clinically alike, and they have equally poor prognosis when 
adjustment is made for patient age (Newcomb et al. 1998; Furnari et al. 2007). 
Nevertheless, these two glioblastoma subtypes possess different clinical histories and 
show distinct patterns of gene expression or aberrations.  
Primary glioblastoma is the most frequently occurring subtype comprising about 90 
% of all cases. It develops acutely de novo, with a short clinical history without 
evidence of pre-existing lower grade precursor lesions and is more common in older 
adults (older than 50 years). Secondary glioblastoma on the other hand is less 
common and occurs in younger patients (younger than 45 years). It develops more 
slowly as a result of progression from a lower grade diffuse astrocytoma (WHO 
grade II) or anaplastic astrocytoma (WHO grade III) to glioblastoma (WHO grade 
IV) (Furnari et al. 2007; Ohgaki and Kleihues 2007). Usually, the time to progression 
from anaplastic astrocytoma to glioblastoma is shorter (about 2 years) than time to 
progression from low grade diffuse astrocytoma (about 5 years) to glioblastoma 
(Ohgaki and Kleihues 2005). However, this is not always the case as there have been 
cases of very rapid progression from anaplastic astrocytoma to glioblastoma in less 
than 1 year (Olar et al. 2012). 
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 Primary and secondary Glioblastomas 1.4.1
Primary glioblastoma is usually characterised by epidermal growth factor receptor 
(EGFR) amplification/overexpression, cyclin-dependent kinase inhibitor 2A 
(CDKN2A / p16) deletion, phosphatase and tensin homolog (PTEN) gene mutations 
and occasionally murine double minute 2 (MDM2) amplification (Reifenberger et al. 
1993; Watanabe et al. 1996; Tohma et al. 1998; Ohgaki et al. 2004) Secondary 
glioblastoma on the other hand is characterised by cellular tumour antigen p53  
(TP53) gene mutations or accumulation (with LOH at chromosome 17p) which are 
known to occur in grade II and grade III astrocytomas and in the majority of cases 
already existed in the initial biopsies of patient tumours (James et al. 1989; von 
Deimling et al. 1992; von Deimling et al. 1993; Kleihues and Ohgaki 2000; Ohgaki 
et al. 2004). These genetic alterations distinguishing primary and secondary 
glioblastomas were found to be exclusive events in the evolution of these 
glioblastomas. This has been shown to be the case particularly when tumours for 
genetic analysis have been carefully selected from patients with confirmed diagnosis 
for either primary or secondary glioblastoma. That is, patients for primary 
glioblastoma had a short clinical history (less than 3 months) and presented with 
tumours that had histopathologic characteristics of glioblastoma at the first biopsy. 
Patients for secondary glioblastoma on the other hand were selected based on at least 
two previous biopsies taken at different time periods (6 months interval) for which 
clinical and histopathologic features had confirmed progression from a low grade 
glioma or anaplastic astrocytoma (Watanabe et al. 1996; Tohma et al. 1998; Kleihues 
and Ohgaki 2000).  
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In addition, a further subgroup of glioblastoma was identified which contain foci 
similar to oligodendroglioma and have been classified in the recent WHO 
classification of tumours of the CNS as glioblastoma with an oligodendroglial 
component (Louis et al. 2007). Some studies have reported that glioblastoma with 
oligodendroglial component (at least focally) make up a proportion (in the range of 
20 %) of glioblastoma tumours analysed (He et al. 2001; Homma et al. 2006; Laxton 
et al. 2013). This subgroup of glioblastoma has been reported to be associated with 
increased survival which was attributed to younger patient age (Homma et al. 2006; 
Wang et al. 2012; Laxton et al. 2013). However, Homma and co-workers reported 
that in their study, the predictive value for longer survival associated with the 
oligodendroglial component in glioblastoma was lost when they made adjustment for 
age and gender in their multivariate analyses (Homma et al. 2006). On the whole, for 
glioblastoma with oligodendroglial component, the terminology, diagnostic criteria 
and outcome are still ambiguous, also their identity as a specific subgroup of 
glioblastoma has yet to be determined (Laxton et al. 2013). 
Albeit none of the identified genetic alterations have not been able to provide a clear-
cut distinction between primary and secondary glioblastomas. Moreover, there are 
some tumours that had genetic alterations that did not quite fit in to either primary or 
secondary subtypes, thus suggesting the existence of other subtypes of the disease 
(Tohma et al. 1998; Kleihues and Ohgaki 2000; Parsons et al. 2008; Ohgaki and 
Kleihues 2013).  
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 Molecular classification of Glioblastomas 1.4.2
More recently, further subtypes of glioblastoma have been identified through 
molecular classification. In one study, three subtypes were identified as follows: 
Proneural subtype characterised by expression of genes associated with neurogenesis 
and the normal brain; Mesenchymal subtype which show activation of gene 
expression pathways characteristic of angiogenesis; and the Proliferative subtype 
with gene expressions indicating cell proliferation (Phillips et al. 2006). In a more 
recent study, four different subtypes of the disease were defined based on the most 
pronounced gene expression alteration and associated mutations determined by 
genomic profiling of glioblastoma (Table 1-2). 
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Subtype Characteristics 
Classical EGFR amplification/overexpression and CDNK2A loss. 
Proneural Focal amplification along with high levels of platelet-derived growth 
factor receptor-A (PDGFRA) gene expression, high expression of 
oligodendrocyte lineage transcription factor (OLIG2), isocitrate 
dehydrogenase 1 (IDH1) mutation and TP53 mutations and loss of 
heterozygosity. 
Neural Expression of neuron markers such as neurofilament light 
polypeptide (NEFL). 
Mesenchymal NF1 loss, PTEN mutation and activation of tumour necrosis factor 
(TNF) and nuclear factor- B (NF-kB) pathways. 
 
Table 1-2: Subtypes of glioblastoma based on major characteristic features 
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Most of the tumours previously diagnosed as secondary glioblastomas were 
classified as the proneural subtype in this study (Verhaak et al. 2010). The Proneural 
subtype has also been linked with younger patient age and genetic profiles such as 
PDGFRA abnormalities, TP53 and IDH1 mutations which had formerly been linked 
to secondary glioblastoma (Watanabe et al. 1996; Tohma et al. 1998; Kleihues and 
Ohgaki, 1999; Ohgaki et al. 2004; Yan et al. 2009). Furthermore, Proneural subtype 
glioblastomas were found to present with better prognosis than other subtypes as 
median survival for this subtype has been found to be remarkably longer than the 
other subtypes (Phillips et al. 2006; Verhaak et al. 2010). Also, although a distinct 
effect of treatment was demonstrated in other subtypes such as the Classical and 
Mesenchymal subtypes, the Proneural subtype did not show any survival benefit 
from aggressive treatment regimens (Verhaak et al. 2010). 
Also, IDH1 mutations have been found to be associated with longer survival. It has 
been shown in separate analyses of glioblastoma patients treated with surgery and 
radiotherapy or radio- and chemotherapy that patients with IDH1 mutant (IDH1
mut
) 
glioblastomas had mean overall survival more than twice as long as that of patients 
with wild type IDH1 (IDH1
wt
) glioblastomas (Nobusawa et al. 2009; Yan et al. 
2009). Likewise, a population – based study (Ohgaki et al. 2004) showed a 
significantly (p = 0.003) longer median overall survival for patients clinically 
diagnosed with secondary glioblastoma (7.8 months) compared to primary 
glioblastoma patients (4.7 months).  
Furthermore, identification of these subtypes and their markers has also made it 
possible to make a clearer distinction between different subtypes of glioblastoma. 
For instance, IDH1 mutations are now recognised as a specific molecular diagnostic 
marker for secondary glioblastomas as they are found to occur in the majority 
(greater than 80 %) of secondary glioblastoma cases but rarely occur (less than 5 %) 
in primary glioblastomas.  
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This mutation was also found to occur with high frequency in WHO grade II (diffuse 
astrocytoma), WHO grade III (anaplastic astrocytoma) from which secondary 
glioblastomas evolve and in oligodendroglial tumors, suggesting this mutation occurs 
early on and may have a key function in the tumour evolution process (Balss et al. 
2008; Watanabe et al. 2009; Yan et al. 2009; Nobusawa et al. 2009; Ichimura et al. 
2009).  
Some studies showed that for some glioblastomas which had IDH1 mutations that 
had been clinically diagnosed as primary glioblastomas, the patients were younger 
(10 – 27 years younger) than the mean age for primary glioblastoma (Nobusawa et 
al. 2009; Yan et al. 2009; Toedt et al. 2011), the tumours had genetic profiles 
(absence of EGFR amplification and TP53 mutations) identical to secondary 
glioblastomas with IDH1 mutation (Nobusawa et al. 2009; Toedt et al. 2011), and 
they had a longer (28.8 months compared to 3.8 months) clinical history than 
tumours without IDH1 mutations (Nobusawa et al. 2009). These findings suggest 
that these tumours with IDH1 mutations may actually be cases of secondary 
glioblastoma in which there had been very rapid progression from lower grade 
tumours which had not been previously diagnosed or tumours arising from lower 
grade lesions which had been clinically quiescent, leading to their erroneous 
classification as primary glioblastomas (Verhaak et al. 2010; Toedt et al. 2011; 
Ohgaki and Kleihues 2013). On the other hand, in some glioblastomas without IDH1 
mutations that had been clinically diagnosed as secondary glioblastoma, the tumours 
showed less frequent TP53 mutations and more frequent p16 deletion than those with 
IDH1 mutations. More than 80 % of these tumours had progressed from anaplastic 
astrocytoma (WHO grade III) whereas most secondary glioblastomas with IDH1 
mutations develop from diffuse (WHO grade II) gliomas (Nobusawa et al. 2009).   
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These may also represent cases in which the tumours had been diagnosed as 
anaplastic astrocytoma when they were really primary glioblastomas that were 
incorrectly diagnosed as a result of errors in sampling (Nobusawa et al. 2009; Toedt 
et al. 2011; Ohgaki and Kleihues 2013). Thus, IDH1 mutation is now considered to 
be a more unequivocal bench mark for diagnosis of secondary glioblastoma than 
conventional clinical and/or pathologic markers (Ohgaki and Kleihues 2013).  
These finding could be potentially useful in determining treatment courses for 
glioblastoma patients such that dose escalation could be applied for patients 
(Classical and Mesenchymal subtypes) who would benefit from such regimens. For 
secondary glioblastoma patients on the other hand, dose escalation may not be 
necessary since most secondary glioblastomas have been classified as the Proneural 
subtype for which aggressive treatment did not yield survival benefit unlike the 
Classical and Mesenchymal subtypes which benefited from dose escalation (Verhaak 
et al. 2010; Ohgaki and Kleihues 2013). 
1.5 Treatment of Glioblastoma 
Presently, standard therapeutic management of newly diagnosed glioblastoma is 
based on an integrative approach comprising surgery followed by concurrent radio–
chemotherapy and then adjuvant chemotherapy (Figure 1-3). This treatment strategy 
was adopted following the publication of the results of the 2004 European 
Organisation for Research and Treatment of Cancer (EORTC) 26981-22981/National 
Cancer Institute of Canada Clinical Trials Group (NCIC) CE3 randomised phase III 
trial (Stupp et al. 2005) which demonstrated an improvement in the median survival 
as well as 2-year survival rates of glioblastoma patients with post-surgical 
concomitant and adjuvant temozolomide (the Stupp regimen) compared to post-
surgical radiotherapy alone (Stupp et al. 2009; Grossman et al. 2010; Khasraw and 
Lassman 2010; Niyazi et al. 2011; Juratli et al. 2013; Hong et al. 2013; Jarzabek et 
al. 2013; Olar and Aldape 2014).  
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However, there is no standardised treatment modality for the management of 
recurrent glioblastoma. Therapeutic options for patients with recurrent disease are 
limited so patients usually receive investigational agents in clinical trials (Wong et al. 
1999; Florio and Barbieri 2012; Hong et al. 2013; Juratli et al. 2013). 
For optimal management of glioblastoma, pathological diagnosis must first be 
established, usually by surgical biopsy before commencing radio- or chemotherapy, 
unless craniotomy is not possible, as in exceptional cases where surgery is 
contraindicated due to a great risk for the patient. In such cases, a stereotactic biopsy 
should be carried out for histological confirmation of diagnosis (Nieder et al. 2006; 
Chamberlain 2010; Lonardi et al. 2005). 
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Figure 1-3: Treatment modalities for glioblastoma 
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 The role of surgery in the treatment of Glioblastoma 1.5.1
Surgical resection is the first treatment strategy in the management of glioblastomas 
(Lonardi et al. 2005; Neider et al. 2006). The ultimate aim of surgery in high grade 
gliomas such as glioblastoma should ideally be to perform a total tumour resection 
which would have produced a cure (Lonardi et al. 2005). However, this is practically 
unfeasible owing to the highly infiltrative nature of the tumour cells which are 
sometimes located at or close to sites of vital brain function and may also involve 
recruitment of cells adjacent to the lateral ventricles. An attempt at total surgical 
resection would therefore pose a risk of functional loss. This restriction in the extent 
of tumour resection makes tumour recurrence imminent (Halperin et al. 1988; Fine 
1994; Sanai and Berger 2009; Raizer 2011; Florio and Barbieri 2012; Agarwal et al. 
2013; Hong et al. 2013; Juratli et al. 2013) and repeated surgeries may not always be 
feasible due to invasion of tumour cells into vital areas of the brain and even where it 
may be carried out, the benefits are limited unless combined with other salvage 
therapies (Wong et al. 1999; Mandl et al. 2008).  
Therefore, the alternative strategy is to perform surgical resection to the greatest 
feasible extent for tumour debulking with the aim of brain decompression and 
reduction of symptoms such as intracranial pressure and other neurological 
symptoms; and improving the patients’ quality of life and survival (Chamberlain 
2010; Lonardi et al. 2005; Sanai and Berger 2009). Maximal surgical resection has 
been shown to lead to better overall outcomes (Simpson et al. 1993; Keles et al. 
1999; Stummer et al. 2006; Stummer et al. 2008; Kreth et al. 2013), and leads to an 
improvement in the efficacy of adjuvant therapy (Stummer et al. 2006) even in 
recurrent disease where there is an indication of a better response to chemotherapy 
and outcome in patients with smaller volume of residual disease (Keles et al. 2004). 
This may be due to a greater permeability of the tumour vasculature leading to higher 
penetration of therapeutic agents.  
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Extent of surgical resection has been identified as an important predictor of survival 
outcome in glioblastoma although some studies did not demonstrate a clear 
association between the extent of surgery and survival (Franklin 1992; Hess 1999). 
Various studies have demonstrated that patients who have maximal resection with 
minimal residual disease have significantly increased survival compared with 
patients who have partial resection (Wood et al. 1988; Simpson et al. 1993; Wong et 
al. 1999; Lacroix et al. 2001). 
 Radiotherapy in the treatment of Glioblastoma 1.5.2
Radiotherapy with external beam irradiation has long been considered to be 
important in the treatment of high grade gliomas such as glioblastoma, as it was 
shown to produce improved survival compared to surgery alone or with best 
supportive care (Andersen 1978; Walker et al. 1978).   
A post-surgical radiation dose of 60 Gy has been found to be optimal following 
studies that showed that this dose produced superior survival compared to lower 
doses (Walker et al. 1979; Chang et al. 1983; Bleehen et al. 1991), with 
demonstration of a clear trend of increased survival when the dose is increased from 
45 – 55 Gy up to 60 Gy (Walker et al. 1979). Further increases in radiation dose up 
to 70 Gy did not produce superior results (Chang et al. 1983). In current standard 
clinical practice, radiation doses of 58 – 60 Gy are administered in 30 – 35 fractional 
doses of 1.8 – 2 Gy each, five days per week (Lonardi et al. 2005; Florio and 
Barbieri 2012; Juratli et al. 2013). The most popularly adopted dosing design 
involves the application of a focal dose up to 50 Gy to the tumour mass and 
surrounding oedema, with a further boost dose (total dose of 60 Gy) applied to the 
contrast enhancing tumour up to a 2 – 3 cm margin in order to reach most (up 80 %) 
of the tumour cells including those that might have infiltrated surrounding areas 
(Halperin et al. 1988; Halperin et al. 1989; Bokstein et al. 2008; Juratli et al. 2013).  
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In spite of improvements in survival with post-surgical radiotherapy, most tumour 
cells appear to be resistant to the therapy indicating the imminence of recurrence 
even after application of the optimal dose (Halperin et al. 1989; Baumann et al. 1992; 
Juratli et al. 2013).  
 Conventional post-surgical treatment for glioblastoma in the past comprised 
radiotherapy alone (Stupp et al. 2009; Raizer 2011). However the survival benefit 
was minimal (Stupp et al. 2005; Stupp et al. 2009; Brada et al. 2010) as it did not 
produce a significant improvement in overall survival and long term survivors were 
rare (Stupp et al. 2009). In current times, radiotherapy is combined with concurrent 
and adjuvant chemotherapy (Stupp et al. 2005) as the addition of chemotherapy has 
previously been shown to improve survival compared to post-surgical radiotherapy 
alone (Walker et al. 1978; Fine et al. 1993; Stewart 2002). 
 Chemotherapy in the treatment of Glioblastoma 1.5.3
The place of chemotherapy in the management of glioblastoma has become 
established in spite of initial controversy and uncertainty about the value of inclusion 
of chemotherapy in treatment protocols owing to failure of initial clinical trials to 
clearly demonstrate improved survival outcomes (Fine et al. 1993; Fine 1994; 
Gundersen 1998; Grossman 2003; Khasraw and Lassman 2010). Post-surgical 
chemotherapy may be administered as neoadjuvant (before radiotherapy), 
concomitant (simultaneously with radiotherapy) or as adjuvant (immediately after 
radiotherapy) chemotherapy (Lonardi et al. 2005; Chamberlain 2010).  
The nitrosoureas had previously been recognised as the mainstay of chemotherapy 
for high grade gliomas (Jakacki et al. 1998; Weller et al. 2013) and have been 
employed, and continue to have a place as single agents (Hoogstraten et al. 1973; 
Walker et al. 1978; Cianfriglia et al. 1980; Rosenthal et al. 2004; Brandes et al. 2004; 
Reithmeier et al. 2010; Wick et al. 2010) and in combination with other agents 
(Kappelle et al. 2001; Stewart 2002; Brada et al. 2010; Weller et al. 2013; Yi et al. 
2014) in glioblastoma therapy.  
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The major factor undermining the therapeutic success of these agents is dose limiting 
myelosuppression mainly neutropenia and thrombocytopenia associated with their 
use, which often necessitates dose delay and reductions thus compromising the 
tumour response to therapy (Cianfriglia et al. 1980; Kriegler et al. 1994; van den 
Bent et al. 1998; Jakacki et al. 1998; Gerber et al. 2007; Chamberlain 2010). 
Temozolomide is the current drug of choice as first line chemotherapy for 
glioblastoma (Stupp et al. 2005; Gerber et al. 2007; Stupp et al. 2009; Brada et al. 
2010; Grossman et al. 2010; Khasraw and Lassman 2010; Agarwal et al. 2011a; 
Raizer 2011; Yust-Katz et al. 2013; Juratli et al. 2013; Olar and Adalpe 2014). 
Temozolomide, an orally active imidazotetrazine derivative of dacarbazine is a 
second generation alkylating agent developed in the 1980s and introduced for 
chemotherapy of primary brain tumours in the 1990s (Newlands et al. 1992; 
Newlands et al. 1997; Juratli et al. 2013).  
Temozolomide replaced nitrosoureas as first line chemotherapy for glioblastoma 
following the demonstration of significant benefits from concomitant and adjuvant 
temozolomide chemotherapy with radiotherapy in the EORTC-NCIC trial. In this 
trial involving 573 patients, this combination regimen produced median survival (at 
28 months follow up) of 14.6 months compared to 12.1 months for radiotherapy 
alone and 2 year survival rate of 26.5 % compared to 10.4 % for radiotherapy alone, 
representing more than 2.5 times longer survival in the combination therapy group 
(Stupp et al. 2005). This survival advantage was an improvement on what had 
previously been demonstrated in a meta–analysis of 12 randomised trials of adjuvant 
nitrosourea chemotherapy which revealed a modest improvement (6 %) in survival 
with the addition of nitrosourea compared to radiotherapy alone (Stewart 2002).  
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Temozolomide is reportedly less toxic than most other alkylating agents and therapy 
is associated with improved quality of life (Newlands et al. 1992; Yung et al. 2000; 
Stupp et al. 2005; Combs et al. 2008; Chamberlain 2010;). However, therapy with 
this agent is also associated with dose limiting myelosuppressive effects, mainly 
thrombocytopenia, neutropenia and some other effects such as lymphopenia and 
induction of myelodysplastic syndrome which may necessitate discontinuation of 
therapy (Newlands et al. 1992; Gerber et al. 2007; Su et al. 2005; Tosoni et al. 2006; 
Chamberlain and Raizer 2009; Chamberlain 2010). Moreover in some studies, there 
was no distinct survival benefit of temozolomide compared to a standard 
procarbazine, lomustine, and vincristine (PCV) combination regimen (Brada et al. 
2010) in a large (447 patients) randomised trial in chemotherapy-naïve patients with 
recurrent high grade gliomas. Also, in a study of 47 patients with newly diagnosed or 
recurrent glioblastoma treated with carmustine wafers, patients who received radio-
chemotherapy with temozolomide and local carmustine delivery (wafers) did not 
have a significant survival advantage compared to patients who had received local 
carmustine alone and there was increased toxicity in the combination group 
(Gutenberg et al. 2013).  
 Anti-angiogenic agents for Glioblastoma therapy  1.5.4
Due to the importance of angiogenesis in tumour development and sustenance 
processes, angiogenic factors such as vascular endothelial growth factor (VEGF) and 
pathways are potential targets for the treatment of glioblastoma (Jarzabek et al. 
2013), a highly vascularised tumour which possesses irregular blood vessels, high 
level of vascular proliferation and elevated expression of angiogenic factors 
particularly VEGF (Brem et al. 1972; Leon et al. 1996; Salmaggi et al. 2003; 
Grossman et al. 2014). Moreover, the degrees of vasculature density and VEGF 
expression have been found to correlate to tumour necrosis, hypoxia, grade and 
biological aggressiveness of the tumour and the overall clinical outcome (Shweiki et 
al. 1992; Leon et al. 1996; Zhou et al. 2003). 
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Bevacizumab, a humanized monoclonal antibody inhibitor of VEGF is the first anti - 
angiogenic agent approved for cancer therapy and is currently the only anti - 
angiogenic agent licensed by the FDA for treatment of recurrent glioblastoma 
(Friedman et al. 2009; Jarzabek et al. 2013; Grossman et al. 2014). The approval was 
based on the success of this agent in two phase II clinical trials (Friedman et al. 2009; 
Kreisl et al. 2009).  
The first trial, was a prospective single institution trial of bevacizumab in 
combination with irinotecan (a topoisomerase I inhibitor frequently used in disease 
relapse, though with limited success) for the treatment of recurrent glioblastoma 
patients. The results of this trial showed 6 – month progression free survival rates of 
42.6 % and 50.3 %, and median overall survival times of 9.2 months and 8.7 months 
for bevacizumab alone and in combination with irinotecan respectively (Friedman et 
al. 2009).  The second trial, a single institution trial of bevacizumab as a single agent 
therapy in 48 patients with recurrent glioblastoma, the 6 – month overall survival 
was 57 %, median overall survival was 31 weeks and 6 – month progression free 
survival was 29 %. Also, radiographic response was achieved in 71 % (Levin 
criteria) and 35 % (MacDonald criteria) of the patients (Kreisl et al. 2009).  
Efficacy and safety of bevacizumab with radiotherapy has also been investigated and 
a study demonstrated  50 % overall response rate, mean overall survival of 12.5 
months, 1 – year survival of 54 % and 6 – month progression free survival rate of 65 
% (Gutin et al. 2009). Therapy with bevacizumab is associated with some toxic 
effects such as intracranial haemorrhage, hypertension, proteinuria and reduced 
wound healing (Vredenburgh et al. 2007; Friedman et al. 2009; Kreisl et al. 2009), 
which are apparently related to the anti - angiogenic effects and depict VEGF 
blockade in healthy tissue (Chamberlain 2011). 
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The incidence of more serious toxic effects such as gastrointestinal perforation, 
cardiac failure and wound healing complications is low (usually less than 2 %) in 
glioblastoma patients (Friedman et al. 2009; Vredenburgh et al. 2007;  Norden et al. 
2008; Gutin et al. 2009). Also, tumour recurrence following bevacizumab result in 
more infiltrative tumours and resistance to therapy (Norden et al. 2008; de Groot et 
al. 2010; Scott et al. 2010). 
Other antiangiogenic agents, namely sunitinib and sorafenib have demonstrated the 
preclinical potential for glioblastoma therapy (Yang et al. 2010; Grossman et al. 
2014), however available clinical data do not compellingly demonstrate their benefit 
in glioblastoma therapy (Neyns et al. 2011; Hainsworth et al. 2010). 
In addition, cediranib an orally available tyrosine kinase inhibitor (TKI) of VEGFR2, 
platelet-derived growth factor (PDGF) receptor-α and –β and stem cell growth factor 
receptor has been evaluated in phase III randomised trials as monotherapy, in 
combination with and compared to lomustine in recurrent glioblastoma. In the study, 
plasma samples were obtained at baseline and in the course of the study in order to 
determine the levels of the soluble biomarkers VEGF, sVEGFR2, as well as basic 
fibroblast growth factor (bFGF) and to calculate changes from baseline levels during 
the study. They recorded an increase in median VEGF levels in the cediranib 
monotherapy (30 mg) arm of 89 %, 108 %, and 106 % above baseline levels at days 
42, 84, and 126, respectively. Similarly, an increase in VEGF levels was recorded at 
each time point in the cediranib (20 mg) plus lomustine arm (day 42, 46%; day 84, 
41%; day 126, 61%). However, these median increases were lower than those for the 
cediranib monotherapy (30 mg) arm. In the lomustine arm on the other hand, median 
VEGF levels at day 42 were similar to those at baseline and decreased by 21% at day 
84. 
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Median baseline levels of sVEGFR2 recorded were similar in the three arms. At day 
42, decreases in median sVEGFR2 levels from baseline of 27% and 22% were 
recorded for the cediranib monotherapy (30 mg) and cediranib 20 mg plus lomustine 
arms, respectively; which were maintained in both arms at days 84 and 126. There 
was no change in median sVEGFR2 levels in the lomustine arm as the levels 
remained similar to baseline levels throughout the trial. There were no consistent 
changes in bFGF levels from baseline levels in any of the three arms. In the study, 
subgroup analyses showed that the baseline VEGF levels had no significant effect on 
either PFS or the overall survival outcome. Overall, the agent did not demonstrate an 
advantage of prolonging progression free survival (Batchelor et al. 2013).  
From the foregoing, it is clear that there is still a great need for the development and 
application of safer and more effective therapeutic modalities for optimal 
management of glioblastoma, with the aim of increasing progression free and overall 
survival outcomes, as well as providing patients with a good quality of life 
(Chamberlain 2010; Agarwal et al. 2011a; Raizer 2011; Malmström et al. 2012). 
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1.6 Challenges of successful Glioblastoma treatment 
The challenges of effective treatment of glioblastoma include: dose limiting toxicity 
of clinically used cytotoxic agents; development of tumour resistance to currently 
employed therapeutics; and limitation in the number of drug candidates due to the 
blood brain barrier (BBB) which restricts the entry of molecules to the brain. 
 Toxicity  1.6.1
The most important toxic effect of cytotoxic chemotherapy is their myelosuppressive 
effects (Lyman et al. 1998) due to their toxic effects on the cells of the bone marrow 
(Maxwell and Maher 1992; Kriegler et al. 1994; Raizer 2011). Myelosuppression 
resulting from cytotoxic chemotherapy represents the most frequent cause of 
combined reduction in peripheral blood cell counts in the developed world (Carey 
2003).  
Chemotherapy induced myelosuppression manifests mainly as neutropenia which 
carries the risk for life threatening infections (Peters et al. 1993; Lyman et al. 1998; 
Crawford et al. 2004; Dale 2002) and thrombocytopenia which predisposes patients 
to bleeding complications (Morstyn et al. 1988; Elting et al. 2001; Gerber et al. 2007; 
Hitron et al. 2011). Chemotherapy dose intensity is greatly restrained by 
myelosuppressive effects of clinically employed cytotoxic agents (Cianfriglia et al. 
1980; Peters et al. 1993; Cairncross et al. 1994; Chamberlain and Raizer 2009; 
Chamberlain 2010). This frequently leads to the necessity for dosing delays, 
reductions or outright discontinuation (Intile et al. 2009; van den Bent et al. 2006; 
Hitron et al. 2011).  
These toxic effects may lead to a need for hospitalisations, additional costs for rescue 
therapy and a poor quality of life for patients (Intile et al. 2009; Hitron et al. 2011). 
Also, it may compromise tumour response and overall survival time as a result of the 
attendant dose reductions and treatment delays (Hitron et al. 2011). 
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 Chemotherapy resistance in Glioblastoma 1.6.2
Tumour resistance to alkylating agents employed in chemotherapy is mainly 
mediated by the overexpression of O
6
-alkylguanine-DNA alkyltransferase (AGAT), 
a ubiquitous protein encoded by the O
6
-methylguanine-DNA-methyltransferase 
(MGMT) gene. AGAT is a DNA repair enzyme that functions alone to remove 
damages in DNA by removing alkyl groups from the O
6
 position of guanine and O
4
 
position of thymine by transferring the alkyl group to a cysteine acceptor residue in 
its own amino acid sequence in a stoichiometric manner, thereby reversing the 
alkylation reaction and restoring DNA structure (Dumenco et al. 1989; Pegg 1990; 
Tano et al. 1990; Gerson 2004). As these (O
6
 position of guanine and O
4
 position of 
thymine) are important alkylation sites for alkylating agents commonly employed in 
cancer chemotherapy, high levels of DNA repair activity of AGAT render tumour 
cells resistant to these agents (Dumenco et al. 1989; Schold et al. 1989; Tano et al. 
1990; Gerson 2004). However, if the toxic (mutagenic) lesions produced by DNA 
alkylation are not repaired, the process of cytotoxicity and apoptosis will be activated 
in the tumour cells leading eventually to cell death (Ochs and Kaina 2000; Gerson 
2004). Upon alkylation of AGAT, the alkylated protein is permanently inactivated, 
thus the protein can act only once and new AGAT protein has to be synthesised in 
order to “replenish the stock” and restore cellular function of this protein (Pegg, 
1990; Tano et al. 1990).  
Studies have suggested that the majority of gliomas express the AGAT protein which 
makes it of clinical significance as it is an important predictor of chemo sensitivity or 
resistance (Hegi et al. 2005; Chamberlain 2010). Activity of the protein is turned off 
by methylation (hypermethylation) through epigenetic silencing of the promoter for 
the gene which leads to decreased levels of the protein (AGAT) resulting in better 
response to chemotherapy (Gerson 2004; Weller et al. 2010).  
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The clinical significance of the promoter methylation status has been demonstrated in 
studies which have shown an increased response to chemotherapy with alkylating 
agents and survival benefits in patients with a hypermethylated promoter (Hegi et al. 
2004; Hegi et al. 2005).  
Since AGAT is consumed in the process of alkylation damage repair, administration 
of alkylating agents in regimens that produce cumulative and continued consumption 
and inactivation of the protein, leading to increased chemosensitivity may lead to 
improved therapeutic efficacy (Dolan et al. 1990). This approach has been evaluated 
by administering protracted doses of temozolomide which has been found to produce 
considerable inactivation of AGAT (Tolcher et al. 2003), and some studies have 
demonstrated survival benefits (Brandes et al. 2006; Wick et al. 2007) for such an 
approach. However, it is not clear if accruing benefits of such regimen can be 
attributed to AGAT depletion since repeated brain biopsy is impracticable (Weller et 
al. 2010). Moreover, some clinical studies have shown that the survival benefit with 
such a dosing regimen is produced in patients with a methylated promoter 
(Herrlinger et al. 2006; Glas et al. 2009; Weiler et al. 2010). 
Furthermore, an alternative approach to increase sensitivity of chemotherapeutic 
agents would be to administer a pseudosubstrate for AGAT before the therapeutic 
agent such that the protein is inactivated and would need to be synthesised again by 
cells (Schold et al. 2004). This approach has been evaluated in a Phase II clinical trial 
in which O
6
-benzylguanine was administered to patients just before administration of 
temozolomide. Although there was restoration of temozolomide sensitivity in 
temozolomide-resistant anaplastic glioma patients, no significant restoration of 
temozolomide sensitivity was observed in patients with temozolomide-resistant 
glioblastoma (Quinn et al. 2009). 
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Due to the key role the AGAT gene promoter methylation status plays in determining 
tumour response to chemotherapy and by extension overall clinical outcomes in 
patients receiving chemotherapy, it is now considered as the most important 
prognostic factor in malignant gliomas such as glioblastoma and is used in clinical 
trials for stratification of patients (Stupp et al. 2009; Weller et al. 2010; Kreth et al. 
2013). 
 The Blood brain barrier (BBB) 1.6.3
The BBB is a system of vascular cellular structures, characterized by continuous 
physical barriers such as tight junctions (which prevent blood- borne substances from 
seeping into the brain parenchyma) between adjacent endothelial cells; a lack of 
fenestrations, very low pinocytotic activity, and metabolic barriers such as enzymes, 
receptors, transporters, and efflux pumps of the multidrug resistance (MDR) 
pathways that regulate the access of molecules to the brain. This is a barrier formed 
in humans and other mammals by the endothelial cells lining the walls of the 
capillaries of the brain and spinal cord (Kniesel and Wolburg 2000; Brightman and 
Reese 1969; Bhaskar et al. 2010; Juillerat- Jeanneret 2008; Stamatovic et al. 2008). 
The BBB is exhibited by all organisms with a well-developed CNS (Abbott 2005).  
Along with the BBB, there are other CNS barriers such as the blood cerebrospinal 
fluid barrier (BCSFB) and the avascular arachnoid epithelium which completely 
encloses the CNS, thus completing the seal between the CNS extracellular fluids and 
the general circulation (Pardridge 1995; Abbott 2004; Begley 2004; Abbott et al. 
2006). At these interfaces, a combination of the different components, that is the 
physical (tight junctions between cells blocking the intercellular or paracellular 
pathway), transport (specific transport mechanisms mediating solute flux), and 
metabolic (enzymes metabolizing molecules in transit) barriers mediate the barrier 
function of the BBB (Abbott et al. 2006).  
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Nevertheless, the BBB is considered the main regulatory site for uptake and delivery 
of drug molecules into the brain parenchyma owing to its large surface area (12- 20 
m
2
 /1.3 kg brain) and short diffusion distance (10- 15 µm) from the capillaries to the 
neurons (Pardridge 1991; Abbott 2004; Schlageter et al. 1999; Abbott 2005; Begley 
2003).  
The presence of the BBB places considerable restriction on the number and type of 
molecules that can access the brain. Only a very restricted number of small (Mwt 
usually < 400-600 Da), lipid soluble molecules can cross the BBB by passive 
diffusion, all other molecules including potentially beneficial therapeutic agents can 
enter the brain only by receptor mediated transcytosis, or by specific carrier systems, 
making the treatment of CNS pathologies such as glioblastoma particularly 
challenging (Misra et al. 2003, Deeken and Wolfgang 2007; Juillerat-Jeanneret 2008; 
Raizer 2011). 
1.6.3.1 Structure of the Blood brain barrier (BBB) 
The brain endothelial cells in close association with other cellular structures such as 
the pericytes, glial cells (astrocytes), microglia, neuronal processes and the basal 
lamina which ensheath the cerebral blood vessels establish and maintain the BBB. 
The interactions between these different cell types contribute to the properties of the 
BBB (Iadecola 2004; Abbott 2005; Abbott et al. 2006). 
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1.6.3.2 Functions of the BBB 
The BBB acts as a physical and metabolic barrier between the CNS and the general 
circulation (Calabria and Shusta 2006). In conjunction with the BCSFB, the BBB 
maintains brain homeostasis and protects the brain from potential damage that could 
arise from neuroactive and other toxic compounds, which may be endogenous 
metabolites or proteins; or diet ingested or environmentally acquired xenobiotics, 
circulating in the plasma. Neurotoxins are actively pumped out of the brain by 
energy- dependent ABC efflux transporters (ATP-binding cassette transporters) 
present in the BBB (Abbott et al. 2010; Calabria and Shusta 2006; Abbott and 
Romero 1996). 
The BBB also provides a stable environment for neural function and maintains 
optimal ionic composition for synaptic signalling by a combination of specific ion 
channels and transporters. As a result, the concentration of potassium in 
cerebrospinal fluid (CSF) and brain interstitial fluid (ISF) is maintained at a defined 
range (≈ 2.5 mM – 2.9 mM ), despite changes in the plasma after meals or exercise, 
experimental manipulations or pathological conditions (Bradbury and Davson 1965; 
Hansen 1985.) Active regulation of calcium and magnesium ions, as well as pH also 
occurs at the BBB (Jeong et al. 2006; Nischwitz et al. 2008; Abbott et al. 2010). 
Furthermore, the BBB also helps to prevent uncontrolled release of neuroexcitatory 
amino acid glutamate (present in blood plasma at high levels) into the brain ISF. This 
protects the neural tissue from permanent neurotoxic/neuroexcitatory damage. The 
BBB also helps to separate between peripheral and central transmitter pools and 
minimizes exchange between the two (Abbott et al. 2006; Bernacki et al. 2008). 
 
 
 
57 
 
Nanoparticle based strategies for the treatment of Glioblastoma 
In addition, the BBB prevents the entry of many macromolecules including plasma 
proteins (such as albumin, pro- thrombin and plasminogen), which can cause brain 
tissue damage in the brain (Nadal et al. 1995; Gingrich and Traynelis, 2000; Gingrich 
et al. 2000).  
Adequate nutritional and metabolic requirements of the BBB are maintained by 
specific transport systems expressed in the BBB which ensure an adequate supply of 
many essential water soluble nutrients and metabolites (with low BBB permeability) 
required by nervous tissue (Abbott et al. 2010).  
1.6.3.3 Circumventricular Organs (CVOs) 
The CVOs refer to those areas of the CNS where the classical BBB capillary 
endothelial cells (thus lacking tight junctions) are not expressed. They have micro-
vessels similar to those of the periphery, thus permitting the diffusion of large 
molecules. These areas include the organum vasculosum of the lamina terminalis, the 
subfornical organ, the median eminence and the area postrema. The exchange 
between the specialised neurons and the blood need to be maintained in the CVOs 
for neuropeptide secretion into the blood and for chemosensitivity (to enable the 
brain to monitor blood composition). However, these regions do not form a leak 
across the BBB due to the presence of tight junctions between specialised ependymal 
cells in CVOs, and between the processes of tanycytes and astrocytic glia that isolate 
the CVOs from the brain parenchyma (Brightman 1977; Schlageter et al. 1999; 
Ganong 2000; Abbott et al. 2006). 
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Moreover, active drug-efflux-transporter proteins such as P-glycoprotein (P-gp), 
multidrug resistance protein, breast cancer resistance protein  and other transporters 
which abound in the luminal membranes of the CNS also actively remove a wide 
range of structurally and functionally unrelated molecules from the brain (Dallas et 
al. 2006 ; Tamai and Tsuji 2000). Also, the surface area of the tight BBB capillaries 
is much greater (5000 times) than that of the permeable fenestrated capillaries of the 
CVOs. Thus, these higher permeability areas do not create a practical route of entry 
(drug delivery) into the brain (Begley 1996). 
1.6.3.4 The Blood-Tumour Barrier (BTB) 
Apart from the physiologically established CNS barriers which prevent access of 
most molecules to the brain parenchyma, the BTB is another barrier thought to 
restrict access of systemically administered chemotherapeutic agents to tumour cells 
thus protecting them from such agents (Cloughesy and Black 1995; Black and 
Ningaraj 2004; Raizer 2011 Agarwal et al. 2011a). Transport of nutrients, growth 
factors, therapeutics and other molecules is regulated by the tumour cell membrane 
which constitutes the barrier. This barrier function by the tumour cells is mediated by 
the expression of drug efflux pumps of the ATP-binding cassette (ABC) gene family 
(similar to those of the BBB) such as P-gp and multidrug resistance protein (MRP) 
expressed by these cells, (Nabors et al. 1991; Demeule et al. 2001; Spiegl-Kreinecker 
et al. 2002; Decleves et al. 2002; Fattori et al. 2007; Agarwal et al. 2011a) and their 
vasculature (Nabors et al. 1991; Tóth et al. 1996). The P-gp efflux pumps have been 
the focus of most studies on this subject, but there have been controversy about the 
expression and role of P-gp efflux pumps in mediating chemo resistance in 
glioblastoma tumours (Agarwal et al. 2011a).  
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Some studies have reported the expression of this drug efflux mechanism in gliomas 
cells (Nabors et al. 1991; Demeule et al. 2001; Fattori et al. 2007) although others 
have reported either the absence (Decleves et al. 2002) or infrequent (Spiegl-
Kreinecker et al. 2002) expression of the efflux mechanism. However, the conflicting 
reports of the various studies might be due in part to inadequacies of the assay 
methods employed, as it has been shown that many antibodies thought to be specific 
for P-gp demonstrated poor specificities (Ashmore et al. 1999). In spite of the 
conflicting reports about the expression of P-gp efflux pumps in glioma cells, it is 
agreed that there is expression of MRPs in glioma cells which reduce tumour 
accumulation of therapeutic agents (Decleves et al. 2002; Spiegl-Kreinecker et al. 
2002). From the foregoing, it is apparent that tumour cells exhibit an additional 
barrier (BTB) mechanism which constitutes another hurdle (in addition to the BBB) 
to be crossed for effective delivery of therapeutic agents for successful treatment of 
brain tumours (Black and Ningaraj 2004; Agarwal et al. 2011a). 
1.6.3.5 Status or integrity of the BBB in glioblastoma 
The BBB is reportedly altered in brain tumours such as glioblastomas which render 
the BBB less intact than in normal healthy brain vasculature (Nieder et al. 2006; Jain 
et al. 2007; Deeken and Wolfgang 2007). Analysis of glioblastoma tumour samples 
revealed molecular alteration in the microvessels which was demonstrated by 
changes in expression of the junctional proteins. These samples also showed 
intermittent rather than continuous endothelial and morphologically altered pericytes.  
(Liebner et al. 2000). However, this BBB disruption does not occur uniformly 
throughout the tumour. Loss of BBB integrity occurs mostly at the contrast 
enhancing tumour regions (tumour core) which is highly angiogenic with new and 
“leaky” blood vessels, while it remains intact in tumours that lack contrast 
enhancement.  
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Since glioblastomas are highly infiltrating tumours, smaller lesions located in 
adjacent areas of the brain will also possess intact BBB/BTB (Deeken and Wolfgang 
2007; Raizer 2010; Agarwal et al. 2011a). Therefore, although high drug 
concentrations may be achieved at the tumour core, this does not reflect the effective 
drug concentration achievable for chemotherapy since this contrast enhancing 
tumour area is usually removed by surgery (Agarwal et al. 2011a). Thus, the 
challenge remains the efficient delivery of therapeutic agents to the tumour cells not 
located at the tumour core and diffusely infiltrating tumour cells that may have 
penetrated distant parts of the brain (Raizer 2010; Agarwal et al. 2011a). 
 Drug delivery to intracranial tumours 1.6.4
Although there is evidence of BBB disruption at the core tumour bed harbouring the 
larger lesions and evidence that this may greatly facilitate delivery of therapeutic 
agents to such sites, this may not yield treatment benefits because such lesions are 
usually removed by surgical resection (Agarwal et al. 2011a). This leaves the 
diffusely infiltrating tumour cells which may be located in seemingly healthy 
adjacent brain areas; successful treatment thus requires delivery of therapeutics to 
these infiltrating tumour cells, which still possess a functionally intact BBB, in 
sufficient and therapeutically effective concentration (Nieder et al. 2006;  Allard et 
al. 2009; Raizer 2011; Agarwal et al. 2011a).  
A number of strategies can be employed for effective delivery of therapeutics to 
glioglastomas and other CNS pathologies. These strategies can be classified into 
invasive and non-invasive strategies.  
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1.6.4.1 Invasive strategies for drug delivery to CNS tumours 
1.6.4.1.1 Disruption of the BBB 
This involves temporary disruption of the BBB by intra-arterial administration of 
hypertonic solutions such as mannitol, urea or saline, with mannitol (approved for 
human use) been the most frequently used (Kroll and Neuwelt 1998) hypertonic 
solution. This has been shown to increase drug (methotrexate) concentration in the 
CSF (Zylber-Katz et al. 2000) and in clinical studies has been shown to lead to 
improved survival outcomes in patients with primary CNS lymphoma (McAllister et 
al. 2000). This strategy has also been employed in the administration of bevacizumab 
in patients with recurrent malignant glioma (Boockvar et al. 2011) and also in the 
chemotherapy of pontine diffuse gliomas (Hall et al. 2006) with improved 
therapeutic outcomes. BBB disruption can also be effected by intracarotid infusion of 
bradykinin and has been shown to increase brain permeability (Nomura et al. 1994; 
Sarker et al. 2000). However, this strategy may not be applicable for long term use 
and the procedures are potentially risky and may produce toxic effects (Agarwal et 
al. 2011a). 
1.6.4.1.2 Direct administration of chemotherapeutics into the CNS 
This strategy involves direct application of the therapeutic agents into the CNS 
thereby by-passing the BBB. This may be achieved by techniques such as 
administration through the intracerebroventricular/intrathecal route, direct 
application of drug impregnated polymer delivery system at the site of action, or 
convection-enhanced delivery (Bobo et al. 1994; Petri et al. 2007). 
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1.6.4.1.2.1 Intraventricular/Intrathecal administration 
 This strategy involves direct intralumbar injection or intraventricular infusion of 
drugs directly into the CSF using a ventricular (Ommaya) reservoir. The Ommaya 
reservoir was introduced as a subcutaneous reservoir and pump (SRP) in 1963 
(Ommaya 1963). The device was designed to overcome the challenges posed by the 
need for repeated sampling or repeated introduction of drugs into the CSF (Ommaya 
1963). The SRP was initially introduced for access to ventricular and spinal CSF 
mainly for the administration of antifungal agents in the treatment of fungal 
meningitis, it has since been applied in the therapy of many other conditions 
especially in various CNS tumours (Ommaya 1984; Chamberlain et al. 1997; 
Sandberg et al. 2000; DeAngelis and Boutros 2005). The Ommaya [originally made 
of self-sealing (if needles of small gauge < no 20 are used) silicone rubber] reservoir 
is subcutaneously implanted in the scalp and connected to the brain ventricles 
through a catheter. Drug solutions can be subcutaneously injected into the implanted 
reservoir and delivered to the ventricles by manual compression of the reservoir 
through the scalp (Ommaya 1984; Misra et al. 2003). Limitations of this method 
include a slow rate of drug distribution within the CSF, increase in intracranial 
pressure, high clinical incidence of hemorrhage, CSF leaks, neurotoxicity and CNS 
infections. (Chamberlain et al. 1997; Misra et al. 2003). 
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1.6.4.1.2.2 Application of drug-impregnated polymer delivery system 
This strategy for local administration of adjuvant chemotherapy to surgical tumour 
resection cavity in the treatment of malignant gliomas was developed in the 1990s 
(Juratli et al. 2013). The only agent approved by the FDA for use as adjuvant 
chemotherapy is Gliadel
®
 wafer. This is a sterile wafer implant composed of the 
biodegradable polymer, polifeprosan 20 {Decanoic acid-4,4ˈ-[1,3-propanediylbis 
(oxy)] bis (benzoic acid) copolymer)} impregnated with carmustine which is released 
slowly (controlled release) at the surgical cavity (Agarwal et al. 2011a; Juratli et al. 
2013). Application of such locally implanted wafers leads to longer and higher local 
drug concentration compared to systemic (bolus) administration with the potential to 
reduce systemic toxicity of carmustine (Juratli et al. 2013).  
Evaluation of these implants in clinical trials demonstrated survival benefits for 
patients who receive carmustine impregnated wafers as part of their post-surgical 
therapy (Westphal et al. 2003; Attenello et al. 2008). From a surgical point of view, 
local intracerebral chemotherapy with carmustine wafers is uncomplicated and is not 
associated with systemic toxicities. Nevertheless, a number of complications have 
been linked with implantation of the wafers including healing abnormalities, 
intracranial infections, cerebral edema, CSF leaks, seizures and cyst formation. Also, 
combination of the intracerebral carmustine with concomitant radiochemotherapy 
may be associated with the risk of increased toxicity (Bock et al. 2010). 
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1.6.4.1.2.3 Convection-enhanced delivery 
Convection-enhanced delivery, a concept described by Bobo and co-workers in 1994 
is another strategy for by passing the BBB by direct delivery of therapeutics to the 
CNS. They developed this strategy based on the hypothesis that fluid convection (or 
bulk flow) created within the brain by interstitial infusion at a pressure gradient can 
be employed to augment diffusion and consequently enhance the distribution of 
molecules including high molecular weight proteins in the brain (Bobo et al. 1994). 
This technique involves the stereotactic application of catheters directly to brain 
tumour or tissue through cranial burr holes. Fluid convection which can deliver 
desired agents at constant concentrations over a relatively large intercerebral volume 
is generated to the catheters by a connected motor-driven pumping device (Juratli et 
al. 2013). This facilitates the direct infusion of therapeutic agent to target tissue, 
which may be the enhancing tumour or non-enhancing infiltrating surrounding areas 
(Agarwal et al. 2011a; Juratli et al. 2013) at predetermined rate and concentration for 
the desired duration (Juratli et al. 2013). This technique has been employed in some 
clinical trials in delivery of therapeutic agents for recurrent gliomas with some 
limited success as well as some reports of treatment related complications (Lidar et 
al. 2004; Kunwar et al. 2010; Bernal et al. 2014). 
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1.6.4.2 Non-invasive strategies for drug delivery to CNS tumours 
Non-invasive techniques for delivery include inhibition of BBB transporters, and 
nanoparticle based delivery systems.  
1.6.4.2.1 Inhibition of BBB transporters 
The drug transport proteins (efflux pumps) at the BBB actively remove molecules 
from the brain thereby restraining the access of some therapeutics which could be 
potentially useful for treatment of some CNS pathologies (Kniesel and Wolburg 
2000; Abbott 2004; Stamatovic et al. 2008; Bhaskar et al. 2010; Agarwal et al. 
2011a). Thus the inhibition of this efflux mechanism could potentially lead to an 
increased concentration of such therapeutics in the brain (Agarwal et al. 2011a). 
Several studies have shown increased brain concentrations of the therapeutic agents 
after administration of efflux pumps inhibitors such as P-gp or BCRP inhibitors such 
as elacridar (GF120918) and zosuquidar (LY335979) (Lagas et al. 2009; Chen et al. 
2009; Agarwal et al. 2011b).  
1.6.4.2.2 Nanoparticle-based delivery systems 
Drug-carrier nanoparticles are submicroscopic colloidal systems that may act as drug 
vehicles, either as nanospheres or nanocapsules depending on the method of 
preparation (Juillerat-Jeanneret 2008; Soppimath et al. 2000). A therapeutic 
nanoparticle system usually comprises the therapeutic agent of interest (small 
molecule, peptide, protein or nucleic acid) and the components (such as lipids or 
polymers) that would assemble with the therapeutic agent into nanoparticles (Davis 
et al. 2008). These systems can increase the solubility of incorporated drug and 
provide a controlled release function at the site of action (Chen et al. 2008).  
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Nanoparticle-based systems represent a promising platform for delivery of 
therapeutics to cross the BBB due to their high specificity, and they tend to 
accumulate at higher concentrations at the site of action than drugs in solution (Chen 
et al. 2008; Davis et al. 2008; Bhaskar et al. 2010). Preferential accumulation of 
nanoparticles at sites of action such as tumour site, inflammatory site and so on, 
occurs as a result of the enhanced permeability and retention (EPR) effect of the 
vasculature (Davis et al. 2008; Singh and Lillard 2009). Subsequently, hydrophobic 
biodegradable polymeric nanoparticles can act as local depot (if so designed) for 
loaded drug, thus providing continuous supply (sustained release) of the therapeutic 
agent at the desired site of action such as solid tumours (Singh and Lillard 2009).  
Nanoparticles possess certain unique features which make them attractive for 
application in drug delivery for cancer therapy (Davis et al. 2008). Nanoparticles 
have the capability to carry and protect a large payload of therapeutic agents (Davis 
et al. 2008). For instance, a nanoparticle (70 nm) was shown to carry about 2, 000 
small interfering RNA (siRNA) molecules (Bartlett and Davis 2007) while an 
antibody conjugate could bear only about 6 siRNA molecules (Song et al. 2005). 
Other therapeutics such as small molecules or peptides could also be loaded into 
nanoparticles in similar manner and multiple classes of therapeutic agents can be 
incorporated within a nanoparticle to exert their various effects in a controlled 
manner (Davis et al. 2008). Also, the pharmacokinetic and biodistribution of 
nanoparticles are not affected by the type or number of payloads they carry since the 
loaded moieties are located within the particle. On the other hand, the 
pharmacokinetics of loaded therapeutic agent could be improved by the size and 
surface properties of the nanoparticle (Davis et al. 2008).  
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Furthermore, nanoparticles can be functionalised with multiple ligands for enhanced 
transport and site specific delivery. Thus a given nanoparticle could be functionalised 
with ligands that would enhance transport to and uptake at the site of action such as 
the brain (for example, a transporter molecule such as transferrin); targeting ligands 
for multivalent binding to specific receptors on the surface of target cells; antibodies 
against tumour markers for targeting and binding to target tumour cells which may 
potentially lead to improved efficacy and reduced toxicity; and appropriate 
fluorescent markers for tracking and imaging purposes (Hong et al. 2007; Bhaskar et 
al. 2010). In addition, modification of the surface properties of polymeric 
nanoparticles by coating them with surfactants such as polysorbate 80 or other 
polysorbates with 20 polyoxyethylene units and coating of non-viral gene delivery 
systems using poly ethylene glycol (PEG) attachment for siRNA delivery have been 
shown to be advantageous in brain targeting (Pardridge 2007; Bhaskar et al. 2010).  
Nanoparticle-based delivery systems may deliver incorporated therapeutic agents to 
the brain mainly by either carrier-mediated transport (CMT) for small molecules or 
endocytotic transcytosis for macromolecules (Pardridge 2007; Abbott et al. 2010; 
Bhaskar et al. 2010).   
1.6.4.2.2.1 Carrier-mediated transport (CMT) or carrier-mediated influx 
CMT are forms of diffusion which may be active or passive (Bhaskar et al. 2010), 
involved in the transport of small molecules (Pardridge 2007). CMT mainly 
facilitates the transport of various essential polar molecules, with the aid of various 
carrier transporters (expressed on the plasma membrane of the brain endothelial 
cells) including glucose (GLUT1 glucose transporter), amino acids (LAT1 large 
neutral amino acid transporter) and nucleosides (CNT2 nucleoside transporter) into 
the brain (Pardridge 2005; Abbott et al. 2010; Bhaskar et al. 2010). 
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1.6.4.2.2.2 Endocytotic transcytosis 
Endocytotic transcytosis represents the major route by which macromolecules such 
as peptides and proteins can gain access to the CNS intact (Abbott et al. 2010). 
Endocytotic transcytosis may occur by adsorptive mediated transcytosis (AMT) or 
receptor mediated transcytosis (RMT) (Abbott et al. 2010; Bhaskar et al. 2010). 
1.6.4.2.2.2.1 Adsorptive mediated transcytosis (AMT) 
AMT is based on electrostatic interaction between a positively charged molecule and 
the negatively charged binding sites on the surface of the brain endothelial cells 
(Abbott et al. 2010; Bhaskar et al. 2010). Thus, for molecules to be eligible for 
transport by the AMT mechanism, they must carry an excess of positive charge 
which would render them cationic for interaction with the negatively charged binding 
sites on the cell surface. Interaction of molecules with the cell surface binding sites 
induces endocytosis which is then followed by transcytosis (Sauer et al. 2005). 
Transport of molecules across the BBB may therefore be facilitated by coupling 
them to short (10 – 30 amino acid sequence) cationic peptides known as cell 
penetrating peptides (CPPs) such as SynB5 [originally deriving from protegrin (the 
SynB peptide vectors)] (Drin et al. 2003) or pAnt-[(43–58); also known as 
penetratin, a fragment of Antennapedia homeodomain] (Derossi et al. 1994; Drin et 
al. 2003); or cationised peptides such as cationised albumin (Pardridge et al. 1990).  
 
 
 
 
 
 
69 
 
Nanoparticle based strategies for the treatment of Glioblastoma 
1.6.4.2.2.2.2 Receptor mediated transcytosis (RMT) 
RMT facilitates the transport of macromolecules such as peptides and proteins across 
the BBB by conjugating the molecules to ligands such as transferrin, insulin or 
lactoferrin which interact with specific receptors on the plasma membrane of the 
brain endothelial cells (Fishman et al. 1987; Baura et al. 1993; Fillebeen et al. 1999; 
Pardridge 2005; Abbott et al. 2010; Bhaskar et al. 2010).  
In RMT, once the macromolecule-ligand conjugates bind to the specific receptors on 
the cell surface, an endocytotic event is triggered. The receptors and bound ligand 
cluster together and form a caveolus which breaks off into a vesicle. The ligand and 
receptors are then internalised into the endothelial cell and passes across the 
cytoplasm to be exocytosed at the opposite side of the cell. Subsequent dissociation 
of ligand from the receptor is thought to occur during cellular transit or during the 
exocytotic process (Abbott et al. 2010). RMT is a prominent transport mechanism 
which has attracted a great deal of interest in drug delivery (Bhaskar et al. 2010). 
1.6.4.2.2.3 Application of nanoparticles in drug delivery to intracranial 
tumours 
Steiniger and co-workers in their study investigated the possibility of a therapeutic 
success using a nanoparticle formulation of doxorubicin, a Pgp efflux pump substrate 
in a rat glioblastoma 101/8 model. The nanoparticle formulation employed in the 
study comprised doxorubicin bound to polysorbate 80 coated poly(butyl 
cyanoacrylate) nanoparticles. They carried out the study to assess the therapeutic 
efficacy of the nanoparticle formulation following previous studies which had shown 
that doxorubicin bound to the polysorbate 80 coated poly(butyl cyanoacrylate) 
nanoparticles was able to cross intact BBB and also achieved therapeutic 
concentrations of doxorubicin in the brain after intravenous administration (Gulyaev 
et al. 1999).  
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They evaluated two different doses of doxorubicin (3 X 1.5 mg kg
-1
 and 3 X 2.5 mg 
kg
-1
) in the study. They reported a markedly increased survival in animals that 
received the formulation of doxorubicin bound to polysorbate 80 coated poly(butyl 
cyanoacrylate) nanoparticles at the two doses studied. In the higher dose (3 X 2.5 mg 
kg
-1
) polysorbate 80 coated poly(butyl cyanoacrylate) nanoparticles group, there 
were long term survivors with survival up to 117 days and 163 days. Similarly, in the 
lower dose (3 X 1.5 mg kg
-1
) polysorbate 80 coated poly(butyl cyanoacrylate) 
nanoparticles group, there was prolonged survival with some of the animals 
surviving for at least 120 days.  
On the contrary, none of the animals treated with doxorubicin alone at the same dose 
levels survived for more than 65 days. Also, the nanoparticle formulation produced 
less peripheral toxicity after systemic administration compared to the formulation of 
doxorubicin alone. Healthy animals treated with doxorubicin alone showed slight 
signs of lung oedema (histologically confirmed), while animals treated with 
nanoparticles did not manifest this effect. Some tumour bearing animals treated with 
doxorubicin alone also showed slight lung oedema albeit without apparent 
histopathology (Steiniger et al. 2004). 
 
A study by Zhang and co-workers demonstrated increased brain concentrations of   
paclitaxel, a P-gp efflux pump substrate by the administration of a nanoparticle 
formulation comprising cyclo-[Arg-Gly-Asp-D-Phe] {c[RGDfk]}-paclitaxel loaded 
hybrid micelles in a mouse model of glioma. Their nanoparticle delivery system 
combined the ability of transferrin to facilitate receptor mediated transcytosis 
(Fishman et al. 1987) of the drug delivery system with the targeting ability of 
c[RGdfk], a peptide known to bind specifically to integrin overexpressed in glioma 
cells (Bello et al. 2001; Desgrosellier and Cheresh 2010). Their results showed that 
the hybrid micelle produced a marked increase in survival time of intracranial U-87 
MG (human glioblastoma) tumour bearing mice.  
 
 
71 
 
Nanoparticle based strategies for the treatment of Glioblastoma 
Tumour bearing mice treated with the transferrin modified c[RGDfk]-paclitaxel 
loaded hybrid micelles had a survival time of 42.8 days, while mice treated with 
transferrin modified paclitaxel loaded micelles (without c[RGdfk]) had a survival 
time of 39.5 days, mice treated with paclitaxel loaded micelles had a survival time of 
34.8 days, those treated with Taxol  had a survival time of 33.6 days, and saline 
treated mice had a survival time of 34.5 days. They also reported that the transferrin 
modified c[RGDfk]-paclitaxel loaded hybrid micelles did not lead to body weight 
loss compared with saline and was less toxic than transferrin modified paclitaxel 
loaded micelles (Zhang et al. 2012).  
Also, Guo and co-workers evaluated the antiglioma effects of transferrin (Tf)-
modified poly ethylene glycol-poly lactic acid (PEG-PLA) nanoparticles conjugated 
with resveratrol (Tf-PEG-PLA-RSV) in glioma bearing rats. Their studies showed 
that the nanoparticle formulation of resveratrol demonstrated superior antiglioma 
effects to the free resveratrol. Also, Tf-PEG-PLA-RSV with the transferrin targeted 
ligand showed improved activity compare to the nanoparticle formulation without 
transferrin. The data showed that both nanoparticle formulations of resveratrol 
produced significantly (p < 0.05) higher tumour inhibition at 15 days post-
inoculation than free resveratrol, although the transferrin modified nanoparticles 
yielded better inhibition than the nanoparticles without transferrin. Also, glioma 
bearing rats treated with free resveratrol had a median survival time of 18 days, rats 
treated with the nanoparticle formulation without transferrin had a median survival 
time of 25 days while rats treated with the tranferrin modified nanoparticle 
formulation, Tf-PEG-PLA-RSV had a median survival time of 36 days. Thus, 
nanoparticle formulation of resveratrol resulted in prolonged survival times 
compared to free resveratrol (Guo et al. 2013). 
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Furthermore, Gao and co-workers demonstrated that the incorporation of lapatinib, a 
poorly water soluble dual EGFR and HER2 inhibitor into core–shell nanoparticles 
improved both the water solubility and anti-glioma effect of the drug. Their studies 
showed that incorporation of lapatinib into the core shell nanoparticles increased the 
water solubility of the drug from 0.007 mg mL
-1
 to over 10 mg mL
-1
, which was 
better than what could be attained by most commercially available injection solvents. 
Evaluation of the anti glioma activities of the core shell nanoparticle formulation in 
glioma bearing mice showed prolonged increase in survival of mice treated with the 
nanoparticle formulation compared to the commercial lapatinib formulation 
(Tykerb). In their study, the mice treated with the high dose (30 mg kg
-1
) 
nanoparticle formulation of lapatinib had a median survival time of 21.0 days, mice 
treated with the low dose (10 mg kg
-1
) nanoparticle formulation had a median 
survival time of 22.0 days, while mice treated with Tykerb (100mg kg
-1
) had a 
median survival time of 19.0 days and saline controls had a median survival time of 
17.0 days. Therefore, their data showed that mice treated with lapatinib incorporated 
into the core shell nanoparticles at two dose levels (10 mg kg
-1
 and 30 mg kg
-1
) had a 
significantly (p < 0.05) increased survival time compared to mice treated with 
Tykerb (100 mg kg
-1
). Thus, administration of lapatinib incorporated into 
nanoparticles at a much lower dose than the commercial formulation resulted in 
better survival outcomes than the higher dose of the commercial formulation (Gao et 
al. 2014). 
In another study, Qian and co-workers demonstrated that the administration of 
carmustine (BCNU) using chitosan surface modified poly (lactide-co-glycolides) 
nanoparticles loaded with BCNU along with O
6
-benzylguanine (BG), which could 
directly deplete MGMT would improve the therapeutic efficacy of BCNU. They 
evaluated this nanoparticle formulation (BCNU + BG nanoparticle) in F98 glioma-
bearing rats in comparison to a BCNU solution group, BCNU nanoparticles group, 
and BCNU + BG (intraperitoneal injection of BG 2 hours before intravenous 
injection of BCNU), with a saline group as the negative controls.  
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Their studies showed that the saline control group had a median survival time of 10.0 
days, the BCNU nanoparticle group had a median survival time of 16.0 days which 
was not statistically different from the median survival time (14.5 days) of the 
BCNU solution group. On the other hand, the BCNU + BG nanoparticle group had a 
median survival time of 23.0 days which was statistically (p < 0.05) different from 
that for the BCNU + BG solution group (19.0 days) as well as the other treatment 
groups. Thus, the administration of BCNU and BG together in a nanoparticle 
formulation yielded superior survival outcomes compared to administration of the 
two drugs separately in solution as well as the nanoparticle containing BCNU alone 
(Qian et al. 2013).  
From the foregoing, administration of therapeutics in nanoparticle formulations 
resulted in superior therapeutic outcomes compared to administration in conventional 
formulations.  
The nanoparticle delivery system employed in the current study is based on 
quaternary ammonium palmitoyl glycol chitosan (GCPQ), a self-assembling chitosan 
amphiphile which had been previously shown to facilitate the delivery of molecules 
to the brain. Studies by Qu and co-workers showed that formulation of the 
intravenous anaesthetic propofol using GCPQ nanoparticles resulted in a more 
efficient encapsulation of propofol than obtained with conventional copolymers. 
Also, the nanoparticle formulation increased the brain activity of propofol by 10 
times compared to commercial formulations of the drug (Qu et al. 2006). 
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Furthermore, Lalatsa and co-workers demonstrated the delivery of leucine
5
-
enkephalin, a hydrophilic peptide to the brain using the GCPQ based nanoparticle 
system. Their work showed that compared to leucine
5
-enkephalin alone, brain 
exposure was increased by 67 % following oral administration of a novel derivative 
(palmitoyl leucine
5
-enkephalin; TPLENK) of the peptide using GCPQ nanoparticle 
formulation while intravenous administration of this nanoparticle formulation 
increased brain exposure by 50 % (Lalatsa et al. 2012a). Also, intravenous 
administration of this nanoparticle formulation (10 mg kg
-1
) produced considerably 
high antinociception in mice while leucine
5
-enkephalin did not produce any 
analgesia at the same dose (Lalatsa et al. 2012a). Furthermore, their studies 
demonstrated that GCPQ nanoparticles increased the stability of leucine
5
-enkephalin 
in the gut and the plasma by protecting the peptide from degradation. This facilitated 
the brain transport of the GCPQ nanoparticle stabilised peptide to the brain (Lalatsa 
et al. 2012a; Lalatsa et al. 2012b). In addition, studies have shown that GCPQ 
nanoparticles do not cross the BBB to any appreciable extent (Lalatsa et al. 2012a) 
and they do not open epithelial tight junctions (Siew et al. 2012). The GCPQ 
nanoparticles appear to deliver their payload to the brain by making contact with the 
brain endothelial cells following which loaded molecules are able to cross the BBB. 
Moreover, intravenously administered polymer have been known to remain in the 
circulation and adhere to the perivascular spaces of arterioles and venules and the 
inner surface of the blood vessels of brain endothelial cells (Garrett et al. 2012), 
which had allowed loaded peptide to cross the BBB (Lalatsa et al. 2012a). 
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1.7 Hypothesis 
One of the major limitations to effective glioblastoma chemotherapy is dose limiting 
peripheral toxicity of clinically used therapeutic agents. This often leads to the 
necessity for dose delays, reductions or sometimes outright discontinuation 
(Cianfriglia et al. 1980; Kriegler et al. 1994; van den Bent et al. 1998; Gerber et al. 
2007; Su et al. 2005; Tosoni et al. 2006; Vredenburgh et al. 2007; Friedman et al. 
2009; Kreisl et al. 2009). This often compromises tumour response which may 
explain the poor clinical outcomes in the majority of cases (Hitron et al. 2011). 
Moreover resistance to chemotherapy (mainly mediated by AGAT), another 
challenge of effective chemotherapy may be overcome by continuous chemotherapy 
administration in order to deplete the resistance mechanism thereby increasing 
chemosensitivity (Tolcher et al. 2003). 
This work is therefore based on the hypothesis that continuous administration of 
lomustine, a cytotoxic (DNA alkylating) nitrosourea compound in a high dose 
nanoparticle formulation will lead to improved therapeutic outcome whilst not 
increasing the incidence of myelosuppressive effects associated with the drug. 
The nanoparticle formulation is based on GCPQ, a self-assembling chitosan 
amphiphile. GCPQ has been shown to exhibit a distinct distribution profile in vivo 
which suggests that the polymer formulation avoids the reticuloendothelial system 
(Lalatsa et al. 2012a). This indicates that nanoparticle-drug formulations based on 
GCPQ will not be readily taken up by the macrophages which are known to abound 
in the bone marrow (Leu et al. 1984; Moghimi et al. 2001; Chellata et al. 2005; 
Owens and Peppas 2006), [Figure 1-4], a major site of lomustine toxicity, due to the 
high susceptibility of the cells of the bone marrow to the toxic effects of cytotoxic 
agents (Pollak et al. 1988; Kriegler et al. 1994; Çetin et al. 2000).   
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Thus, the high dose lomustine-GCPQ nanoparticle formulation would lead to 
improved survival outcomes without attendant toxic effects (Figure 1-4) 
 
Figure 1-4: Schematic depicting administration of high dose chemotherapy using nanoparticle 
based drug formulation versus conventional aqueous drug formulation 
Key:  
  Aqueous drug formulation 
Nanoparticle based drug formulation 
 
 
 
 
 
Brain tumour 
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1.8 Aims and objectives 
The aim of this study is to demonstrate that a high dose nanoparticle lomustine-
GCPQ formulation will lead to improved survival outcomes without an increase in 
the incidence of toxic effects. This aim will be achieved through the following 
objectives: 
1. To synthesise and characterise GCPQ 
2. To prepare and characterise high dose lomustine-GCPQ nanoparticle (Q-
LOM) formulation 
3. To establish and characterise a mouse model of human glioblastoma  
4. To assess in vivo anti-glioma activities of the Q-LOM formulation in tumour 
bearing mice 
5. To assess the toxicity of the Q-LOM formulation in healthy mice 
6. To study the in vitro uptake of GCPQ particles in macrophage cell line 
7. To synthesise and characterise self-assembling peptide amphiphiles as 
potential delivery systems for anti-glioma agents 
8. To synthesise and characterise a therapeutic peptide as a candidate for 
chemotherapy of intracranial tumours.  
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Chapter 2 Evaluation of Anti-tumour Activities of GCPQ-
Lomustine (Q-LOM) Formulation 
2.1 Introduction 
Chemotherapy has become a component part of the standard of care for glioblastoma 
(Lonardi et al. 2005; Neider et al. 2006, Stupp et al. 2005; Stupp et al. 2009; 
Khasraw and Lassman 2010; Juralti et al. 2013) in spite of previous uncertainty 
about its value (Fine 1994; Gundersen 1998; Stewart et al. 2002; Grossman 2003; 
Khasraw and Lassman 2010) in improving therapeutic outcome. Currently, 
temozolomide is the first line chemotherapeutic agent employed in conjunction with 
and subsequent to surgical resection and radiotherapy in the management of newly 
diagnosed glioblastoma (Stupp et al. 2005; Gerber et al. 2007; Brandsma et al. 2008; 
Stupp et al. 2009; Brada et al. 2010; Raizer 2011; Khasraw et al. 2010; Grossman et 
al. 2010; Yust-Katz et al. 2013; Juratli et al. 2013; Lwin et al. 2013). Prior to the 
introduction of temozolomide, adjuvant glioblastoma chemotherapy was nitrosourea 
based, both as single agents and as combination regimens (Cianfriglia et al. 1980; 
Jakacki et al. 1998; Wong et al. 1999; Levin 1999; Jakacki et al. 2008; Brada et al. 
2010; Chamberlain 2010; Florio and Barbieri 2012).   
Lomustine [CCNU, 3-(2-chloroethyl)-1-cyclohexyl-3-nitrosourea)] is a synthetic 
alkylating nitrosourea compound. It is highly lipophilic and possesses BBB 
penetrating ability which makes it valuable in the treatment of intracranial tumours 
(Oliverio et al. 1970; Cheng et al. 1972; Weiss and Issell 1982; Jakacki et al. 2008; 
Batchelor et al. 2013).  
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Although lomustine bears only one chloroethylating unit on its structure, it is able to 
produce inter strand cross linking in DNA (Oliverio et al. 1970; Hoogstraten et al. 
1973; Kohn 1977; Pratt et al. 1994).  
 
Figure 2-1: Lomustine [(CCNU; 3-(2-chloroethyl)-1-cyclohexyl-3-nitrosourea; molecular 
weight: 233.7] 
Lomustine undergoes decomposition in physiologic conditions to produce 2-
chloroethyl diazene hydroxide (alkylating) and an isocyanate (carbamoylating) 
intermediates. The major alkylating group, 2- chloroethyl carbonium ion is generated 
by spontaneous decomposition of the 2-chloroethyl diazene hydroxide intermediate 
at physiologic pH (Cheng et al. 1972; Reed et al. 1975; Montgomery et al. 1975; 
Weiss and Issell 1982; Pratt et al. 1994). Alkylation of nucleic acids (DNA and 
RNA) and proteins is as a result of the reaction of 2- chloroethyl carbonium ion with 
cellular constituents. The chloroethyl carbonium ion reacts with the O
6
 and N
7
 sites 
of guanine, with guanines in the midst of a run of guanines been more susceptible to 
attack than guanines in other base sequences, such as an isolated guanine.  
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The isocyanate on the other hand binds mainly to proteins by reacting with the lysine 
(ϵ- amino group) residues of proteins (Cheng et al. 1972; Weiss and Issell 1982; 
Briscoe et al. 1990; Pratt et al. 1994).  
Antitumour activities of lomustine appear to be due mainly to DNA alkylation and 
cross linking, while carbamoylating activity does not contribute to any appreciable 
extent to antitumour activity (Panasci et al. 1977; Kann Jr. 1978). Interstrand DNA 
cross links are produced subsequent to alkylation of DNA by the 2 – chloroethyl 
carbonium ion. This proceeds via a two-step reaction in which there is an initial rapid 
chloroethylation of a guanine residue (at the O
6
 position) in one strand of DNA, 
followed by a slower reaction in which there is elimination of the chloride (Cl
-
) ion 
and subsequent alkylation of the opposite strand of DNA resulting in the formation 
of a cross link (Ewig and Kohn 1977; Kohn 1977).  
Alkylation damage in DNA can be repaired by the O
6
-alkylguanine-DNA 
alkyltransferase (AGAT), the DNA repair protein which removes alkyl groups from 
the O
6
 position of guanine (a major site of alkylation) by alkylating agents. This 
leads to the development of resistance of tumour cells to alkylating agents which 
may result in lack of therapeutic success with these agents (Dumenco et al. 1989; 
Tano et al. 1990; Ochs and Kaina 2000; Kanugula and Pegg 2003; Gerson 2004; 
Hegi et al. 2005; Chamberlain 2010).  
In clinical practice, an initial dose of lomustine (100 – 130 mg m-2) is usually given, 
with a rest period of 6 – 8 weeks before doses are repeated. Dose reductions or 
delays may be necessary if there is myelosuppression which would be manifested in 
non-recovery of haematologic parameters (Cianfriglia et al. 1980; van den Bent et al. 
1998; van den Bent et al. 2006; Jakacki et al. 1998). These dose reductions and 
treatment delays have been shown to compromise tumour response and overall 
survival (Hitron 2011). 
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2.2 Materials and methods 
 Materials 2.2.1
2.2.1.1 List of materials 
S/n Material Supplier 
1 Lomstine Sigma; Sigma-Aldrich Corporation, 
St. Louis, MO, USA 
2 Carmustine Sigma 
3 Etoposide Sigma  
4 Glycol Chitosan [≥ 60 % (titration)] Sigma 
5 Palmitic acid N- hydroxysuccinimide 
ester  
Sigma 
6 Hydrochloride acid Fisher Scientific, UK,  
Loughborough, UK 
7 Ethanol, Absolute  
(Analytical reagent grade) 
Fisher Scientific, UK  
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S/n Material Supplier 
8 Methanol (HPLC grade) Fisher Scientific, UK 
9 Water (HPLC grade) Fisher Scientific, UK 
10 Methanol- d4 Sigma-Aldrich Corporation 
11 1- Methyl- 2- pyrollidone Sigma-Aldrich Corporation 
12 Sodium bicarbonate Sigma-Aldrich Corporation 
13 Sodium hydroxide Fluka; Sigma-Aldrich Corporation 
14 Sodium iodide Sigma-Aldrich Corporation 
15 Iodomethane Sigma-Aldrich Corporation 
16 Amberlite IRA- 96 Fluka 
17 Diethyl ether Sigma-Aldrich Corporation 
18 Dialysis membranes Medicell membranes Ltd, London, 
GB 
19 20 % Dextrose injection AAH Pharmaceuticals Ltd, Coventry, 
GB 
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S/n Material Supplier 
20 Water for injections (BP) AAH Pharmaceuticals  
21 U-87 MG cell line  
(ATCC
®
 HTB-14
™
)  
American Type Cell Culture Collection  
Manassas, VA, USA 
22 Minimum essential medium Life Technologies, Paisley, UK 
23 Fetal bovine serum Labtech International Ltd, Uckfield, 
East Sussex, UK 
24 Trypsin- EDTA (0.05%) Life Technologies 
25 Dubelcco’s phosphate buffered 
saline (DPBS) 
Life Technologies 
26 L- Glutamine Life Technologies 
27 Sodium pyruvate Life Technologies 
 
 
 
 
 
 
84 
 
Nanoparticle based strategies for the treatment of Glioblastoma 
 Methods 2.2.2
2.2.2.1 Synthesis and characterisation of GCPQ 
GCPQ was synthesized according to methods described by Uchegbu et al. 2001 and 
characterised by NMR spectroscopy, the molecular weight was determined by multi-
angle laser light scattering and gel permeation chromatography (GPC/ MALLS). 
1HNMR spectra were acquired on a Bruker AMX Ultrashield™ 400 MHz 
Spectrometer and molecular weight was determined by GPC/ MALLS using an 
Agilent 1200 system coupled to a Wyatt QELS Quasi light scattering laser. 
2.2.2.2 Preparation and characterisation of lomustine [GCPQ-lomustine (Q-
LOM) and ethanolic lomustine (LOM-ETOH)] formulations 
2.2.2.2.1 Preparation of Lomustine (Q-LOM and LOM-ETOH) formulations 
Lomustine nanoparticle formulation (Q-LOM) was prepared by probe sonicating a 
dispersion of GCPQ (20 mg mL
-1
), lomustine (2 mg mL
-1
), Soybean oil (10 mg mL
-1
) 
and polysorbate 80 (5 mg mL
-1
) in 5 % 
w
/v dextrose  solution on ice for 30 minutes.  
The ethanolic lomustine formulation was prepared by vortexing lomustine (2 mg) in 
absolute ethanol with polysorbate 80 (5 mg mL
-1
) in 5 % 
w
/v dextrose solution (final 
ethanol concentration of 10 % 
v
/v). The resulting colloidal mixture was then filtered 
(0.22 µm) to remove drug crystals and yield a non-particulate formulation.  
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2.2.2.2.2 Characterisation of Lomustine formulations 
A calibration curve for lomustine (with carmustine as internal standard) was prepared 
for analysis of the drug content of the formulations. Chromatograms were acquired 
on an Agilent Technologies 1200 Series HPLC system using an Onyx C18 
Monolithic (5 μm; 100 x 4.6 mm; Phenomenex UK) column with the temperature set 
at 40
o 
C. Samples were eluted using a methanol: water (60: 40) mobile phase at a 
flow rate of 1.5 mL min
-1
, with detection at 230 nm. The formulation was dissolved 
in methanol and analysed using the same conditions. 
Particle size for the formulation was determined by transmission light microscopy 
(TEM) imaging (Philips (FEI) CM 120 Bio Twin Transmission Electron 
Microscope) with an AMT digital camera (5 mega pixels; AMT Deben, UK Ltd) and 
dynamic light scattering (DLS) size measurements (Zetasizer Nano series, Malvern 
Instruments). 
2.2.2.3 Preparation and characterisation of etoposide formulation 
2.2.2.3.1 Preparation of etoposide formulation 
GCPQ–etoposide nanomedicine formulations were prepared by probe sonicating 
GCPQ (10 mg mL
-1
), etoposide (2 mg mL
-1
), soybean oil (10 mg mL
-1
) and Tween 
80 (2 mg mL
-1
) in 5 % 
w
/v dextrose solution on ice for 30 min. The formulation was 
then centrifuged at 5, 000 rpm for 15 minutes to remove free drug crystals. The 
supernatant was carefully collected into a separate vial immediately after 
centrifugation.   
 
 
 
 
86 
 
Nanoparticle based strategies for the treatment of Glioblastoma 
2.2.2.3.2 Characterisation of etoposide formulation 
A calibration curve was prepared for etoposide to determine the drug content of the 
formulation. The chromatograms were acquired using the Agilent HPLC system and 
column as described above, with the column temperature set at 40
o 
C. The samples 
were eluted using a mobile phase comprising of methanol: water (50: 50) at a flow 
rate of 1 mL min
-1
 and the detection wavelength was set at 254 nm. 
The particle size for the formulation was determined by TEM and DLS. 
2.2.2.4 In vivo antitumour studies 
2.2.2.4.1 Cell culture and preparation for tumour implantation 
U-87 MG cells (ATCC
®
 HTB-14™; originally from a 44 year-old male Caucasian 
glioblastoma patient) were cultured in Minimum Essential Medium (MEM) 
supplemented with FBS (10 % 
v
/v); sodium pyruvate (1 mM) and L-Glutamine (2 
mM). Cells were maintained in culture for up to 14 days (splitting every 2 – 3 days 
when 75 –  80% confluence was reached in the 75cm2 tissue culture flask) before 
they were used for tumour implantation. 
For tumour implantation, cells at 75 – 80 % confluence were trypsinized and 
centrifuged (800  g at 4 
o
C for 3 minutes) and then suspended in plain medium to a 
final concentration of 50 million cells mL
-1
 in a 2ml plastic tube (equipped with a 
push cap) and placed on ice until they were implanted.    
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2.2.2.4.2 Tumour implantation  
Female CD1 nude mice [Charles River, UK Ltd, Kent, UK; (20 – 30 g)], housed in 
individually ventilated cages, with a maximum of 5 mice per cage and maintained in 
standard regulated laboratory conditions in the Biological Services Unit (BSU) 
within the School were used for the study. The mice were accommodated in the 
appropriate room with the temperature maintained at about 22 – 25 oC, humidity at 
60 % and a 12 – hour light (from 07: 00 hours) and dark (from 19: 00 hours) cycle. 
The mice were acclimatized in the BSU for at least 5 – 7 days before studies 
commenced. All mice had access to food and water ad libitum as soon as they were 
housed in the BSU and throughout the period of study. The study was conducted in 
accordance with the policies and regulations of the Home Office as stipulated in the 
Animals and Scientific Acts 1986 UK, for the handling and care of laboratory 
animals used in scientific research, the recommendations of the BSU and with the 
approval of the ethics committee.  
Mice were anaesthetised (inhaled isofluorane) and secured to a stereotaxic frame 
(BENCHmark
TM
) with a mouse adaptor. An incision was made by opening the skin 
and inner membranes between the eyes towards the back of the cranium. After 
locating the bregma (the intersection of the coronal and sagittal sutures), a hole was 
drilled in the skull with the coordinates: + 0.5 mm anterior and – 2 mm lateral to the 
bregma (determined by a BENCHmark™ digital stereotaxic control panel), using a 
sterile (70 % ethanol) dental drill. A sterile (70 % ethanol) 10 μL Hamilton syringe 
loaded with 2µL cell suspension (100,000 cells) in plain medium was gently lowered 
into this hole to a depth of 3.3 mm below the skull surface. After 1 min, the syringe 
was withdrawn by 0.3 mm (final injection depth 3 mm) and the cell suspension was 
injected at a speed of 0.1 μL min-1 after which the syringe was left in place (3mm 
depth) for 5mins. Subsequently, the syringe was slowly withdrawn and the incision 
was closed using a 5 - 0 suture after which an analgesic (Rimadyl; 5 mg kg
-1
) was 
administered by intraperitoneal injection.  
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The mice were weighed and reviewed on the following day for any signs of ill health 
or discomfort. Subsequently, they were weighed every 2- 3 days and monitored for 
any signs of ill health. Mice showing prolonged weight loss ≥ 15 % of their initial 
body weights were euthanized using a carbon dioxide (CO2) chamber and the brains 
were harvested and fixed in formalin for 24 hours prior to MRI analysis. 
2.2.2.4.3 Evaluation of antitumour activities of lomustine formulations 
Following tumour implantation (as described above), mice were randomly assigned 
to one (n = 6) of three groups. The first group was treated with the high dose 
lomustine (13 mg kg
-1
) nanomedicine formulation, the second group was treated with 
the low dose lomustine (1.2 mg kg
-1
) ethanolic formulation, while the third group 
served as controls and received no drug treatment. Drug treatment was started on day 
7 post tumour implantation and the formulations were administered to the mice by 
tail vein injection once daily for 10 consecutive days. Mice were weighed daily prior 
to drug administration to assess tolerability of the dosing regimen employed. 
2.2.2.4.4 Evaluation of antitumour activities of etoposide formulations 
Mice were randomly assigned to one (n = 5) of three groups after tumour 
implantation (as described above). The first group received 7.5 mg kg
-1
 (High Q-
ETOP) of the nanomedicine formulation, the second group received 1.5 mg kg
-1
 
(Low Q-ETOP) of the nanomedicine formulation, while the third group were the 
control mice and received no drug treatment.  
Drug treatment was started 7 days post tumour implantation and the formulations 
were administered to the mice once daily by tail vein injection. Mice were weighed 
daily prior to drug administration to assess tolerability of dosing regimen employed. 
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2.2.2.4.5 Tumour analysis by MRI 
Images were collected using a 1.5 T Phillips Intera scanner at the Exeter MR 
Research Centre, University of Exeter, UK. A high resolution T2-weighted Turbo 
Spin-Echo (TSE) sequence was used (TR 3000 ms, TE 110 ms, flip angle 90 degrees, 
number of slices 54, voxel size 0.14 X 0.14  X 0.14 mm
3
, 10 averages). High-
resolution images were achieved by utilizing a microscopy coil (23 mm diameter). 
Tumour bearing mice brains were embedded in a mixture (50 : 50) of agarose gel (1 
% 
w
/v) and formaldehyde solution (4 % 
w
/v) prior to imaging, to fix the tissue and 
minimize shifting of the samples during measurement. 
Image parameters were established in a preliminary experiment, so as to optimize 
tumour edge detection.  OSIRIX software (Pixmeo SARL, Switzerland) was utilized 
to analyse the MRI images and to measure the tumour volume, after a manual 
determination of the edges in a slice-by-slice process.    
2.2.2.4.6 Statistical analysis 
Statistical analysis was performed using Minitab
®
 16 software (Minitab, Inc., 
Pennsylvania, USA). The treatment groups were compared two at a time for each 
time point using ANOVA followed by Tukey post hoc test. The significance level 
was set at p < 0.05.  
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2.3 Results 
 Synthesis and characterisation of GCPQ  2.3.1
GCPQ was successfully synthesised with 22 ± 2.1 % degree of palmitoylation and 
13.4 ± 0.8 % degree of quaternisation as determined by 
1
HNMR (Table 2-1; Figure 
2-2). The molecular weight as determined by GPC/ MALLS (Figure 2-3) was: Mw: 
9.4 ± 0.7 kDa; Mn: 7.7 ± 0.9 kDa and Mw / Mn: 1.3 ± 0.2 (Table 2-1) 
 
GCPQ 
batch 
1
HNMR characterisation Molecular weight determination 
% 
Palmitoylation 
% 
Quaternisation 
Mw 
(kDa) 
Mn 
(kDa) 
Mw / Mn 
 
1 23.7 13.2 9.5  8.6 1.1 
2 19.1 13.5 9.3 7.8 1.2 
3 23.4 14.4 10.2 6.5 1.6 
4 21.9 12.4 8.4 7.8 1.1 
Mean 22 13.4 9.4 7.7 1.3 
Standard 
deviation 
2.1 0.8 0.7 0.9 0.2 
 
Table 2-1: Characterisation data for GCPQ batches
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Figure 2-2: 
1
H NMR spectra for GCPQ 
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Figure 2-3: A: GPC/ MALLS chromatogram; B: dn/dc graph for GCPQ 
Key: Red line: Light scattering detector signal; Blue line: Refractive index detector signal; Pink 
line: Quasi-elastic light scattering detector signal 
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 Preparation and characterisation of lomustine (Q-LOM and ethanolic 2.3.2
lomustine) formulations 
2.3.2.1 Determination of drug content of lomustine formulations 
A calibration curve was prepared for lomustine using carmustine as internal standard 
(Figure 2-4). This calibration curve yielded a lomustine / carmustine area ratio versus 
lomustine concentration line with the equation y = 0.1876x – 0.005 (R2 = 0.9999), 
and a height ratio versus lomustine concentration line with equation y = 0.1091x – 
0.0035 (R
2
 = 0.9993).  
 
Figure 2-4: Calibration curve for lomustine with carmustine as internal standard 
 
A calibration curve was also prepared using the concentration of lomustine alone 
(without carmustine as internal standard). This calibration curve yielded an area 
versus lomustine concentration line with the equation y = 9.8739x + 0.1585 (R
2
 = 
0.9998) and a height versus lomustine concentration line with the equation y = 
0.9995x + 0.0673 (R
2
 = 0.9999) (Figure 2-5). 
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Figure 2-5: Lomustine calibration curve 
 
Drug content of lomustine formulations was determined using the equation of the 
line produced by the area versus lomustine concentration (y = 9.8739x + 0.1585) 
from the calibration curve prepared using lomustine concentration alone (Figure 2-5).  
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2.3.2.2 Particle size determination for lomustine formulations 
TEM images showed that Q-LOM formulation yielded particles in two distinct size 
ranges 80 – 470 nm and 0.2 – 1.1 µm (Figure 2-6). 
 
Figure 2-6: TEM images showing Q-LOM formulation 
Freshly prepared nanoparticle formulation of lomustine containing: lomustine (2 mgmL
-1
); 
GCPQ (20 mg mL
-1
, 2 % w/v); polysorbate 80 (5 mg mL
-1
, 0.5 % w/v); soya bean oil (10 mg mL
-
1
, 1 % w/v) in 5 % w/v dextrose solution. Particle size measurements are as generated by the 
AMT digital camera software. 
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However, DLS size data for the lomustine nanoparticle formulation revealed an 
average size of 271.4 nm with polydispersity index of 0.5 (Figure 2-7).  
 
 
 
 
 
 
 
B 
A 
 97 
 
Nanoparticle based strategies for the treatment of Glioblastoma 
 
 
Figure 2-7: DLS graphs showing particle size distribution for Q-LOM by A: intensity; B: 
number; and C: volume 
Freshly prepared nanoparticle formulation of lomustine containing: lomustine (2 mg mL
-1
); 
GCPQ (20 mg mL
-1
, 2 % 
w
/v); polysorbate 80 (5 mg mL
-1
, 0.5 % 
w
/v); soya bean oil (10 mg mL
-1
, 
1 % 
w
/v) in 5 % 
w
/v dextrose solution. 
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 Preparation and characterisation of etoposide formulations 2.3.3
2.3.3.1 Determination of drug content of etoposide formulations 
The calibration curve prepared for etoposide produced a line with the equation y = 
6.1445x + 0.5063 (R
2
 = 0.9998) for area of etoposide versus etoposide concentration 
and a line with equation y = 0.5092 + 0.0801 (R
2
 = 0.9998) for height of etoposide 
versus concentration (Figure 2-8).  
 
Figure 2-8: Calibration curve for etoposide 
 
The equation of the line produced by the area versus etoposide concentration (y = 
6.1445x + 0.5063) from the etoposide calibration curve (Figure 2-8) was used to 
determine the concentration of etoposide formulations. 
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2.3.3.2 Particle size determination for GCPQ- Etoposide Formulation 
TEM images of the GCPQ- etoposide formulation revealed particle sizes in the range 
15 – 300nm (Figure 2-9). 
 
Figure 2-9:  TEM images for GCPQ- etoposide formulation 
Freshly prepared nanoparticle formulation of etoposide containing: etoposide (2 mg mL
-1
); 
GCPQ (10 mg mL
-1
, 1 % 
w
/v); polysorbate 80 (2 mg mL
-1
, 0.2 % 
w
/v); soya bean oil (10 mg mL
-1
, 
1 % 
w
/v) in 5 % 
w
/v dextrose solution. Particle size measurements are as generated by the AMT 
digital camera software. 
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DLS size data for the etoposide nanoparticle formulation revealed an average size of 
176.7 nm with a polydispersity index of 0.2 (Figure 2-10). 
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Figure 2-10: DLS graphs showing particle size distribution for GCPQ- etoposide formulation by 
A: intensity; B: number; and C: volume  
Freshly prepared nanoparticle formulation of etoposide containing: etoposide (2 mg mL
-1
); 
GCPQ (10 mg mL
-1
, 1 % 
w
/v); polysorbate 80 (2 mg mL
-1
, 0.2 % 
w
/v); soya bean oil (10 mg mL
-1
, 
1 % 
w
/v) in 5 % 
w
/v dextrose solution. 
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 Tumour implantation 2.3.4
MRI images acquired revealed successfully tumour implantation and establishment 
in the mice models (Figure 2-11) 
 
Figure 2-11: T2 weighted image of an in situ brain tumour  
 
 
 
 
 
 
 
 
 
Tumour 
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 Tumour analysis by MRI 2.3.5
MRI analysis data obtained for harvested tumour bearing mice brains revealed the 
presence of established intracranial tumours at 7 days post implantation (Figure 
2-12), with the tumour volumes determined to be 2.12 ± 0.37 mm
3
. The tumour sizes 
increased progressively over time until about 20 days (tumour volume = 91.8 ± 7.57 
mm
3
), the time point at which untreated tumour bearing mice reach the 15 % weight 
loss and are culled (Figure 2-13).  
 
            
Figure 2-12: 3D MR images of 7 days post implantation intracranial tumours 
Tumour volumes: A = 2.5 mm
3
; B = 2.0 mm
3
; C=1.8 mm
3
.  
 
          
Figure 2-13: 3D MR images of fully developed intracranial tumours 
Tumour volumes: A = 98.1 mm
3
; B = 93.9 mm
3
; C= 83.4 mm
3
. 
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The tumour images (Figure 2-12; Figure 2-13) show high resolution 3D MR images 
of the harvested mice brain tumours as generated by the Osirix software (MAC 
application) from the slices generated from individual tumours during the MRI 
process. In order to compute the volume for each tumour, regions of interest (ROI) 
are defined in all the slices with detectable tumour area. The ROI is defined by 
drawing a polygon around the tumour area in each slice with the aid of the 
appropriate Osirix software command. Initially, ROIs are defined in some 
representative slices from the first slice through the slices in the middle until the last 
slice. Importantly, ROIs must be defined in the first and the last slices. Once the 
ROIs are defined in the representative slices, ROIs are automatically generated for all 
the other slices using the appropriate Osirix software command. The ROIs are then 
checked to make sure they are accurately defined for the tumour area in each slice 
and adjusted where necessary. Following the satisfactory generation of all the ROIs, 
the tumour volume is then computed automatically for the tumour using the 
appropriate Osirix software command which also simultaneously generates the 3D 
tumour images shown above (Figure 2-12; Figure 2-13).  
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 In vivo anti-tumour studies 2.3.6
2.3.6.1 Evaluation of antitumour activities of lomustine formulations  
Mice were successfully treated with the appropriate lomustine formulation once daily 
for 10 consecutive days. Weight measurements revealed that this dosing regimen was 
well tolerated in the mice (Figure 2-14 A – C). 
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Figure 2-14: Weight measurement of treated and untreated tumour bearing mice over time. 
Treatment groups: Q-LOM group: 13 mg kg
-1
 lomustine nanoparticle formulation, injected (tail 
vein) once daily for 10 consecutive days (≈ 200 µL of formulation, volume adjusted according to 
the weight of each mouse); LOM-ETOH group: 1.2 mg kg
-1
 ethanolic lomustine formulation, 
injected (tail vein) once daily for 10 consecutive days (≈200 µL of formulation, volume adjusted 
according to the weight of each mouse); CONTROL group: No treatment.  
Key: Blue arrow: Treatment start date (Day 7); Red arrow: Treatment end date (Day 16).  
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Mice treated with the high dose lomustine (13 mg kg
-1
) nanomedicine formulation 
had a mean survival time of 33.2 days, while mice treated with the ethanolic 
lomustine (1.2 mg kg
-1
) formulation had a mean survival time of 22.5 days and the 
untreated control mice had a mean survival time of 21.3 days (Figure 2-15) 
 
  
Figure 2-15: Kaplan Meier plot for tumour bearing mice from tumour implantation to time of 
cull (humane end point)  
Treatment groups: Q-LOM group: 13 mg kg
-1
 lomustine nanoparticle formulation, injected (tail 
vein) once daily for 10 consecutive days (≈200 µL of formulation, volume adjusted according to 
the weight of each mouse); LOM-ETOH group: 1.2 mg kg
-1 ethanolic lomustine formulation, 
injected (tail vein) once daily for 10 consecutive days (≈200 µL of formulation, volume adjusted 
according to the weight of each mouse); CONTROL group: No treatment. 
Key: Blue arrow: Treatment start date (Day 7); Red arrow: Treatment end date (Day 16).  
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2.3.6.2 Evaluation of antitumour activities of etoposide formulations 
Mice in this study could not be injected on consecutive days as planned because of 
the weight loss recorded.  The dosing regimen had to be altered to allow one or two 
days of rest between doses for all the mice in the high dose etoposide nanomedicine 
group. The frequency and total number of doses administered depended on the 
recovery of each mouse as determined by recovery of body weight. Also, two mice 
in the low dose etoposide nanomedicine group were not injected on consecutive days 
due to loss in body weight. One of these was culled on dosing day 7 due to loss of 
body weight (Figure 2-16 A – C). 
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Figure 2-16: Weight measurement of treated and untreated tumour bearing mice over time 
Treatment groups: High Q-ETOP group: 7.5 mg kg
-1
 etoposide nanoparticle formulation, 
injected (tail vein) once daily (≈ 200 µL of formulation, volume adjusted according to the weight 
of each mouse); Low Q-ETOP group: 1.5 mg kg
-1
 etoposide nanoparticle formulation, injected 
(tail vein) once daily (≈200 µL of formulation, volume adjusted according to the weight of each 
mouse); CONTROL group: No treatment. Planned consecutive (once) daily dosing was not 
achieved in this experiment due to weight loss observed in all the mice in the high dose 
nanomedicine (High Q-ETOP) as well as 2 mice in the low dose nanomedicine (Low Q-ETOP) 
groups 
Key: Blue arrow: Treatment start date (Day 7).  
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Mean survival time for the High Q-ETOP group was 15.6 days, while the untreated 
control mice had a mean survival time of 20.8 days (Figure 2-17). 
 
 
Figure 2-17: Kaplan Meier plot for tumour bearing mice from tumour implantation to time of 
cull (humane end point) 
Treatment groups: High Q-ETOP group: 7.5 mg kg
-1
 etoposide nanoparticle formulation, 
injected (tail vein) once daily (≈ 200 µL of formulation, volume adjusted according to the weight 
of each mouse); Low Q-ETOP group: 1.5 mg kg
-1
 etoposide nanoparticle formulation, injected 
(tail vein) once daily (≈200 µL of formulation, volume adjusted according to the weight of each 
mouse); CONTROL group: No treatment. Planned consecutive (once) daily dosing was not 
achieved in this experiment due to weight loss observed in all the mice in the high dose 
nanomedicine (High Q-ETOP) as well as 2 mice in the low dose nanomedicine (Low Q-ETOP) 
groups   
Key: Blue arrow: Treatment start date (Day 7).  
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2.4 Discussion and conclusions 
Animal models have long been employed in the study of cancer. These studies 
include the development and evaluation of anticancer therapies before introducing 
such therapies in humans (Burger and Fiebig 2002; Sausville and Burger 2006; 
Teicher 2006). The cancer models may be murine tumours (Steiniger et al. 2004; 
Qian et al. 2013) or human tumour xenografts established by transplantation of either 
human cancer cell lines or biopsies from cancer patients in immunodeficient host 
animals (Lee and Weinmann 2008; Baklaushev et al. 2012) to preclude the incidence 
of host rejection of the transplant (Selek et al. 2014). Lomustine had been evaluated 
in various animal models for brain tumours. 
Tamura and co-workers evaluated lomustine in a rat glioma model. They studied the 
effect of different total dose levels and the effect time of initiation of treatment on the 
effectiveness of chemotherapy. They reported that lomustine was highly effective 
when a dose of 3 x 40 mg kg
-1
 (total dose of 120 mg kg
-1
) was administered 
intraperitoneally. This dose was found to increase the life span of tumour bearing 
animals by 53 – 86 %. Their data also showed that small total doses of 15 mg kg-1 
and 30 mg kg
-1
 did not prolong the survival of animals treated with these doses of the 
drug. Also, single injections of lomustine at larger doses of 90 mg kg
-1
 and 120 mg 
kg
-1
 which are higher than the LD10 [approximately 60 mg kg
-1
 (Levin et al. 1970)] 
were toxic and decreased rather than increase the life span of treated animals by 38 
% and 65 % respectively. Also, there were no significant differences in survival 
times between groups of animals in which treatment had been initiated earlier and 
and those in which treatment was initiated later. They concluded that in the 
assessment of the beneficial or detrimental effects of lomustine in animal brain 
tumour models, single doses of lomustine corresponding to 60 – 80 % of the LD10 
given in several injections proved to be adequate (Tamura et al. 1979). 
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Also, Bethune and co-workers demonstrated improved therapeutic efficacy of a 
liposome formulation of lomustine in a 36B-10 (malignant rat astrocytoma) tumour 
model without a concomitant increase in toxicity. Rats bearing established 
subcutaneously implanted 36B-10 tumours were treated with either free lomustine or 
the liposomal lomustine formulation by intraperitoneal injection on day 14 following 
tumour implantation. Their pharmacokinetic studies suggested a two-fold plasma 
exposure resulting from the liposomal formulation compared to the free drug. Also, 
single dose as well as multiple dose (three weekly doses) treatments with the 
liposomal formulation resulted in approximately two-fold reduction in tumour 
progression compared to the free drug. In addition, they also reported that drug 
concentration in the tumours were found to be 10-fold greater than that in plasma 
following administration of the liposomal formulation. On the contrary, tumour drug 
concentration after administration of the free drug was similar to that in the plasma. 
Their data therefore suggests that the improved efficacy of the liposomal formulation 
of lomustine may be as a result of increased accumulation of the drug within the 
tumours (Bethune et al. 2001).  
Furthermore, etoposide a semisynthetic podophyllotoxin derivative which has 
demonstrated pronounced antitumor activity against a variety of cancers such as 
testicular cancer, monocytic or myelomonocytic leukemia, non-Hodgkin's 
lymphomas and hepatocellular carcinoma (Cavalli 1982) has also been employed in 
animal studies. 
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For instance, in a fairly recent study, etoposide loaded poly(ethylene glycol)-co-
poly(sebacic acid) [PEG–PSA) particles (Etop/PEG–PSA) was shown to demonstrate 
enhanced efficacy in a xenograft mouse model of human small cell lung cancer 
compared to the free drug. Intratumoural administration of a single dose of 
Etop/PEG–PSA (on day 14 following tumour implantation) in mice bearing 
subcutaneously implanted NCI-H82 (human lung tumour) cells resulted in effective 
suppression of tumour growth. There was 100 % survival of mice treated with 
Etop/PEG–PSA by day 31. On the other hand, mice treated with multiple doses of 
the free drug either by intratumoural or intraperitoneal injection had to be humanely 
sacrificed by day 24. In contrast to multiple doses of the free drug which resulted in 
median survival times of 11 days (intraperitoneal) and 16 days (intratumoural), a 
single intratumoural (bolus) dose of Etop/PEG–PSA resulted in a significantly (p < 
0.05) increased median survival time of 47 days for treated mice (Tang et al. 2010). 
In the current studies, GCPQ nanomedicine formulations improved the solubility of 
lomustine, a poorly aqueous soluble drug. The GCPQ formulation afforded a 2 mg 
mL
-1
 formulation of the drug thus enabling the Q-LOM formulation to be 
administered at a higher dose (13 mg kg 
-1
) which was 10 times what could be 
administered using the ethanolic formulation. The dose (1.2 mg kg
-1
) employed for 
the ethanolic formulation was limited by the poor aqueous solubility of lomustine 
and the drug level achievable with the 10 % 
v
/v ethanol and polysorbate 80 (5 mg mL
-
1
) formulation. 
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Weight loss is a general indicator of drug-associated toxicity (Hofland et al. 2005), 
thus the extent of weight loss induced by a drug would be an indication of the toxic 
effects of that drug. Weight loss amongst other side effects had been found to 
constitute a restriction in therapy with lomustine in a sizeable number of patients 
(van den Bent et al. 2003). In the present study, weight measurements revealed no 
difference in mice that had received the high dose Q-LOM formulation compared to 
the controls and those that received the low dose ethanolic formulation (Figure 2-14). 
Also, this group of mice did not manifest signs of discomfort or ill health throughout 
the treatment period. 
The mice that were treated with the high dose Q-LOM formulation had a mean 
survival time of 33.2 days which was significantly different (p < 0.05) from the mean 
survival time (22.5 days) for mice treated with the low dose ethanolic formulation 
and the untreated control mice (21.3 days) [Figure 2-15]. Thus, the Q-LOM 
formulation produced therapeutic and survival benefit as it enabled dose 
intensification by enabling the administration of a higher dose in a continuous dosing 
regimen, which produced prolonged survival in the mice that received this 
formulation compared to the other groups, without leading to additional gross 
toxicity.  
Drugs employed as anticancer agents can exert either cytostatic or cytotoxic effects. 
Therefore, their effects can be assessed by their ability to produce a reduction in 
tumour volumes and/ or prolongation of survival (Raizer 2011). The prolonged 
survival provided by the Q-LOM formulation demonstrates the cytostatic efficacy of 
the drug using the nanomedicine formulation and the dosing regimen employed in 
this study.  
 
 
 
 116 
 
Nanoparticle based strategies for the treatment of Glioblastoma 
The daily dosing regimen afforded continuous and prolonged exposure of tumour 
cells to the drugs thereby leading to an increase in chemosensitivity (Dolan et al. 
1990; Tolcher et al. 2003; Tosoni et al. 2006). This strategy could be used to lead to 
an increased depletion or consumption of the AGAT protein and an increase in 
tumour penetration by the drug (Raizer, 2011). Moreover, findings from the work of 
Wick and co-workers demonstrated that administration of temozolomide in a dose-
dense schedule of 150 mg m
-2
/day in an alternate weekly (days 1 through 7 and days 
15 through 21; every 4 weeks) regimen resulted in clinically important improved 
treatments outcomes. The alternate weekly dosing regimen was found to result in a 
6-month progression-free survival (PFS-6) rate of 43.8 % and median PFS of 24 
weeks in glioblastoma patients (Wick et al. 2007). The treatment outcome resulting 
from this dose dense regimen (PFS-6: 43 %; median PFS: 24 weeks) was superior to 
treatment outcomes (PFS-6 rate: 21 %; median PFS: 12 weeks) obtained in a large 
(225 patients) multicentre phase II study of temozolomide (versus procarbazine) in 
glioblastoma patients at first relapse (Yung et al. 2000) as well as the treatment 
outcomes (PFS-6 rate: 15 %; median PFS: 9 weeks for glioblastoma patients) in a 
large (375 patients) meta-analysis of eight consecutive clinical trials (Wong et al. 
1999). Also, the treatment outcome obtained from the alternate weekly regimen was 
superior to that resulting from a low-dose temozolomide protracted schedule of 75 
mg m
-2
/day for 21 days every 28 days (three weeks on, one week off). This dosing 
schedule produced PFS-6 rate of 30.3 % and overall median PFS was 16.1 weeks 
(Brandes et al. 2006). The survival outcomes resulting from the alternate weekly 
regimen and the three weeks on, one week off dosing schedules were found to be 
independent of the MGMT gene promoter methylation status (Brandes et al. 2006; 
Wick et al. 2007), as a methylated MGMT gene promoter in tumour tissue was not 
associated with prolonged PFS (Wick et al. 2007).  
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Thus, from these two studies employing dose intensification in the form of increasing 
the dosing frequency, the lack of correlation of the MGMT gene promoter 
methylation status with survival outcomes indicates that the increased exposure of 
tumours to the drug may have resulted in increased depletion of MGMT such that 
tumours possessing an unmethylated MGMT gene promoter (more chemoresistant 
tumours) also became more sensitive to chemotherapy. 
The superior outcomes (PFS-6: 43 %; median PFS: 24 weeks) resulting from the 
higher dose (150 mg m
-2
/day) temozolomide in an alternate weekly regimen (Wick et 
al. 2007) demonstrates that the administration of chemotherapy at higher dose 
intensity could potentially lead to more beneficial treatment outcomes. This indicates 
that depletion of MGMT resulting from the alternate weekly administration of 
temozolomide (150 mg m-2/day) may overcome the chemotherapeutic challenges of 
an unmethylated MGMT promoter (Wick et al. 2007). 
Therefore, the significantly (p < 0.05) increased survival time of 33.2 days (without 
additional gross toxicity) resulting from the high dose lomustine (Q-LOM; 13 mg kg
-
1
) nanomedicine formulation compared to survival time (22.5 days) in the low dose 
lomustine (1.2 mg kg
-1
) ethanolic formulation in the present study, can be linked to 
the increased exposure of the tumours to the drug as a result of the administration of 
10 consecutive daily injections of the formulation at the high (13 mg kg
-1
) dose. This 
suggests that continuous tumour exposure to lomustine using the high dose 
nanomedicine formulation in a continuous dosing regimen may result in depletion of 
MGMT in tumour cells thereby increasing tumour response to the therapy. 
This indicates that the administration of the high dose lomustine formulation (Q-
LOM; 13 mg kg
-1
) in a dose intense regimen may result in beneficial therapeutic 
outcomes in the chemotherapy of tumours with an unmethylated MGMT gene 
promoter as well as tumours expressing a methylated promoter.  
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The nanomedicine formulation of lomustine (Q-LOM) thus enabled the 
administration of the drug in a dose intense regimen which produced therapeutic and 
survival benefits, producing a mean survival time that is 1.5 times longer than the 
low dose ethanolic treatment group and untreated control mice, while not leading to 
additional toxicity. This formulation therefore has potential as a dose intensification 
therapeutic, in that lomustine may be given at a higher dose and in more frequent 
doses provided it is encapsulated in nanoparticles. This will avoid the usual rest 
periods of 6 – 8 weeks (or longer in some cases), employed in chemotherapy with 
lomustine (Cianfriglia et al. 1980; van den Bent et al. 1998; van den Bent et al. 2006; 
Jakacki et al. 1998). Moreover, dose intensification with lomustine in the past had 
been unsuccessful due to haematologic toxicity which led to dose delays and 
reduction (Caincross et al. 1994), and the overall achievable dose was not different 
from the standard regimen (Jackaki et al. 1998).  
On the contrary, dose intensification with etoposide nanomedicine formulation was 
not feasible using the nanomedicine formulation. There was no therapeutic or 
survival benefit associated with the high dose (7.5 mg kg
-1
) nanomedicine 
formulation of the drug. Firstly, once daily dosing was not achievable with the 
nanomedicine formulation. All the mice in high dose (7.5 mg kg
-1
) nanomedicine 
(High Q-ETOP) treatment group experienced loss of body weight which necessitated 
alteration of the initial planned dosing regimen. The weight loss observed in this 
treatment group necessitated an alteration of the planned consecutive daily dosing 
schedule to allow for rest periods of one or two days (as appropriate, based on body 
weight measurements) between doses. 
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Two out of the five mice in the high dose etoposide nanomedicine (High Q-ETOP; 
7.5 mg kg
-1
) treatment group could receive a total of only 3 doses due to a drop in 
body weight close to 15 % of the initial body weight, which is the severity limit for 
the experiment. Furthermore, the remaining three mice in the group could receive 
only 5 doses, also with days of rest in between due to the loss in body weight 
recorded for the mice. Also, two mice in the low dose nanomedicine (Low Q-ETOP; 
1.5 mg kg
-1
) group could not receive the planned daily doses due to a drop in their 
body weight. The body weight loss recorded could be attributed to etoposide 
treatment related gross toxicity, as weight loss is a known toxic effect associated 
with etoposide therapy (Holm et al. 1996; Hofland et al. 2005). 
Secondly, the mice that had been treated with the high dose nanomedicine 
formulation (High Q-ETOP; 7.5 mg kg
-1
) did not derive a survival benefit from the 
therapy. Mice treated with the high dose nanomedicine formulation had a shorter 
mean survival time (15.6 days) compared to untreated control mice (20.8 days) 
[Figure 2-17]. Moreover, the experiment was terminated as the high dose 
nanomedicine formulation (High Q-ETOP; 7.5 mg kg
-1
) did not yield any therapeutic 
benefit. Two mice in the low dose nanomedicine (Low Q-ETOP; 1.5 mg kg
-1
) 
treatment group were culled prior to reaching the end point of 15 % loss of body 
weight when the experiment was terminated. Thus, the nanomedicine formulation of 
etoposide did not lead to a protection of treated animals from the toxic effects of the 
drug as the mice treated with the high dose etoposide nanomedicine experienced 
gross toxicity while not deriving any survival benefit (Figure 2-17).   
Therefore, in contrast to the high dose lomustine (13 mg kg
-1
) nanomedicine 
formulation that permitted continuous drug administration for 10 consecutive days 
with attendant therapeutic benefit, a high dose etoposide (7.5 mg kg
-1
) nanomedicine 
formulation produced gross toxic effects in mice without providing any therapeutic 
or survival benefit. 
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Chapter 3 Evaluation of Myelosuppressive Effects of Q-LOM 
Formulations 
3.1 Introduction 
Myelosuppression is the major dose limiting toxicity associated with most clinically 
used cytotoxic agents employed in cancer chemotherapy. This puts a restraint on the 
extent of potentially advantageous dose intensification with chemotherapeutic agents 
as it curtails both the dose and frequency of administration (Newlands et al. 1992; 
Peters et al. 1993; Carey 2003; Tolcher et al. 2003; Stupp et al. 2005; Su et al. 2005; 
Chamberlain 2010; Gerber et al. 2007; Combs et al. 2008; Chamberlain and Raizer 
2009). Myelosuppression results from the indiscriminate toxic effects of cytotoxic 
agents on normal cells as well as tumour cells (Maxwell and Maher 1992; Kriegler et 
al. 1994; Raizer 2011) with rapidly proliferating cells such as the haematopoietic 
cells being the most sensitive (Pollak et al. 1989; Kriegler et al. 1994; Çetin et al. 
2000). Toxicity is as a result of obliteration of cycling progenitors in the bone 
marrow which in turn leads to reduced peripheral blood cell count which does not 
recover until there is replenishment by the quiescent progenitors and stem cells 
(Maxwell and Maher 1992; Kriegler et al. 1994; Dale 2002). Also, in patients 
receiving long term adjuvant chemotherapy, there is a risk of permanent damage to 
self-renewal tissues such as the bone marrow. Once damaged, the bone marrow has 
reduced proliferative potential, which constitutes a significant challenge in the event 
of a requirement for the use of further chemotherapy for eradication of gross 
metastasis (Smaaland et al. 2002).  
Neutropenia and thrombocytopenia are two clinically important myelosuppressive 
effects of cytotoxic drugs which can lead to fatal complications, sepsis in the case of 
neutropenia and haemorrhage in the case of thrombocytopenia (Schofield 1986; Dale 
2002; Hitron et al. 2010; McMahon and Kwaan 2012; Lyman et al. 2013). 
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Neutropenia arises as a result of reduction in the number of granulocytes in 
peripheral circulation. As granulocytes are involved in the body’s defence against 
infections, neutropenia puts patients at risk of life threatening infections (Morstyn et 
al. 1988; Lyman et al. 1998; Dale 2002; Crawford et al. 2004). Risk of developing 
infections is determined by the degree as well as the duration of neutropenia (Lyman 
et al. 1998; Crawford et al. 2004). Development of febrile neutropenia necessitates 
hospitalisation and aggressive treatment with intravenous antibiotics as the risk of 
development of septicaemia is increased (Lyman et al. 1998; Crawford et al. 2004). 
Thrombocytopenia arising from reduced platelet counts is also very significant as it 
may lead to thrombotic and bleeding complications. This often makes 
hospitalisations and platelet transfusions necessary as supportive measure in 
chemotherapy (Intile et al. 2009; Hitron et al. 2011; McMahon and Kwaan 2012).  
Chemotherapy induced myelosuppression often leads to the need for dose delays and 
reductions which compromise tumour response and the overall survival of patients 
(Hitron et al. 2011). Measures taken to reduce the extent and duration of 
myelosuppression usually include autologous bone marrow support, such that 
myelosuppression does not determine the maximal tolerated dose (MTD) of a 
chemotherapeutic regimen. The MTD would then be determined by effects of 
chemotherapy on the non-haematopoietic organs. Infusion of committed peripheral 
blood progenitor cells (PBPC) have also been used which results in cells that are 
enriched with large numbers of circulating committed myeloid progenitors (Peters et 
al. 1993). The additional treatments required to combat these myelosuppressive 
effects lead to increased expense, have limited success and may not prevent 
chemotherapy-induced genetic damage to cycling progenitor cells (Intile et al. 2009).  
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The greatest concern in the use of high dose chemotherapy is the duration of 
suppression, that is if the stem cells will recover quickly enough to prevent fatalities 
resulting from sepsis and haemorrhage associated with prolonged neutropenia and 
thrombocytopenia (Schofield 1986; Smaaland et al. 2002).  
This study has demonstrated a potential for dose intensification with lomustine using 
a nanomedicine formulation of the drug without leading to a proportionate increase 
in toxicity.  
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3.2 Materials and methods 
 Materials 3.2.1
3.2.1.1 List of materials 
S/n Material Supplier 
1 Lomustine Sigma  
2 GCPQ Synthesised 
3 Cholesterol Sigma 
4 L- α- Phosphatidyl choline 
(from egg yolk) 
Sigma 
5 Nile red (Bioreagent, suitable 
for fluorescence) 
Sigma 
6 CD45–Vioblue mouse 
antibody 
MACS; Miltenyi Biotech, GmbH, Germany 
7 CD61–APC Mouse and rat 
antibody 
MACS; Miltenyi Biotech 
8 Anti-TER–119 PE mouse 
antibody 
MACS; Miltenyi Biotech 
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S/n Material Supplier 
9 MACSQuant™ Running buffer MACS; Miltenyi Biotech 
10 Dubelcco’s Phosphate buffered 
saline (DPBS) 
Life Technologies 
11 J774A.1 cell line  European Collection of Cell Cultures 
(ECACC); Culture Collections, Public 
Health England, Salisbury, UK 
12 Dulbecco's Modified Eagle's 
Medium (DMEM) (ATCC®  
30-2002™) 
LGC Standards, Teddington, Middlesex, 
UK 
13 Ringer’s Solution Thermo Scientific; Oxoid  
Limited, Basingstoke, Hampshire, UK 
14 Ethanol, Absolute  
(Analytical reagent grade) 
Fisher Scientific, UK,  
 
15 Chloroform (HPLA grade) Fisher Scientific, UK,  
 
16 50 % Dextrose solution AAH Pharmaceuticals 
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S/n Material Supplier 
17 Water for injections (BP) AAH Pharmaceuticals  
18 Fetal bovine serum Labtech International Ltd, Uckfield, 
East Sussex, UK 
19 Phosphate buffered saline (PBS) – 
EDTA 
Lonza Group Ltd, Verviers, Belgium 
20 Glass bottom tissue culture dishes MatTek, Corporation, Ashland,  
MA, USA 
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 Methods 3.2.2
3.2.2.1 Drug treatment for evaluation of myelosuppressive effects of lomustine 
formulations 
Male CD-1 mice (Harlan Laboratories Limited, Derbyshire, UK) housed in plastic 
cages, with a maximum of 5 mice per cage, maintained in standard regulated 
laboratory conditions in the Biological Services Unit (BSU) within the School were 
used for the study. The mice were accommodated in suitable rooms with the 
temperature maintained at about 22 – 25 oC, humidity at 60 % and a 12 – hour light 
(from 07: 00 hours) and dark (from 19: 00 hours) cycle. The mice were acclimatized 
in the BSU for 5 – 7 days before studies commenced. All mice had access to food 
and water ad libitum as soon as they were housed in the BSU and throughout the 
period of study. The study was conducted in accordance with the policies and 
regulations of the Home Office as stipulated in the Animals and Scientific Acts 1986, 
UK, the recommendations of the BSU for the handling and care of laboratory 
animals and with the approval of the ethics committee. 
Lomustine formulations for administration to the mice were prepared as described in 
the preceding chapter (2.2.2.2.1). 
Mice were assigned to one (n = 5) of three groups to receive either the high dose 
formulation (QLOM; 13 mg kg
-1
), the low dose formulation (Lom- ETOH; 1.2 mg 
kg
-1
), or no drug treatment (Control). Mice were administered the appropriate 
formulation by tail vein injection once daily for 10 consecutive days and were 
subsequently sacrificed at pre-determined time points after completion of the dosing 
regimen for analysis of blood parameters. 
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3.2.2.2 Sample collection for analysis of blood parameters 
To obtain blood samples for analysis, mice were administered a terminal dose of 
anaesthetic agent (Euthatal) by intraperitoneal injection and allowed to become fully 
anaesthetised. Once confirmed to be fully under anaesthesia (pinching the hind limb 
with a pair of forceps and eliciting no response), the skin was cut open from the 
abdominal region up to the thoracic region to expose the rib cage. The heart was then 
exposed by carefully cutting open the sternum and blood was withdrawn by cardiac 
puncture. The blood was immediately transferred into an ethylenediaminetetraacetic 
acid (EDTA) treated blood collection tube and mixed to prevent the formation of 
clots. The blood samples were analysed using an automated clinical haemocytometer 
for the determination of cell counts for different blood components. A portion of the 
samples were further analysed by flow cytometry for the determination of absolute 
cell counts.  
3.2.2.3 Preparation and analysis of blood samples by flow cytometry 
Absolute blood cell counts were determined by staining blood samples with mouse 
specific antibodies for the different blood components (leucocytes, erythrocytes and 
platelets). Blood samples were stained with CD45- Vioblue for of leucocyte count 
(for white blood cells), Anti-TER- 119 PE for erythrocyte count (for red blood cells) 
and CD61- APC for platelet count. Blood sample for each mouse (60 µL) was 
transferred into a 5 ml FACS tube and 10 µL of the appropriate antibody was added. 
The mixture was incubated at 4 
o
C (refrigerator) for 10 minutes, after which 1 ml of 
MACS Quant running buffer was immediately added to stop staining (prevent over 
staining). Further dilution of the samples was then made to achieve the required 
dilution for analysis. For erythrocytes and platelets, a final sample dilution of 1 in 
1000 was made while a dilution of 1 in 20 was made for leucocytes. The samples 
were then analysed on the flow cytometer for determination of the cell counts for 
each blood component. 
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3.2.2.4 Cell uptake studies 
3.2.2.4.1 Preparation and characterisation of Nile red loaded nanoparticles 
3.2.2.4.1.1 Preparation of Nile red loaded GCPQ (GCPQ NR) formulation 
GCPQ NR formulation for cell treatment for flow cytometry analysis was prepared 
by probe sonicating Nile red (50 µg mL
-1
) and GCPQ (1 mg mL
-1
) in 5 % 
w
/v 
dextrose solution on ice for 30 minutes. This was followed by centrifugation at 1,000 
g for 30 minutes at 4
o
 C to eliminate free precipitated dye. The supernatant was then 
carefully collected immediately after centrifugation. A GCPQ NR formulation for 
cell treatment and for confocal microscopy imaging was prepared by adding 100 µL 
of a solution of Nile red (100 µg ml 
-1
) in ethanol to a dispersion of GCPQ (1 mg mL
-
1
), in 5 % 
w
/v dextrose solution with free precipitated dye removed as described 
above. 
3.2.2.4.1.2 Preparation of Nile red loaded liposome (Liposome NR) formulation 
Liposome NR formulations for cell treatment for flow cytometry analysis were 
prepared as described by McPhail et al. 2000, with some modifications. Briefly, Nile 
red (50 µg mL
-1
), egg phosphatidylcholine (3 mg mL
-1
) and cholesterol (1.4 mg mL
-
1
) were dissolved in chloroform (10 mL) and the resulting solution evaporated to 
dryness at 40° C using a rotary evaporator. The thin lipid film obtained was then 
hydrated with 5 % 
w
/v dextrose solution (5 mL) by shaking for 30 min at room 
temperature to yield a homogenous dispersion of egg phosphatidylcholine liposomes. 
This dispersion was subsequently probe sonicated on ice for 15 minutes to yield nano 
sized liposome formulation. This formulation was then centrifuged at 1,000 g for 30 
minutes at 4
o
 C to eliminate precipitated free dye and the supernatant was carefully 
collected immediately after centrifugation.  
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A Liposome NR formulation for cell treatment and for confocal microscopy imaging 
was prepared by adding 100 µL of a solution of Nile red (100 µg mL 
-1
) in 
chloroform to egg phosphatidylcholine (3 mg mL
-1
) and cholesterol (1.4 mg mL
-1
) 
dissolved in chloroform (10 mL). The resulting solution was evaporated to dryness at 
40° C using a rotary evaporator (IKA
®
 HB 10 Digital, IKA
®
-Werke GmbH & Co. 
KG, Staufen, Germany). The thin lipid film obtained was then hydrated with 5 % w/v 
dextrose solution (5 mL) by shaking for 30 min at room temperature to yield a 
homogenous dispersion of egg phosphatidylcholine liposomes. This dispersion was 
subsequently probe sonicated on ice for 15 minutes to yield nano sized liposome 
formulation.  Precipitated free dye was removed as described above.  
The concentration of Nile red (fluorescence) in both GCPQ NR and Liposome NR 
were adjusted to give similar concentrations in both formulations before cell 
treatment. 
3.2.2.4.1.3 Characterisation of Nile red loaded nanoparticles 
A calibration curve for determination of Nile red content of nanoparticle 
formulations was prepared by measuring the fluorescence intensity of serial dilutions 
of Nile red in methanol using a fluorescence spectrometer (LS – 50 B, Perkin Elmer 
Inc, USA) with FL WinLab (Perkin Elmer Inc, USA) software. The equation of the 
line produced by plotting the fluorescence intensity versus Nile red concentration 
was used to determine the concentration (as a measure of intensity) of Nile red in 
GCPQ and Liposome NR formulations.  
To determine the fluorescence intensity, hence the concentration of Nile red in 
GCPQ NR and Liposome NR formulations, the formulations were diluted 1 in 10 
with methanol and the Nile red intensity was then measured using the fluorimeter. 
The fluorescence intensity of the formulations was adjusted by diluting with 5 % 
w
/v 
dextrose solution so that both GCPQ NR and Liposome NR formulations had similar 
fluorescence intensities prior to cell treatment. 
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The Nile red loaded nanoparticle (GCPQ NR and Liposome NR) formulations were 
characterised using TEM and DLS to determine particle size.  
3.2.2.4.2 Evaluation of uptake of Nile red loaded nanoparticles in macrophage 
(J774A. 1) cell line  
J774A. 1 cells were cultured in Dulbecco's Modified Eagle's Medium (ATCC- 
DMEM) modified to contain 4 mM L-glutamine, 4500 mg/L glucose, 1 mM sodium 
pyruvate, and 1500 mg/L sodium bicarbonate,  and supplemented with 10 % fetal 
bovine serum. The cells were maintained in culture for at least 14 days before they 
were used for uptake experiments. Uptake of Nile red loaded nanoparticles in  
J774A. 1 cells was assessed quantitatively by flow cytometry and qualitatively by 
confocal microscopy. 
For flow cytometry and confocal microscopy imaging, cells were seeded and 
prepared for analysis according to methods described by Fernado et al. 2010 and 
Kim et al. 2012 with some modifications.  
3.2.2.4.2.1 Evaluation of uptake of Nile red loaded nanoparticles in J774A. 1 
cell line by flow cytometry 
J774A. 1 cells were seeded in 6 – well plates at a density of 300, 000 cells / well 
(working volume of 2 mL / well) and incubated for 72 hours before treatment with 
200 µL of either GCPQ NR or Liposome NR formulation, with some wells left 
untreated as control. Cells were treated for predetermined time periods of 5 minutes, 
10 minutes, 30 minutes, 1 hour, 2 hours, or 4 hours. Cells were then washed 3 times 
with DPBS solution [calcium chloride anhydrous (CaCl2; 0.9 mM), magnesium 
chloride (MgCl2.6H2O; 0.5 mM), potassium chloride (KCl; 2.7 mM, potassium 
phosphate monobasic (KH2PO4; 1.5 mM), sodium chloride (NaCl 137.9 mM), 
sodium phosphate dibasic (Na2HPO4.7H2O; 8.1 mM), pH 7.0 – 7.2] (2 mL / well) 
and then incubated in cold PBS – EDTA [KH2PO4 (1.9 mM), NaCl (138.9 mM), 
Na2HPO4.2H2O (6.6 mM), Titriplex III (EDTA Na2; 1.4 mM), lithium chloride 
(LiCl; 10.1 mM); pH 7.5)] (1 mL / well) for 1 – 2 minutes.  
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Cells were then harvested by gently scraping and pipetting the cell suspension which 
was then centrifuged and resuspended in cold Ringer solution [Sodium chloride (38.5 
mM), Potassium chloride (1.4 nM), Calcium chloride hexahydrate (0.5 mM), Sodium 
bicarbonate (0.6 mM); pH 7]. Nanoparticle uptake was quantified as determined by 
Nile red fluorescence detection using the flow cytometer (MACSQuant Analyzer, 
Miltenyi Biotec, Germany). A total of 20, 000 cells (events) were measured in each 
sample within the Nile red positive channel. The experiment was carried out in 
quadruplet for each formulation and the untreated control cells. 
3.2.2.4.2.2 Evaluation of uptake of Nile red loaded nanoparticles in J774A.1 cell 
line by confocal microscopy 
For confocal microscopy imaging, the cells were seeded in glass (thickness no. 1.0 
cover slip) bottom 35 mm tissue poly–d–lysine coated tissue culture dishes at a 
density of 75,000 cells / dish and incubated for 48 hours. Cell uptake of the Nile red 
formulations was then monitored in a time lapse experiment set up on a Zeiss LSM 
710 laser scanning microscopy imaging unit (LASOS Laserteknik GmbH, Carl Zeiss 
Promenade 10). Images were captured first at 3 minutes after treatment with the 
appropriate Nile red formulation and subsequently after every 5 minutes. The images 
were analysed using Zen 2009 software.  
3.2.2.4.3 Statistical analysis 
Statistical analysis was performed using Minitab
®
 16 software (Minitab, Inc., 
Pennsylvania, USA). The treatment groups were compared two at a time for each 
time point using ANOVA followed by Tukey post hoc test. The significance level 
was set at p < 0.05. Error bars represent the standard deviations of the mean values 
for each group. 
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3.3 Results 
 Drug treatment for evaluation of myelosuppressive effects of lomustine 3.3.1
formulations 
All mice received the total number (10) of doses planned for the study on time 
without any necessity for dose delay or reduction in the any of the treatment groups. 
There was no manifestation of gross toxic symptoms by animals across the treatment 
groups as weight measurement did not reveal unacceptable reduction in body weight 
in the treated animals (Figure 3-1 A – E) 
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Figure 3-1: Weight measurement for animals culled for analysis of blood samples at A: Day 1; 
B: Day 7; C: Day 14; D: Day 21 and E: Day 30 after completion of 10 consecutive daily doses of 
lomustine formulations 
Key: Blue arrow: Treatment start date; Red Arrow: Treatment end date. Weights were recorded 
from commencement of dosing until mice were culled for collection of blood samples for 
analysis. Days 1, 7, 14, 21 and 30 correspond to number of days following completion of 10 
consecutive daily doses of lomustine formulations. 
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 Analysis of blood samples using the haemocytometer 3.3.2
Analysis of blood samples after completion of 10 consecutive daily doses for 
lomustine formulations treated and untreated control animals for full blood cell 
counts revealed no effect of either the higher dose (13 mg kg
-1
) nanoparticle 
lomustine formulation or the low dose (1.2 mg kg
-1
) ethanolic formulation of 
lomustine on the white blood cell counts of treated animals (Figure 3-2 A). 
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Figure 3-2: Full blood count parameters for treated (lomustine formulations) and control 
(untreated) animals 
Days 1, 7, 14, 21 and 30 correspond to number of days following completion of 10 consecutive 
daily doses of lomustine formulations. 
Key: : Significantly different p < 0.05 (One-way ANOVA with Tukey post hoc test) 
 
Conversely, there was a transient drop in the red blood cell counts of animals that 
received the high dose nanoparticle formulation which had recovered by day 7. 
However, there was a persistent drop in haemoglobin levels for animals in this 
treatment group and recovery was confirmed after 21 days (Figure 3-2 C). 
Also, there was a reduction in platelet counts for both high dose (13 mg kg
-1
) 
nanoparticle formulation and low dose (1.2mg kg
-1
) ethanolic formulation treated 
groups of animals. The low dose formulation treated animals recovered after 7 days 
while the high dose formulation treated animals recovered after 14 days (Figure 3-2 
D). 
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 Analysis of blood samples by flow cytometry 3.3.3
Flow cytometry analysis of blood samples for determination of the counts for 
different cell populations in the whole blood of the treated and untreated animals 
revealed no effect of either formulation on the leucocyte and erythrocyte counts of 
the animals. On the other hand, the high dose formulation treated animals 
experienced a transient drop in their platelet counts which had recovered by Day 7 
(Figure 3-3 C). 
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Figure 3-3: Blood cell counts for determination of leucocytes, erythrocytes and platelets counts 
for treated (lomustine formulations) and control (untreated) animals using a flow cytometer  
Days 1, 7, and 21 correspond to number of days following completion of 10 consecutive daily 
doses of lomustine formulations. 
Key: : Significantly different p < 0.05 (One-way ANOVA with Tukey post hoc test). 
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 Evaluation of uptake of Nile red loaded nanoparticles in macrophage 3.3.4
(J774A.1) cell line 
3.3.4.1 Preparation and characterisation of Nile red loaded nanoparticles 
3.3.4.1.1 Determination of Nile red content of nanoparticles 
The calibration curve for Nile red fluorescence intensity versus concentration yielded 
a straight line with the equation y = 247.18x + 3.348 (R
2
 = 0.9991). This calibration 
curve was used to determine the concentration of Nile red encapsulated within the 
nanoparticles prepared (Figure 3-4) 
 
 
Figure 3-4: Calibration curve for Nile red 
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3.3.4.1.2 Determination of particle size for Nile red loaded nanoparticles  
TEM images for GCPQ NR formulations showed nanoparticles in the size range 100 
– 370 nm in diameter (Figure 3-5) 
 
Figure 3-5: TEM micrograph for GCPQ NR formulation 
Nile red (50 µg mL
-1
) with GCPQ (1 mg mL
-1
) in 5 % 
w
/v dextrose solution, vortexed for 30 
seconds, then probe sonicated (QSonica, Connecticut, USA) on ice for 30 minutes at amplitude 
25. Particle size measurements are as generated by the AMT digital camera software. 
 
 
 
 142 
 
Nanoparticle based strategies for the treatment of Glioblastoma 
Particle size measurements by DLS yielded an average size of 211.6 nm with 
polydispersity index of 0.6 (Figure 3-6 A – C). 
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Figure 3-6: DLS graphs showing particle size distribution for GCPQ NR by A: intensity; B: 
number; C: volume 
Nile red (50 µg mL
-1
) with GCPQ (1 mg mL
-1
) in 5 % w/v dextrose solution, vortexed for 
30seconds, then probe sonicated (QSonica, Connecticut, USA) on ice for 30 minutes at amplitude 
25.  
 
 
 
 
 
 
 
 
C 
 144 
 
Nanoparticle based strategies for the treatment of Glioblastoma 
TEM micrograph for Liposome NR formulations on the other hand revealed particles 
of 51.5 – 147.5 nm in diameter (Figure 3-7).  
 
Figure 3-7: TEM micrograph for Liposome NR formulation 
Nile red (50 µg mL
-1
) with egg phosphatidylcholine (3 mg mL
-1
) and cholesterol (1.4 mg mL
-1
) 
in 5 % w/v dextrose solution. Probe sonicated (QSonica, Connecticut, USA) on ice for 15 
minutes at amplitude 25 after liposome preparation. Particle size measurements are as generated 
by the AMT digital camera software. 
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DLS size measurements for this formulation revealed an average size of 160.5 nm 
with polydispersity index of 0.2 (Figure 3-8 A – C). 
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Figure 3-8: DLS graphs showing particle size distribution for Liposome NR by A: intensity; B: 
number; C: volume 
Nile red (50 µg mL
-1
) with egg phosphatidylcholine (3 mg mL
-1
) and cholesterol (1.4 mg mL
-1
) 
in 5 % w/v dextrose solution. Probe sonicated (QSonica, Connecticut, USA) on ice for 15 
minutes at amplitude 25 after liposome preparation. 
 
 
 
 
 
 
 
 
 
C 
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3.3.4.2 Evaluation of uptake of Nile red loaded nanoparticles in J774A.1 cell 
line by flow cytometry  
Analysis of the uptake of Nile red loaded nanoparticles in macrophage cell line 
revealed a more rapid uptake of the liposome formulation (Liposome NR) than the 
GCPQ formulation (Figure 3-9). 
 
Figure 3-9: Flow cytometry analysis of the uptake of GCPQ NR and Liposome NR in J774A.1 
cells over time 
 [Nile red (50 µg mL
-1
) with GCPQ (1 mg mL
-1
) in 5 % w/v dextrose solution, vortexed for 
30seconds, then probe sonicated (QSonica, Connecticut, USA) on ice for 30 minutes at amplitude 
25] and Liposome NR [Nile red (50 µg mL
-1
) with egg phosphatidylcholine (3 mg mL
-1
) and 
cholesterol (1.4 mg mL
-1
) in 5 % w/v dextrose solution. Probe sonicated (QSonica, Connecticut, 
USA) on ice for 15 minutes at amplitude 25 after liposome preparation] particles in J774A.1 cells 
over time. 
Key:  : Significantly different from Nile red loaded GCPQ particles p < 0.01 (One-way 
ANOVA with Tukey post hoc test). 
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Time Control 
(n = 4) 
Liposome NR 
(n = 4) 
GCPQ NR 
(n = 4) 
Mean (%) Standard 
deviation 
Mean (%) Standard 
deviation 
Mean (%) Standard 
deviation 
5 mins 0.01 0.01 64.46 10.58 12.41 4.96 
10 mins 0 0 89.34 2.71 23.70 2.00 
30 mins 0.01 0.01 96.15 1.82 48.40 5.55 
1 hr 0 0 98.72 0.47 70.99 3.59 
2 hrs 0 0 98.31 0.93 76.76 3.38 
4 hrs 0 0 95.92 1.65 76.73 3.28 
 
Table 3-1: Uptake of GCPQ NR and Liposome NR in J774A.1 cells over time 
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3.3.4.3 Assessment of the uptake of Nile red loaded nanoparticles in J774A. 1 
cell line by confocal microscopy imaging 
Confocal microscopy images in time lapse experiments for both GCPQ NR and 
Liposome NR treated cells showed intracellular location of the nanoparticles from 
the earliest time point in which images were captured (Figure 3-10).  
 
 
 
 
 
 
Figure 3-10: Confocal microscopy images showing uptake of GCPQ NR and Liposome NR in 
J774A.1 cells over time 
 
 
 
GCPQ NR 3 minutes post treatment GCPQ NR 8 minutes post treatment GCPQ NR 18 minutes post treatment 
Liposome NR 3 minutes post treatment Liposome NR 8 minutes post treatment Liposome NR 18 minutes post treatment 
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3.4 Discussion and conclusions 
Chemotherapy induced myelosuppression represents a great limitation to the extent 
of potentially beneficial dose intensification with most clinically used cytotoxic 
agents (Tolcher et al. 2003; Su et al. 2005; Tosoni et al. 2006; Gerber et al. 2007) 
although increasing the dose intensity leads to an increase in response rates (Boesen 
et al. 1994; Crawford et al. 2004). 
In this study, the effect of continuous exposure to high dose chemotherapy with 
GCPQ based nanomedicine formulation of lomustine on the haemopoietic system 
was evaluated. Due to the myelosuppressive effects of lomustine, chemotherapy with 
the drug is usually associated with rest periods to allow for recovery of patients 
haematological parameters (Cianfriglia et al. 1980; van den Bent et al. 1998; van den 
Bent et al. 2006; Jakacki et al. 1998). 
All doses were administered as scheduled without the need for dosing delays or 
reduction throughout the study. The animals were monitored for any signs of ill 
health or weight loss throughout the period of study. Weight measurements revealed 
that the high dose (13 mg kg
-1
) nanomedicine formulation was well tolerated by the 
animals that received this formulation (Figure 3-1). An excessive weight loss (≥ 15 
% of initial body weight; severity limit for the study) would have been an indication 
of toxicity and would have necessitated dosing delay or outright disruption, as weight 
loss is a side effect of lomustine therapy (van den Bent et al. 2003). Thus the animals 
that received the nanomedicine formulation administered at a dose 10 times higher 
than the ethanolic formulation did not manifest gross toxic effects compared to the 
latter. 
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Analysis of blood samples for determination of blood cell counts using an automated 
clinical haemocytometer showed no effect of either the low dose or high dose 
formulations on the white blood cells of treated animals (Figure 3-2 A). Thus, 
administration of a high dose of lomustine using the nanomedicine formulation in a 
continuous daily dosing regimen did not induce a suppression of the white blood 
cells in the treated animals. This is could be of clinical significance as neutropenia 
has been considered to be the commonest and most important toxicity arising from 
chemotherapy with cytotoxic agents (Dale 2002; Crawford et al. 2004). Neutropenia 
is usually the first haematologic toxicity to arise from cytotoxic chemotherapy due to 
the short (6 – 14 hours) life span of granulocytes (Nathan 1987). Neutropenia is of 
great clinical importance as it poses the risk of predisposing patients to infections 
which may lead to sepsis which may be potentially fatal (Lyman et al. 1998; Dale 
2002).  
The platelets are the next cell type to be affected after the granulocytes due to their 
life span of 7 – 10 days in humans (4 – 5 days in mice). This is reflected in the 
current study as haemocytometer cell counts showed that all animals in both the low 
and high dose treatment groups experienced a significant reduction in their platelet 
counts compared to untreated controls at Day 7 following completion of the dosing 
regimen (Figure 3-2 D). The platelet counts on this day represent the nadir for both 
treatment groups. Although the high dose treatment group had a lower nadir value 
than the low dose group, there was no significant difference between the platelet 
counts for both groups. The platelet counts for the low dose group had recovered by 
day 14, while for the high dose group the counts were recovered by day 21 (Figure 
3-2 D). Reduced platelet counts are of clinical significance as chemotherapy induced 
thrombocytopenia leads to an increase in the risk of bleeding complications which 
may necessitate treatment delays or dose reductions. It also leads to the need for 
platelet transfusions and hospitalisation (Gerber et al. 2007; Intile et al. 2009; Hitron 
et al. 2011; McMahon and Kwaan 2012).  
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Toxic effects of chemotherapy on red blood cells are the last to be observed owing to 
their relatively longer life span of 100 – 120 days (Smaaland et al. 2002). In this 
study, there was a transient drop in red blood cell counts in animals that received the 
high dose nanoparticle formulation with a recovery by day 7 after dosing had been 
completed (Figure 3-2 B). On the other hand, there was a persistent drop in 
haemoglobin levels of this group of animals with recovery after 21 days (Figure 3-2 
C). Haemoglobin synthesis (in red blood cells) begins at an early stage in the 
formation and differentiation of the red blood cells and by the time they leave the 
bone marrow (as reticulocytes), they continue to form only minute quantities of 
haemoglobin for one or two days until they become matured red blood cells. Thus 
red blood cells at maturation are already carrying their maximum haemoglobin 
content (Hall 2011). Therefore, since the red blood cell counts were recovered by day 
7 (Figure 3-2 B), the persistent drop in haemoglobin counts recorded may not 
necessarily be clinically significant. Moreover, the haemoglobin levels were at least 
90 % of the cell counts recorded for the control animals by day 7 and onwards after 
dosing had been completed.   
On the other hand, analysis of blood cell counts by flow cytometry using cell type 
specific antibodies showed a significant drop in the platelet counts of high dose 
formulation treated animals only on Day 1 (Figure 3-3 C) while both leucocyte and 
erythrocyte counts were unaffected. Although the platelet counts seemed not to be 
fully recovered by day 7, there was no statistical difference in the platelet counts in 
this group compared to the low dose group (p = 0.541) and the untreated controls (p 
= 0.065). This may be an indication of a quicker recovery of these cell counts than 
have been reflected by counts determined using the clinical haemocytometer. 
However, further studies are required to confirm this. 
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Nitrosoureas including lomustine are known to produce cumulative and delayed 
myelosuppression, producing nadir counts later than most other cytotoxic agents 
(Pratt et al. 1994; Jakacki et al. 1998; Smaaland et al. 2002). This study has 
demonstrated an alteration in the expected pattern of myelosuppression with 
lomustine. The animals were seen to recover from the myelosuppressive effects of 
the high dose nanomedicine formulation rather than experience delayed effects as 
would be expected from a conventional formulation of the drug. This is demonstrated 
in weight measurements (Figure 3-1 A – E) and the data obtained by analysis of the 
haematologic parameters (Figure 3-2 A – D). For instance, mice in the later time 
points (Days 14 – 30) would be expected to experience progressive weight loss and 
lower blood cell counts than those in the earlier time points due to delayed 
myelosuppression. On the contrary, in both sets of mice treated with the high dose 
(13 mg kg
-1
) nanomedicine and the low dose (1.2 mg kg
-1
) ethanolic formulation, 
there was no indication of increasing myelosuppressive effects of the drug 
(lomustine). The mice showed an increase in their body weights (Figure 3-1 A – E; 
Appendix I A – E) and recovery of blood cell counts (Figure 3-2 A – D) with time 
after dosing had been completed.  
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Furthermore, cellular uptake of Nile red loaded nanoparticles was studied in J774A.1 
(murine macrophage cell line) cells. The uptake of GCPQ nanoparticles using GCPQ 
NR in the J774A.1 cells was studied as a surrogate for the pattern of uptake of the 
nanoparticles in vivo by macrophages. The uptake of GCPQ NR nanoparticles by 
J774A.1 cells was compared to that of Nile red loaded liposome nanoparticles 
(Liposome NR). Liposomes are one of the most widely studied carriers for targeted 
delivery of materials to macrophages (Ahsan et al. 2002). Therefore, Liposome NR 
was a suitable nanoparticle system for comparison with GCPQ NR.   
Flow cytometry analysis of the uptake of Nile red loaded nanoparticles reveal a more 
rapid uptake of Liposome NR than the GCPQ NR formulations. At the earliest time 
(5 min) point recorded, the cell uptake of the liposome particles was greater than 60 
% of the total number of cells. This is in contrast to GCPQ particles for which there 
was only 12 % uptake at the same time point. At 10 minutes post treatment, uptake 
of liposome particles was already greater than 80 % and had become saturated (96.88 
%) after 30 minutes. For GCPQ particles on the other hand, uptake after 30 mins was 
just approaching 50 % and even after 4 hours was just getting to 80 % (Figure 3-9). 
Confocal microscopy images (Figure 3-10) confirmed the cytoplasmic localisation of 
the Nile red loaded particles. Semi-quantitative assessment of fluorescence intensity 
in the cells by ImageJ (Windows) software was done in an attempt to determine a 
time-based increase in nanoparticle uptake by the cells. The analysis showed an 
initial increase in the calculated mean intensity in the early time points (3 minutes to 
8 minutes) for both GCPQ NR and Liposome NR. 
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Subsequently, there was no further increase as later time points showed a decrease 
rather than an increase in the fluorescence intensity (Appendix II A, B). This may be 
attributed to quenching of the fluorescence of the dye or bleaching due to the 
exposure of the samples to the laser. Moreover, images captured at the later time 
points showed less fluorescence (reduced brightness) than the earlier images 
(Appendix III A, B). However, this analysis is interpreted with caution as the current 
experiment was not specifically set up to do this semi-quantitative analysis. 
Therefore, although the confocal microscopy images did not show a time-based 
increase in nanoparticle uptake, they confirmed that the fluorescence signal measured 
by flow cytometry was due to nanoparticles that had been taken up into the cells. 
J774A.1 cells exhibit many properties of macrophage cells (Fernando et al. 2010) 
and thus permit the study of the uptake of nanoparticles by macrophages (Fernando 
et al. 2010; Missirlis and Hubbell 2010). 
In a study, the in vitro uptake of amphiphilic (polymeric) hydrogel nanoparticles 
formulated from PEG and Pluronic
®
 F127 was investigated. Flow cytometry data 
showed a time (and dose) dependent increase of fluorescence in the J774A.1 cells, 
which could be correlated with nanoparticle association over time. Also, the uptake 
of the fluorescently (fluorescein) labelled amphiphilic hydrogel nanoparticles by 
J774A.1 cells was compared to that of commercial anionic Fluospheres
®
 of similar 
average size. Uptake of the amphiphilic hydrogel nanoparticles was greatly reduced 
compared to that of the commercial anionic Fluospheres
®
. After 4 hours of 
incubation of nanoparticles with J774A.1 cells, fluorescence measurements in 
buffered cell lysates revealed a 50-fold higher association of the commercial anionic 
Fluospheres
®
 with the cells compared to the amphiphilic hydrogel nanoparticles 
(Missirlis and Hubbell 2010).  
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Macrophages abound in many tissues including the Kupffer cells of the liver, bone 
marrow, brain, lungs, spleen, and guts and are involved in the uptake and subsequent 
clearance of nanoparticles from systemic circulation (Leu et al. 1984; Moghimi et al. 
2001; Chellata et al. 2005; Owens and Peppas 2006). 
Haematopoietic stem cells (HSCs), which produce all the necessary cells for 
replenishing the blood and immune systems are known to reside in the bone marrow 
which is the preferred site for haematopoiesis in adults (Chow et al. 2011; Winkler et 
al. 2010). The functions of the HSCs is maintained under strictly controlled 
processes to sustain a constant number of the different blood cell types (red blood 
cells, leukocytes and platelets) in the circulation (Winkler et al. 2010). Macrophages 
have been identified as a constituent part of the haematopoietic microenvironment 
(Mori et al. 1990). In particular, macrophages play an important role in 
erythropoiesis as they are have been found to form part of the erythroblastic islands, 
which are specialised microenvironments where mammalian erythrocytes proliferate 
and differentiate. Erythroblastic islands comprise a central (“nurse”) macrophage 
surrounded by erythroblasts at different stages of maturation. The erythroblasts are 
connected to the central macrophage through cytoplasmic protrusions from the 
macrophage and the cell interaction at the erythroblastic island is crucial for both 
early and late stages of erythroid maturation (Manwani et al. 2008).   
 Also, some recent studies have demonstrated the significance of bone marrow 
macrophages in the haemostasis of red blood cells (Chow et al. 2013; Ramos et al. 
2013). In their studies, both groups of workers (separately) depleted macrophages 
(CD 169
+
) in adult mice. 
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The data from both groups showed that macrophage depletion in the steady state did 
not produce significant anaemia. However, both studies reported that in the presence 
of anaemia, macrophage depleted mice showed delayed haematocrit recovery and 
reticulocytosis compared to mice that did not have macrophage depletion (Chow et 
al. 2013; Ramos et al. 2013). Also, the studies by Chow and co-workers showed that 
sustained (3 – 4 weeks) macrophage depletion in the steady state resulted in 
decreased serum iron concentration, transferrin saturation, mean corpuscular 
haemoglobin and reticulocyte haemoglobin content. Their studies also showed that 
depletion of the macrophages was accompanied by delayed recovery of erythroblast 
and peripheral erythrocyte following challenge with a myeloablative agent (5-
fluorouracil) (Chow et al. 2013). In addition, Ramos and co-workers showed that 
there was reduced erythroid expansion in the bone marrow and spleen after 
phlebotomy in macrophage depleted mice, compared to controls. Based on their 
studies, they reiterated that although iron is crucial in sustaining stress erythropoiesis, 
the pathways triggered by macrophages are quantitatively important in the 
erythropoietic response after phlebotomy-induced anaemia (Ramos et al. 2013). 
Furthermore, bone marrow macrophages have been shown to be involved in 
maintaining the HSC niche. A study by Mori and co-workers had previously shown 
that some bone marrow resident macrophages stained positively for anti-Forssman 
glycosphingolipid antibody which is known to be positive for resident macrophages 
of hematopoietic foci and negative for monocytes, peritoneal macrophages, Kupffer 
cells and macrophages derived from granulocyte-macrophage colony forming cells. 
Based on their findings, they suggested that bone marrow resident macrophages may 
have a role in haematopoiesis (Mori et al. 1990).  
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Also, more recent studies have implicated bone marrow macrophages in promoting 
the retention of HSCs through interaction with some Nestin expressing cells in the 
niche (Chow et al. 2011), and depletion of bone marrow macrophages was found to 
result in mobilisation of HSCs into the blood (Winkler et al. 2010; Chow et al. 2011). 
The pattern of uptake of GCPQ nanoparticles by macrophage cells has not been 
previously reported. Thus, this in vitro study elucidated the fate of GCPQ 
nanoparticles when exposed to macrophage cells, which could be an indication of 
what would be expected upon in vivo administration of GCPQ nanoparticles. The 
most clinically important dose limiting toxicity for cytotoxic drugs including 
lomustine is myelosuppression involving bone marrow cells which is known to be 
populated by macrophages. Therefore, the relatively low toxicity observed following 
administration of the high dose lomustine (13 mg kg
-1
) nanoparticle formulation in 
may be due to the low and slow uptake of the formulation by the bone marrow. 
 The work by Chow et al. (2013) showed that following myeloablative therapy in the 
presence of macrophage depletion, there was delayed recovery of peripheral 
erythrocytes and decreased reticulocyte haemoglobin content. In this study, it was 
observed that there was a persistent drop in the haemoglobin levels of mice that were 
treated with the high dose nanomedicine (Q-LOM) formulation, with recovery after 
21 days (Figure 3-2 C). This would have suggested that the slow recovery of the 
haemoglobin levels was possibly an effect of the drug formulation on the bone 
marrow macrophages of the treated mice, leading to additional toxic effects on the 
haemoglobin of the treated mice. However, the red blood cells of the treated mice 
were recovered by day 7 after dosing was completed (Figure 3-2 B). Also, the 
haemoglobin levels recorded at all the time points were at least 90 % of the levels 
recorded for untreated control mice. Taken together, these points reinforce the 
possibility that the observed drop in haemoglobin levels may not be clinically 
significant.  
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Figure 3-11: Schematic showing macrophage uptake resulting in blood cells exposure to 
myeloablative agent 
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In addition, it has been previously shown that chloroethylnitrosoureas with glucose 
carriers produced reduced myelosuppressive effects; particularly, they did not 
produce significant depression in peripheral neutrophil count in mice when 
administered at an LD10 dose (Anderson et al. 1975; Panasci et al. 1977). Thus, the 
presence of the sugar moieties in the GCPQ backbone may also have contributed to 
the relatively low myelosuppressive effects of the high dose nanoparticle formulation 
of lomustine employed in this study. Moreover, it has been previously shown 
(Lalatsa et al. 2012a) in the distribution kinetics of GCPQ nanoparticles following 
intravenous administration that the particles do not accumulate to an appreciable 
extent in the liver and spleen and were not detected in the lungs and heart. This 
distribution pattern exhibited by GCPQ nanoparticles suggests that GCPQ particles 
(Lalatsa et al. 2012a) unlike other particulate systems and other polymeric 
nanoparticles like liposomes seem to avoid the reticuloendothelial system (Moghimi 
et al. 2001; Vauther et al. 2003). 
Thus, the results of this study indicates that the administration of the cytotoxic drug 
lomustine using a GCPQ nanoparticle based formulation leads to a reduction in the 
myelosuppressive effects of the drug by changing the mode of tissue or organ 
distribution of this drug. This has permitted the administration of the drug at a much 
higher dose in a continuous manner. This is potentially beneficial for the 
administration of the drug in a dose intense manner which would lead to greater 
therapeutic benefits while avoiding a commensurate increase in toxic effects. 
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Chapter 4 Synthesis and Characterisation of Self-assembling 
Peptide Amphiphiles 
4.1 Introduction 
The optimal therapy of glioblastoma as well as other intracranial neoplasia is still 
very much an enigma as there still exixts a great need for the development of more 
effective therapeutic agents (Chamberlain 2010; Agarwal et al. 2011a; Raizer 2011; 
Malmström et al. 2012). A number of small molecule therapeutics has been clinically 
employed in the chemotherapy of brain tumours with varying degrees of sucess. 
However, their usefulness is greatly limited by their myelosuppressive side effects 
(Carey 2003; Chamberlain 2010). Also, in spite of tremendous research efforts up till 
the present time, which has resulted in a better understanding of the molecular basis 
of glioblastoma, as well as the discovery and introduction of various targeted 
therapies, advancement is far from rapid (Olar and Adalpe 2014). Thus, this leaves a 
lot to be desired as far as a cure or even optimal management is concerned. In light 
of this, it is imperative to exploit all possible avenues for the development of novel 
therapies aimed at the effective treatment of glioblastoma and other intracranial 
tumours.  
Therefore, this chapter is aimed at the development of peptide-based molecules as 
potential candidates for application in the delivery of therapeutic molecules to the 
brain for the treatment of intracranial tumours. This aim will be achieved through the 
synthesis and characterisation of three self-assembling peptide amphiphiles (PAs). 
Two of these PAs were designed to be potential drug delivery systems for anti-
glioma agents. The third PA is an analogue of a therapeutic peptide designed as a 
potential bio-therapeutic agent for the treatment of intracranial tumours. 
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4.2 Peptides and proteins 
Peptides are molecules comprising amino acids covalently linked through the 
formation of an amide bond and may vary in size from 2 amino acids (dipeptide) to 
high molecular weight proteins (Pardridge 1991; Audie and Boyd 2010) containing 
up to 100 or more amino acid residues, termed polypeptides (Koolman and Roehm 
2005). The term peptide is usually applied to molecules comprising 50 amino acid 
residues or less (Sato et al. 2006; Watt 2006; McGregor 2008; van der Walle and 
Olejnik 2011) while larger molecules are referred to as proteins (van der Walle and 
Olejnik 2011). However, there is no unanimous agreement on the definition of terms 
for the two categories as there are borderline molecules such as insulin (51 amino 
acid residues) which is usually regarded as a peptide but is referred to as a protein by 
others (van der Walle and Olejnik 2011).  
Peptides and proteins have been implicated in many pathological conditions 
including but not limited to those of the central nervous system. For instance, insulin 
resistance resulting from defective expression and dysfunctions in insulin signalling 
pathways is implicated in type 2 diabetes and cardiovascular disease (Sasso et al. 
2004; Neeland et al. 2012; Henriksen and Prasannarong 2013). Similarly, the β-
amyloid polypeptide with diphenylalanine peptide as the core recognition motif is 
implicated in the pathologies of neurological diseases such as Alzheimer’s disease 
and transmissible spongiform encephalopathies (TSEs) (Harper and Lansbury 1997; 
Zhang 2003; Adler-Abramovich et al. 2006). 
It is particularly striking that short peptide sequence domains (active site) within 
protein systems such as enzymes are responsible for performing their biological 
functions (Lucchese et al. 2007). 
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4.3 Peptides and proteins drugs (Bio-pharmaceuticals) 
Peptides and proteins have been employed as therapeutics from the 1920s forward 
with the approval of insulin, thyroid hormone and factor VIII (Lee 1991; van der 
Walle and Olejnik 2011), and they remain promising target molecules for the 
treatment and management of many pathological conditions (Audie and Boyd 2010; 
van der Walle and Olejnik 2011).  
Peptide and protein drugs, categorised as bio-pharmaceuticals or biological drugs 
(Watt 2006; Antosova et al. 2009) may emerge as the back bone of therapy for 
diseases previously regarded as pharmaceutically untreatable by conventional 
methods (Johnson-Léger et al. 2006; Watt 2006) such as chronic renal failure, 
dwarfism and infertility for which successful management using protein therapeutics 
have now been achieved (Johnson-Léger et al. 2006).  
The most frequently commercialised of this class of therapeutics includes insulin for 
the treatment of diabetes, therapeutic vaccines for anti-hepatitis A and/or B 
immunisation, growth hormones and monoclonal antibodies for anticancer and 
autoimmune diseases therapy (Johnson-Léger et al. 2006; Walsh 2006) with 
monoclonal antibodies making up half of the molecules in development (Johnson-
Léger et al. 2006). 
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 Peptides as bio-pharmaceuticals 4.3.1
Peptides possess some unique advantages compared to antibodies and other proteins 
as well as small molecule therapeutics. Advantages of peptide drugs compared to 
small molecules include: ability to disrupt protein – protein interactions; frequently 
highly potent receptor agonists and they may overcome the undruggable targets 
barrier; higher target selectivity, specificity and affinity; minimal systemic toxicity 
since their degradation products are amino acids; they do not usually accumulate in 
tissues due to their short half-life, thus reducing the risk of complications arising 
from their metabolites (Loffet 2002; Ladner et al. 2004; Hummel et al. 2006; Sato et 
al. 2006; McGregor 2008; Vlieghe et al. 2010). 
Peptides also offer certain advantages relative to proteins such as antibodies 
including: activity of small peptides will normally depend on the functional groups 
of constituent amino acids whereas for proteins their activity will also depend on the 
maintenance of specific 3-D structures (van der Walle and Olejnik 2011); smaller 
size which permits better tissue or tumour penetration; lower immunogenicity; higher 
activity per unit mass (15 – 60 fold) compared to proteins and antibodies; higher 
stability (room temperature storage for long periods is acceptable); lower royalty 
stack than antibodies; and lower production cost since they can be synthesised 
chemically rather than expressed by recombinant technology (Graff and Wittrup 
2003; Ladner et al. 2004; Sato et al. 2006; McGregor 2008; Vlieghe et al. 2010). 
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4.4 Self-assembly 
Self-assembly is a free energy–driven process involving the organisation of 
components into well-defined, organized, and functional patterns or structures at 
multiple length scales, as a consequence of specific and local non covalent molecular 
interactions with little or no external intervention (Zhang and Altman 1999; 
Rajagopal and Schneider 2004; Whitesides and Grzybowski 2002; Lehn 2002; Ayres 
et al. 2010; Cui et al. 2010; Stupp and Palmer 2014). Self-assembly is a practical 
solution for fabricating a wide range of nanostructures (Service 2005), and is also 
simple in application, thus it holds great promise in the construction of nano-sized 
materials (Palmer and Stupp 2008;  Palmer et al. 2007; Cui et al. 2010). 
Self-assembly in aqueous medium is driven by weak intermolecular forces like 
hydrophobic interactions, van der Waals bonds, electrostatic interactions, hydrogen 
and coordination bonding (Cui et al. 2010; Whitesides 2002; Zhang 2003; Stendahl 
et al. 2006). Even though each of the various interactions mediating self-assembly is 
weak in isolation, if there are an adequate number of these interactions in operation, 
they can produce remarkably stable structures (Cavalli et al. 2010). 
 Peptide based nanostructures 4.4.1
Peptides have been identified as excellent starting materials for the design of self- 
assembling nanostructures for a number of reasons namely: they are biocompatible 
and biodegradable; their structures are relatively simple compared to other bio 
molecules such as proteins and nucleic acids; they can be synthesized quite easily on 
a large scale; they offer a great level of versatility in chemical and biological 
modifications; (Zhang 2002; Cui et al. 2010; Colombo et al. 2007). In addition, the 
capability of peptides for adopting specific secondary structures creates a distinct 
opportunity for the design of structurally controllable nanomaterials (Cui et al. 2010). 
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A certain class of peptides, β-sheet forming peptides exhibits an intriguing capability 
to assemble into one dimensional (1D) nanostructures through the formation of 
intermolecular hydrogen bonds (Hartgerink et al. 2001), which can interact further to 
bring about the formation of higher order (3D) networks. The biodegradable feature 
of peptides can be further exploited for building bioactive hydrogels that can mimic 
the native extracellular matrix (ECM) both structurally and functionally by the 
incorporation of specific amino acid sequences or by controlling their self-assembly 
(Cui et al. 2010). 
4.4.1.1 Self-assembling peptides  
Zhang and co-workers serendipitously discovered a novel class of self-assembling 
peptides which comprise alternating hydrophilic and hydrophobic amino acid 
residues (ionic self-complementary) within the same peptide molecule. They found 
that the self–complementary peptide (Ala-Glu-Ala-Glu-Ala-Lys-Ala-Lys)2 (EAK16) 
from a region of alternating hydrophobic and hydrophilic residues in zuotin (a yeast 
protein that had been previously identified for its ability to bind preferentially to left-
handed Z-DNA), forms very stable β-sheet structures in water and spontaneously 
assemble to form stable macroscopic membranes in the presence of monovalent salts 
and serum (Zhang et al. 1993).  
A second class of self-assembling peptides comprising a broad class of peptide 
amphiphiles (PAs) was developed by the Stupp laboratory. These PAs typically 
consist of an alkyl chain which is attached to a short peptide sequence capable of 
forming intermolecular hydrogen bonding and which drives self-assembly into 
nanofibers through the formation of β-sheets.  
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These PAs also possess a region of charged amino acids for enhanced solubility in 
water and for the design of pH and salt-responsive nanostructures and networks. In 
addition, these PAs possess a fourth portion which is used for the presentation of 
bioactive signals, usually through epitopes that can interact with cells or proteins 
(Hartgerink et al. 2001; Palmer et al. 2007; Palmer and Stupp 2008; Webber et al. 
2009; Webber et al. 2011). These PAs combine the structural features of amphiphilic 
surfactants with the functions of bioactive peptides. These PAs self-assemble into 
high-aspect-ratio nanofibers under specific solution conditions such as pH, ionic 
strength and temperature (Cui et al. 2010). 
Furthermore, another class of self-assembling PAs has been shown to self-assemble 
into high axial ratio nanofibres. This class of PAs was described recently by Mazza 
and co-workers. Their work showed that a PA comprising only a β-sheet forming 
short peptide sequence covalently linked to an alkyl chain was able to self-assemble 
into high axial ratio nanofibres in aqueous solution. In this class of PAs, the β-sheet 
forming peptide region also serves as the active epitope (Mazza et al. 2013).  
4.4.1.1.1 Peptide amphiphiles 
Peptide amphiphiles (PAs) comprise the class of the most commonly studied self- 
assembled nanofibers (Ayres et al. 2010). Peptides that form β-sheets are able to 
assemble into nanofibres through intermolecular hydrogen bonding. Further 
interaction of these nanofibres can in turn lead to formation of three-dimensional 
networks (Beniash et al. 2005; Webber et al. 2009; Cui et al. 2010). These  peptide 
based nanostructures are amenable to the design of bioactive hydrogels that can 
mimic the structure and function of the native ECM due to their biodegradability and 
tunability for incorporation of specific amino acid sequences and control over their 
self-assembled structures (Cui et al. 2010). 
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4.4.1.1.1.1 Mechanism of PA self-assembly 
Self-assembly of PAs in aqueous medium is governed by forces that arise from 
energy contributions including: hydrophobic interaction of the alkyl tails; hydrogen 
bonding among the β-sheet forming peptide segments, both of which favour 
aggregation of the PA molecules; and electrostatic repulsion between charged amino 
acid residues which does not favour aggregation. Thus, the assembly can be 
controlled by factors such as the amino acid sequence, concentration of the peptide, 
pH of the solution, temperature, ionic strength and nature of the solvent (Fung et al. 
2008; Cui et al. 2010). Consequently, the final structure and properties of the 
assembled material such as size, shape and interfacial curvature depends on a balance 
of the contributing (attractive and repulsive) forces (Cui et al. 2010; Paramonov et al. 
2006).  
Tsonchev and co-workers have demonstrated that self-assembly of a class of PAs 
into cylindrical micelles rather than spherical micelles which would have been the 
energetically favoured shape if the assembly were driven only by hydrophobic 
interactions as previously thought (Tsonchev et. al. 2003; Paramonov et al. 2006) is 
as a result of the electrostatic interactions of the PA headgroups. Their work revealed 
that a unique directional electrostatic attraction occurs between the PA headgroups 
contrary to the expected repulsive interactions. This electrostatic attraction prevails 
over hydrophobic attraction of the alkyl tail resulting in the formation of cylindrical 
micelles.  
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Figure 4-1: Schematic depicting self-assembly of PA in aqueous medium 
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They considered a PA possessing an arginine residue and a phosphate group in the 
PA molecule. At pH values of about 3, the headgroup exists as an amphiphilic 
zwitterion in which the carboxylic acid is neutralized, the arginine is positively 
charged and the phosphate group is negatively charged. As a result, the headgroup 
bears a net charge of zero, but the two charges present create a large dipole that is 
approximately perpendicular to the backbone of the molecule. This creates the 
platform for attractive interactions between the hydrophilic headgroups in the self-
assembly (Tsonchev et al. 2004). 
Also, Velichko and co-workers in their simulation study showed that in a system 
comprising both hydrophobic interactions and hydrogen bonding (such as in a PA), 
phase behaviour and assembly mechanisms would depend on the strength of 
intermolecular bonding. In these systems, although the critical micelle temperature 
(CMT) is the most important parameter, formation of hydrogen bonds by the peptide 
blocks leads to significant changes in the phase behaviour. Hydrogen bonding below 
the CMT leads to the formation of β-sheets with large size polydispersity. The 
connection of amphiphilic molecules into β-sheets leads to an increase in the local 
concentration of hydrophobic units. Consequently, there is strengthening of the 
hydrophobic interaction between β-sheets, and rolls or stacks of β-sheets are formed. 
Formation of hydrogen bond above the CMT leads to changes in the micellar 
structure with formation of β-sheets randomly distributed in the entire micellar 
corona. With an increase in hydrogen bonding energy however, the spherical 
symmetry becomes unstable leading to the formation of cylindrical fibres with the β- 
sheets aligned parallel to the fibre axis (Velichko et al. 2008).  
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Furthermore, Paramonov and co-workers (2006) have demonstrated that hydrogen 
bonding by the four amino acids closest to the core of the nanofibre is crucial in the 
formation of elongated cylindrical nanostructures. Interruption of hydrogen bonding 
in this part of the PA molecule would lead to a loss of ability to form the elongated 
cylindrical structures and spherical structures would be preferentially formed.  
In addition, simulation studies on a self-assembling PA developed by Mazza and co-
workers showed that PAs comprised only of a β-sheet forming short peptide 
sequence and an alkyl chain would also preferentially assemble into nanofibres. 
Their work revealed that in this kind of PA, the peptide backbone wraps around and 
lines the exterior of the fibre, while the alkyl chains form the hydrophobic core of the 
nanofibre. The alkyl chains lie perpendicular to the long axis of the fibre, pointing 
towards the centre of the nanofibre (Mazza et al. 2013). Thus, their work showed a 
pattern of arrangement uniquely different from the conventional cylindrical micelle-
like structure previously reported (Hartgerink et al. 2001) to be the characteristic 
pattern of arrangement of self-assembling PAs (Mazza et al. 2013). 
Hence, assembly of PAs to cylindrical nanofibers in aqueous solution is a product of 
the combined effects of hydrophobic collapse of the alkyl tails and tendency for 
hydrogen bonding among the β-sheet forming peptide segment (Cui et al. 2010). 
Hydrophobic collapse leads to aggregation of the alkyl tails away from the aqueous 
media and packing in the centre of the micelle leaving the peptide segments exposed 
to the aqueous environment. The peptide segments in turn form intermolecular 
hydrogen bonds parallel to the long axis of the fibre (Webber et al. 2009; Paramanov 
et al. 2006; Hartgerink et al. 2001). The driving force for self-assembly may also be 
enhanced by intermolecular contact of the side chains of adjacent hydrophobic amino 
acids through close association of the hydrophobic side chains (Beniash et al. 2005). 
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4.4.1.1.1.2 Applications of PAs 
Self-assembled PA nanofibers have potential applications in tissue engineering, 
material sciences, molecular electronics, molecular medicine and drug delivery 
(Colombo et al. 2006) and this has been demonstrated by various workers. 
 Hartgerink and co-workers used pH-induced self-assembly of a PA to make 
nanostructure scaffold similar to ECM. The PA was designed to permit reversible 
cross-linking through intermolecular disulfide bridge formation to increase chemical 
robustness of the fibre. The resulting cross-linked fibres can direct mineralization of 
hydroxyapatite (HA) to form a composite material with the same alignment as that 
found between collagen fibrils and HA crystals in bone (Hartgerink et al. 2001). 
Guler and co-workers in their study demonstrated the encapsulation of pyrene, a 
small hydrophobic molecule, within the cores of self-assembling PAs. Encapsulation 
and aggregation of pyrene within the hydrophobic cores was demonstrated by the 
formation of pyrene excimers using fluorescence spectrofluorometry. Excimer 
formation was found to be more efficient in cylindrical nanofibre forming PAs 
covalently functionalized with pyrene linked to the hydrophobic cores but was less 
efficient in similar molecules that assembled into spherical aggregates. This was 
thought to be as a result of the formation of well-organized nanofibers, which may 
enable closely packed, geometrically organized pyrene segments leading to an 
increased local concentration of pyrene within the nanofibers. The spherical (micelle-
like) supramolecular aggregates however, would provide a liquid-like environment 
for the pyrene rather than the well-ordered β-sheet structures found in the nanofibers. 
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Moreover, excimer formation requires direct contact between two pyrene units, thus 
the extent and rate of excimer formation would reflect the internal dynamics of the 
macromolecule to which the pyrene moieties are covalently attached (Duhamel 
2012). This study indicates that encapsulation can lead to solubilisation of 
hydrophobic drugs such as pyrene in the core of nanostructures creating the 
possibility of combining encapsulation of hydrophobic drugs with presentation of 
bioactive epitopes for targeted drug delivery (Guler et al. 2005). 
Beniash and co-workers have demonstrated the use of PA nanofibers in cell 
transplantation and tissue engineering. They developed PA molecules that can 
assemble into robust nanostructured networks when added to synthetic physiological 
fluids or cell culture media in the presence of polyvalent metal ions. Self-assembly of 
the PA can entrap cells suspended in the fluid in the nanofibre matrix, and the cells 
survive, proliferate, and internalize the fibres, suggesting they may be utilizing the 
PA molecules in their metabolic processes (Beniash et al. 2005).  
Nagai and co-workers have reported the potential for self-assembling peptide 
nanofibers based on an ionic self- complementary peptide sequence to provide 
controlled release kinetics. They demonstrated this using diffusion property in 
hydrogels and used phenol red, bromophenol blue, 8-hydroxypyrene-1, 3, 6-
trisulfonic acid trisodium salt (pyranine, 3-PSA), 1, 3, 6, 8-pyrenetetrasulfonic acid 
tetrasodium salt (4-PSA), and Coomassie Brilliant Blue G-250 (CBBG). They found 
from their work that the diffusivities of the dyes decreased with increasing peptide 
concentration, indicating that the release kinetics can be managed by controlling 
molecular interactions of the nanofibers and the dyes (Nagai et al. 2006). 
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Furthermore, Huang and co-workers demonstrated the competence of an artificial 
matrix composed of self- assembling PA nanofibers displaying high density RGDS 
epitopes to provide both permissive and inductive signals to the enamel organ 
epithelium it comes in contact with. The matrix was able to induce the proliferation 
and differentiation of ameoblasts capable of synthesizing, organizing and 
biomineralization of an enamel nodule separated physically from the authentic 
enamel. This demonstrates that authentic enamel may be synthesised and used as a 
replacement for enamel lost as a result of disease, trauma or congenital defects 
(Huang et al. 2010). 
Tysseling-Mattiace and co-workers have demonstrated the possibility of inhibition of 
glial scar formation and regeneration after spinal cord injury by employing three-
dimensional nanostructures formed by PAs displaying high densities of the 
pentapeptide laminin epitope, Isoleucine-lysine-valine-alanine-valine (IKVAV), 
which is known to promote neurite sprouting and to direct neurite growth (Tashiro et 
al. 1989; Schense et al. 2000) on their surfaces. In vivo treatment with the PAs 
reduced astrogliosis, cell death and led to an increase in the number of oligodendria 
at the site of injury as well as promoting regeneration of ascending sensory fibres and 
descending motor fibres. PA treatment also led to significant behavioural 
improvement based on the Basso, Beattie and Bresnahan (BBB) locomotor scale 
(Basso et al. 1996; Joshi and Fehlings 2002). They found that from 5 weeks of 
IKVAV PA treatment and beyond following experimental spinal cord injury, animals 
that had received the PA treatment displayed significant behavioural improvement 
compared to a glucose control group.  By the ninth week, the mean BBB score for 
the control group was 7.03± 0.8, compared to a score of 9.2 ± 0.5 (p ˂ 0.04) for the 
PA treatment group. This shows significant recovery because a score of 7 implies no 
functional movement despite an extensive range of movement in all three joints in 
the hindlimb, whereas a score of 9 indicates dorsal stepping in which the animal 
steps on the dorsal side of its foot during locomotion, that is, the hindlimb movement 
has a functional use (Tysseling-Mattiace et al. 2008). 
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In addition, Webber and co-workers have developed a synthetic cell-free VEGF-
mimetic therapy based on PA nanostructures. The PA nanofibers displayed the 
VEGF-mimetic peptide on their surfaces at high density after self-assembly. The 
VEGF-mimetic filaments were found to induce VEGF receptors phosphorylation and 
promote proangiogenic behaviour in vitro. Furthermore, the murine hind-limb 
ischemia model was used to evaluate the potential of the VEGF- mimetic PA 
nanostructures as therapy for ischemic disease. There was increased tissue perfusion, 
functional recovery, limb salvage and treadmill endurance in mice that had received 
VEGF- mimetic PA compared to those treated with a mutant PA (with systematic 
replacement of four specific residues known to be near the peptide–receptor-binding 
interface with structurally distinct amino acids), VEGF peptide alone, and saline. 
Also, the VEGF-mimetic PA performed as well or better than the recombinant 
protein (VEGF165) in every measured outcome. Their results suggest that the 
bioactive nanostructures could provide a synthetic therapeutic strategy for 
regeneration of microcirculation and restoration of perfusion to ischemic tissue in 
cardiovascular disease and could be an alternative to VEGF protein-based strategies 
(Webber et al. 2011). 
 
Also, Mazza and co-workers have demonstrated the delivery of an active peptide to 
the brain using a self-assembling PA comprising an alkyl (C16) chain linked to a β-
sheet forming peptide (dalargin) which was also the active peptide. Their results 
showed that following intravenous administration, brain levels of the PA (palmitoyl 
dalargin; pDal) with respect to plasma increased steadily for up to 90 minutes and 
pDal was detected in the brain for up to 4 hours post administration (Mazza et al. 
2013). 
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4.5 Peptide synthesis 
Peptide synthesis (chemistry) is based on the reaction of a carboxylic acid and an 
amino group of alpha (α) - amino acids leading to the formation of an amide bond 
and liberation of water yielding a peptide as the product (Gesellchen and Santerre 
1991). Peptide synthesis emerged from the works of Emil Fischer in his attempts at 
total chemical synthesis of molecules which possessed properties similar to 
“albumoses” (proteins). He also introduced the term “peptide” in 1906 (Kent 1988; 
Gesellchen and Santerre 1991) based on the nomenclature of saccharides (‘ide’) and 
the word peptone (‘pept’; the products of enzymatic cleavage of proteins) to describe 
the product of amino acids linkage through amide bonds (van Nispen 1987).  
For successful synthesis of desired peptide sequences, it is imperative to take 
measures to prevent unintended reaction of other carboxylic acid and amino groups 
present in the reaction medium otherwise there would be formation of any number or 
combination of unwanted products. This necessitates the employment of suitable 
protecting groups for various functionalities of amino acids not directly involved in 
the formation of amide bonds. Thus for a coupling reaction to lead to the formation 
of a desired dipeptide, the N
α
 – amino group of one amino acid and the C – terminal 
carboxylic acid group of the other amino acid are protected  with suitable groups. In 
this way, the desired amide bond can be formed once the free carboxyl group is 
activated to yield the desired dipeptide (van Nispen 1987; Lloyd-Williams et al. 
1997; Gesellchen and Santerre 1991). The development of the carbobenzyloxy or 
Cbz (an amide) protecting group (which can be selectively removed after amide bond 
formation) by Bergmann and Zervas in 1932 produced a great boost to successful 
and predictable synthesis of desired peptides (Gesellchen and Santerre 1991). Further 
advances over the next decade climaxed in the successful synthesis of oxytocin by du 
Vigneaud and co-workers in 1954 (du Vigneaud et al. 1954), which many consider to 
mark the milestone in the field of peptide synthesis research (Gesellchen and 
Santerre 1991).  
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 Peptide synthesis techniques  4.5.1
In biological systems, ribosomal peptide synthesis occurs in the N to C direction that 
is the peptide chain grows from the amino end towards the carboxyl end. In chemical 
peptide synthesis however, synthesis is usually carried out in the reverse (C to N) 
direction that is from the carboxyl end towards the amino end. This is due to the 
inherent risk of racemisation (via oxazolone formation) when chemical peptide 
synthesis is carried out in the N to C direction.  (Felix and Merrifield 1970; 
Gesellchen and Santerre 1991; Henkel et al. 1997; Johansson et al. 2000). 
Racemisation occurs upon activation of the carboxyl end (C terminus) of the second 
amino acid (that is activation after formation of a dipeptide) for coupling to the third 
amino acid. Activation of the C terminus of the dipeptide leads to oxazolone 
formation between the carbonyl group of the first amino acid and the activated C-
terminus of the second amino acid (Gesellchen and Santerre 1991; Henkel et al. 
1997). Although several attempts have been made at chemical peptide synthesis in 
the N to C direction with varying degrees of success (Felix and Merrifield 1970; 
Henkel et al. 1997; Johansson et al. 2000), chemical synthesis in the C to N direction 
remains the most widely utilised procedure in routine chemical peptide synthesis 
(Johansson et al. 2000). 
Peptide synthesis can be carried out using either solution or solid phase techniques. 
Solution phase synthesis was the conventional technique employed for peptide 
synthesis (Gesellchen and Santerre 1991; Corradin et al. 2010). In solution phase 
peptide synthesis, the formation of a dipeptide from two amino acids in a controlled 
manner necessitates that one of the amino acids is protected at the N- terminus while 
the other is protected at the C- terminus. The resultant protected dipeptide is then 
isolated after amide bond formation for purification and characterisation. 
Subsequently, the N
α – protecting group can be removed if necessary and the 
dipeptide can be isolated, purified and characterised.  
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The dipeptide can then be further coupled with another amino acid with the resulting 
protected tripeptide isolated, purified and characterised. This cycle could be repeated 
until the desired peptide is obtained and this is termed linear synthesis. Conversely, 
in another strategy termed convergent synthesis, protected peptide segments are 
coupled to form the desired peptide (Kent 1988; Lloyd-Williams et al. 1997). The 
opportunity for isolation and characterisation of intermediate products during the 
process of solution synthesis makes detection of side reactions, incomplete 
deprotection or coupling reactions easy, such that undesired products can be removed 
before advancing with subsequent steps. Nevertheless, these procedures slow down 
the overall synthesis process such that an appreciable amount of time and energy will 
be needed for the synthesis of comparatively small peptides. Furthermore, synthesis 
in solution is greatly affected by solubility problems especially due to the poor 
solubility of larger protected intermediate products, such that in some cases chemical 
reaction for amide bond formation cannot occur. Racemisation of the C-terminal 
amino acid of activated peptide fragments is also a challenge in solution phase 
synthesis (Kent 1988; Lloyd-Williams et al. 1997). 
4.5.1.1 Solid phase peptide synthesis (SPPS) 
SPPS involves the synthesis of peptide chains on an insoluble solid support to which 
the C- terminal amino acid is attached by means of its carboxyl group (Merrifield 
1963; Gesellchen and Santerre 1991; Bodanszky 1993; White and Chan 2000). The 
supports employed are resins that swell in the solvents used, forming a porous gel 
structure (which allows reagents to readily penetrate) within which the peptide 
synthesis occurs (Merrifield 1963; Lloyd-Williams et al. 1997). This technique was 
developed by Robert Merrifield in 1962 (Gesellchen and Santerre 1991) in an 
attempt to overcome the technical problems of solution phase synthesis such as 
solubility and purification in the synthesis of large peptides.  
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Subsequently, he published the synthesis of a tetrapeptide (L-leucyl-L-alanylglycyl-
L-valine) on a solid support (resin) composed of chloromethylated copolymer of 
styrene and divinylbenzene (200 – 400 mesh) beads in January 1963 to demonstrate 
the feasibility of the approach (Merrifield 1963).  
By design, in SPPS the problem of solubility no longer exists since the peptide chain 
is assembled on an insoluble support (Kent 1988; Lloyd-Williams et al. 1997). Also, 
isolation of intermediate products is no longer feasible since the growing peptide 
chain is firmly attached to the resin, however this is not necessarily consequential if 
coupling reactions are pushed to completion (Lloyd-Williams et al. 1997). Moreover 
in SPPS, intermediate peptide products can be easily separated from excess reagents 
(including starting materials) and products of side reactions by filtration and washing 
with appropriate solvent (Kent 1988; Gesellchen and Santerre 1991; Bodanszky 
1993; Lloyd-Williams et al. 1997; White and Chan 2000; Corradin et al. 2010).  
4.5.1.1.1 General Scheme for SPPS 
In SPPS, the C-terminal amino acid is chemically attached to the solid support which 
acts as protecting group for the carboxyl group (Lloyd-Williams et al. 1997), with its 
α- amino group (Nα) protected with a “temporary” protecting group while other side 
chain functionalities are protected with “permanent” protecting groups. To proceed 
with synthesis, the “temporary” Nα- protecting group is removed and an excess of the 
next N
α
-protected amino acid with its carboxyl group activated by a coupling reagent 
is introduced and left to react with the preceding amino acid in the presence of a 
weak organic base leading to formation of the amide bond. After the coupling (amide 
bond formation) reaction, excess reagents are removed by washing and the protecting 
group at the N-terminus is removed before the next amino acid is added. The use of 
large excesses of N
α
-protected amino acids can function to push coupling reactions to 
completion (Lloyd-Williams 1997; Chan and White 2000) with little or no 
racemisation (Lloyd-Williams et al. 1997). 
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Coupling and deprotection steps are repeated until the target peptide sequence is 
achieved. The synthesised peptide is then liberated from the resin with the permanent 
protecting groups for side chain functionalities removed simultaneously (Kent 1988; 
Gesellchen and Santerre 1991; Bodanszky 1993; Lloyd-Williams et al. 1997; White 
and Chan 2000; Corradin et al. 2010) [Figure 4-2: General SPPS method]. The crude 
free peptide is then isolated, purified and characterised (Lloyd-Williams et al. 1997).  
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Figure 4-2: General SPPS method 
Key: 
Pr: N
α
- protecting group; I: Deprotection conditions for N
α
- protecting group; II: Wash step;      
III: Coupling reaction conditions for amide (peptide) bond formation; IV: Cleavage reaction 
conditions for liberation of target peptide 
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Due to the success of peptide synthesis on insoluble polymeric supports developed 
by Merrifield, most peptides are now synthesised using solid phase techniques 
(Lloyd-Williams et al. 1997; Albericio 2000) and SPPS has remained the method of 
choice for synthesis of small peptide hormones up to 20 amino acids in length (van 
der Walle and Olejnik 2011).  
SPPS can be carried out using one of two major techniques namely: Merrifield’s 
SPPS (Merrifield 1963) and 9-fluorenylmethoxycarbonyl (Fmoc) SPPS (Lloyd-
Williams 1997; Chan and White 2000); depending on the choice of protecting 
scheme (Albericio 2000). 
4.5.1.1.2 Merrifield SPPS 
In contemporary Merrifield SPPS, peptide assembly occurs on a 
hydroxymethylphenylacetamidomethyl polystyrene (PAM) resin to which the C- 
terminal amino acid is anchored through a benzyl ester linkage with the resin. The 
original chloromethyl polystyrene is now rarely used due to high incidence of side 
reactions during synthesis of longer peptides (Chan and White 2000). In this 
technique, the tert- butyloxycarbonyl (Boc) group is employed as N
α
-protecting 
group while the side chain functionalities are protected by benzyl- or cyclohexyl – 
based protecting groups (Lloyd-Williams 1997; Chan and White 2000). Merrifield 
SPPS depends on a system of graduated acidolysis for selective removal of 
temporary and permanent protecting groups (Meienhofer et al. 1979; Lloyd-Williams 
1997; Chan and White 2000; Merrifield 1986). Hence, the Boc group for α-amino 
group protection is removed by neat trifluoroacetic acid (TFA) or 33% TFA in 
dichloromethane (DCM), while the Bzl group for side chain protection is removed by 
strong acids such as anhydrous hydrogen fluoride (HF) or trifluoromethanesulfonic 
acid, with concurrent release of the peptide from the resin (Chan and White 2000; 
Lloyd-Williams 1997; Albericio 2000).  
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Although it is possible to cleave the Boc group without significant damage to the 
benzyl ester resin linkage, a small but not trivial part of amino acid or peptide is lost 
to cleavage from the resin during each deprotection step (Bodanszky 1993). Also, 
prolonged exposure of peptide chains to TFA for deprotection to remove the Boc 
group may be detrimental in the synthesis of long peptides and proteins (Atherton et 
al. 1978), and may result in premature removal of the Bzl group (Albericio 2000). In 
addition, the strong acidic conditions required to remove the Bzl group may be 
deleterious for peptides containing fragile sequences and these may not be able to 
survive such conditions (Albericio 2000). 
Peptide synthesis using the Merrifield technique is on a decline as the need for the 
use of special polytetrafluoroethylene (PTFE) - lined apparatus for containment of 
the highly toxic liquid HF has been a deterrent to many in the adoption of this 
strategy for SPPS (Chan and White 2000). 
4.5.1.1.3 Fmoc SPPS  
Fmoc SPPS strategy was developed in order to eradicate the need for repetitive acid 
treatment required for removal of the N
α
-protecting group (Atherton et al. 1978) such 
that the N
α
-protecting group can be removed using a different strategy such as base 
treatment (amongst other strategies). The Fmoc group was selected as a suitable 
candidate based on its favourable properties including rapid quantitative cleavage in 
mild conditions such as piperidine in aprotic solvents like dimethylformamide 
(DMF). This also permitted the use of acid labile tert-butyl (tBu) group as protecting 
group for side chain functionalities as it is known to be completely stable to base 
treatment.  
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This combination of “temporary” and “permanent” protecting groups for the Nα and 
side functionalities respectively thus allows for an orthogonal (chemical selectivity) 
strategy in the removal of the different groups (Atherton et al. 1978; Meienhofer et 
al. 1979). Since the protecting groups belong to unrelated classes of compounds, 
each can be removed independently and in any order, in the presence of the other 
groups by different mechanisms. As a result of this, the Fmoc strategy allows for the 
use of milder reaction conditions and greater flexibility than the Boc strategy 
(Albericio 2000).  
Thus, in contemporary Fmoc SPPS, the N
α
 groups are protected by the base labile 
Fmoc group which can be removed by treatment with piperidine in DMF, while the 
side chain functionalities are protected with acid labile groups such as tBu and trityl- 
based protecting groups which can be removed by TFA treatment (Gesellchen and 
Santerre 1991; Bodanszky 1993; Chan and White 2000).  
This orthogonal (Fmoc/tBu) strategy employed provides a number of advantages 
over the Merrifield (Boc/Bzl) strategy. Firstly, the repeated base treatment required 
for deprotection of the N
α
 groups during synthesis has no impact on the integrity of 
the resin and the side chain protecting groups (Gesellchen and Santerre 1991). 
Secondly, there is no need for a neutralisation step after deprotection by acidolysis as 
the amino group is released in the free form for amide bond formation with the next 
amino acid after deprotection by base treatment. Also, the number of washing steps 
are reduced since deprotection and coupling reactions are carried out in the same 
solvent (DMF). Lastly but importantly, the use of the tBu group as side chain 
protecting group removes the need for the use of final deprotection and cleavage with 
the highly toxic and strongly acidic liquid HF (Gesellchen and Santerre 1991; 
Bodanszky 1993). 
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4.5.1.2 Purification of synthetic peptides 
High performance (or high pressure) liquid chromatography (HPLC) is the most 
commonly used method for purification of peptides of different origins (including 
synthetic peptides), quantity and complexity. HPLC has been found to be especially 
applicable in purification of a peptide of interest from the crude mixture from SPPS 
which normally contains impurities that are frequently very similar to the target 
peptide (Mant et al. 1997; Smith and Hanly 1997; Aguilar 2004a).  Such impurities 
are usually terminated sequences, deletion or chemically modified peptides which 
may be different from the target peptide by missing only one amino acid residue 
(Mant et al. 1997; Aguilar 2004a).   
HPLC has been particularly successful owing to several intrinsic characteristics of 
the technique which are correlated to reproducibility, typically high recovery, ease of 
manipulation for required selectivity and the exceptionally high level of resolution 
achievable under various conditions for molecules possessing very similar properties 
and structurally dissimilar molecules (Aguilar 2004a).  
Detection of peptide eluents from HPLC analysis can be achieved at wavelength 
values between 210 – 220 nm due to the characteristic absorbance of peptide bonds 
in this range (far ultraviolent; < 220 nm). However, peptides containing amino acids 
such as tyrosine and tryptophan which possess aromatic side chains may be detected 
at higher wavelengths of 250 – 290 nm (Shaw 1994; Mant and Hodges 1996; Aguilar 
2004b; Mant et al. 2007). 
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There are different HPLC modes that can be employed in the peptide separations 
such as size exclusion HPLC which effects separation based on size (SEC), ion-
exchange HPLC which exploits the net charge to effect separation and reversed-
phase HPLC in which separation of molecules and hence purification depends on 
hydrophobicity. The levels of separation or purification may be optimised by making 
subtle changes in the chromatographic conditions (such as the mobile phase) 
specifically for each mode employed. A combination of different modes may also be 
necessary in some cases for optimal purification (Mant et al. 1997; Aguilar 2004a).   
4.5.1.2.1 Reversed-phase HPLC (RP HPLC)  
RP HPLC is recognised as the method of choice for the purification (Shaw 1994; 
Mant et al. 1997; Smith and Hanly 1997; Aguilar 2004; Mant et al. 2007) as well as 
assessment of purity of synthetic peptides (Smith and Hanly 1997). RP HPLC 
usually gives better results than other modes of HPLC in terms of speed and 
efficiency and it is the mode that presents the greatest platform for controlling 
specific characteristics of both mobile and stationary phases to obtain optimal 
separation of peptides (Mant et al. 1997). The stationary phase employed in RP 
HPLC is micro particulate silica beads derivatised with covalently bonded alkyl 
chains such as octyl (C8), octadecyl (C18) or phenyl groups (Fallon et al. 1987; Shaw 
1994; Smith and Hanly 1997; Mant et al. 2007). Elution of peptides is effected using 
a mixture of water and water – miscible organic solvents such as acetonitrile or 
methanol as mobile phase with the addition of ionic modifiers such as TFA (Fallon et 
al. 1987; Mant and Hodges 1996; Smith and Hanly 1997; Aguilar 2004b). In RP 
HPLC, separation is a function of hydrophobic interaction of component molecules 
(in the mixture to be purified) present in the mobile phase with the hydrophobic 
groups attached to the surface of the stationary phase (Aguilar 2004b).  
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In purification of peptides, elution is carried out using gradient methods whereby the 
concentration of the organic component of the mobile phase is increased over a pre-
set time period (Aguilar and Hearn 1996; Mant and Hodges 1996; Aguilar 2004b) 
and peptides are eluted in order of increasing net hydrophobicity (Aguilar 2004b; 
Mant et al. 2007).  
The mobile phase systems usually employed in RP HPLC have advantages such as 
volatility which translates to ease of removal without the need for desalting 
procedures following preparative purification procedures (Mant and Hodges 1996; 
Mant et al. 1997; Lindner and Helliger 2004; Mant et al. 2007). Also, TFA 
commonly used in the mobile phase is volatile and it eliminates ionic interaction 
between with residual underivatised silanol silica groups (negatively charged at pH ≥ 
3 – 4) of the stationary phase and positively charged amino acid by preventing their 
ionisation at the low pH values generated (Mant et al. 2007). 
RP HPLC presents various advantages which make it an attractive HPLC mode. The 
inertness of the stationary phase employed may be considered to be the most 
important of these advantages. This permits the use and manipulation of various 
solvent systems and additives as well as different pH and temperature conditions 
(Fallon et al. 1987).  Also, RP HPLC mode provides exceptional resolution of 
closely related as well as structurally dissimilar molecules in varying 
chromatographic conditions; mobile phase characteristics may be varied relatively 
easily in order to achieve the desired selectivity and RP HPLC usually gives high 
recoveries leading to high product yields (Aguilar 2004b). 
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4.5.1.3 Characterisation of synthetic peptides 
4.5.1.3.1 Mass spectrometry 
Mass spectrometry (MS) is a sensitive and robust micro analytical technique valuable 
for selective detection and determination of the amount of analyte samples based on 
the separation of the ionized analyte sample molecules according to their mass to 
charge ratios (m/z) by the application of electric and magnetic fields (Wait 1993; 
Watson and Sparkman 2007). MS originated from experimental works by Sir J. J. 
Thompson (Thomson 1913) in his study into the passage of electricity through gases, 
which led to his discovery of the electron and his measurement of the charge – to – 
mass ratios in 1897 (Nobel Prize in Physics 1906). In subsequent works, he studied 
positive ions using similar methods and built the first “mass spectrometer” (parabola 
spectrograph) which enabled the separation of narrow ray beams into positive ray 
parabolas, each of which correspond to a specific charge – to – mass ratio (Griffiths 
1997; Suizdak 2006).  
MS is indispensable in the characterisation of synthetic peptides for the 
determination of their molecular weight. This is necessary to confirm that the 
synthetic product obtained by RP HPLC purification (prominent peak) actually 
corresponds to the target peptide as this is not always the case (Smart et al. 1996). 
In order to carry out MS analysis of analyte compounds, it essential to first generate 
gas phase ions of such compounds, which can  then be separated based on their 
different  mass – to – charge ratios and detected by a detector (Smith et al. 1990; Ho 
et al. 2003; de Hoffmann and Stroobant 2007; Watson and Sparkman 2007). The 
process of ion formation determines the scope and applicability of the method (Smith 
et al. 1990). 
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MS is a reasonably sensitive technique with capability for detection limits down to 
the picomole and femtomole scales and lower (Hillenkamp and Karas 1990; Wait 
1993; Suizdak 1994; Solouki et al. 1995; Morris et al. 1997; Watson and Sparkman 
2007), thus requiring very small amount of analyte (picomole or nanomole 
quantities) for analysis (Wait 1993). MS is an attractive analytical technique for bio 
molecules owing to the very high sensitivity limits obtainable, the potential for 
highly accurate mass determination, and the ability for structural elucidation of 
molecules under investigation (Hillenkamp and Karas 1990). Nevertheless, MS is a 
destructive technique as analytes are invariably consumed in the process of analysis 
(Wait 1993; Jonsson 2001).  
4.5.1.3.1.1 Ionisation in MS 
Ionisation in MS comprises both the methods by which ionisation can be achieved 
and the ionisation sources which refer to the mechanical devices that allow ionisation 
to take place (Suizdak 2006). 
4.5.1.3.1.1.1 Ionisation in methods MS 
Ionisation of analytes for MS analysis can be achieved through various mechanisms 
such as protonation, deprotonation, cationisation, transfer of a charged molecule to 
the gas phase, electron ejection and electron capture. Each mechanism of ionisation 
has applications in the ionisation of various analyte types to which they are 
particularly suited (Suizdak 2006).  
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4.5.1.3.1.1.1.1 Protonation 
Ionisation of analytes by protonation involves the addition of a proton to the 
molecule (Suizdak 2006; de Hoffmann and Stroobant 2007) resulting in a net 
positive charge (1+ for each proton added). The positive charges are usually localised 
on the more basic residues (like amines) of such molecules to produce stable cations. 
Ionisation of peptides for MS is frequently achieved by the protonation method. 
Protonation can be accomplished through matrix assisted laser desorption ionisation 
(MALDI), electrospray ionisation (ESI) and atmospheric pressure chemical 
ionisation (APCI) (Suizdak 2006). 
4.5.1.3.1.1.2 Ionisation sources in MS 
Historically (before 1970), electron ionisation (EI) and chemical ionisation (CI) 
served as the main ionisation sources for MS analysis (Harrison and Cotter 1990; 
Suizdak 2006; Watson and Sparkman 2007). However, these techniques are 
applicable only to significantly volatile and thermally stable analytes as they produce 
gas phase ions only from gas phase molecules. Thus they cannot be applied to 
thermo labile analytes and those that lack sufficient vapour pressure (Wait 1993; 
Williams and Fleming 1996; de Hoffmann and Stroobant 2007; Watson and 
Sparkman 2007). Also, EI produces extensive fragmentation such that the molecular 
ion may sometimes not be observed (Wait 1993; Williams and Fleming 1996; de 
Hoffmann and Stroobant 2007). The associated fragmentation is usually reproducible 
and distinctive for each molecule, providing an important tool for structural 
elucidation of unknown compounds. However, fragmentation is sometimes so much 
that comparatively non informative low–mass ions are predominant in the resulting 
spectra (Wait 1993). 
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In addition, the application of EI has been restricted to small molecules with masses 
falling outside the mass range of typical bio molecules (Wait 1993; Suizdak 2006; 
Watson and Sparkman 2007). Nevertheless, EI and CI remain important in 
combination with techniques such as gas chromatography/ MS (GC/MS) and liquid 
chromatography MS (LC/MS) techniques (Watson and Sparkman 2007). 
Subsequently, more recent techniques such as fast atom/ ion bombardment (FAB), 
MALDI and ESI were developed which have broadened the scope of application of 
MS (Suizdak 2006; Watson and Sparkman 2007). The development of these 
techniques which has brought about many advances in the analysis of biomolecules 
including larger molecules up to 100 kDa (Harrison and Cotter 1990; Williams and 
Fleming 1996; Suizdak 2006) was inspired by the attendant constraints of the earlier 
techniques such as EI (Suizdak 2006).  
Albeit, ESI and MALDI have emerged as the methods most favoured for MS 
analysis of biomolecules (Suizdak 1994; Suizdak 2006; Watson and Sparkman 
2007). These techniques provide the platform for the simple, rapid and accurate 
generation of molecular weight information for a wide variety of analytes. This has 
enabled conventional characterisation in small molecule and protein synthesis as well 
as compounds such as those derived directly from biological matrices (Suizdak 
1994). 
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4.5.1.3.1.1.2.1 ESI MS 
ESI is commonly applied in the analysis of a wide variety of molecules including 
peptides, proteins, oligonucleotides, carbohydrates, lipids, synthetic and 
biopolymers, as well as small polar molecules (Smith et al. 1990; Loo 2000; Suizdak 
2006; de Hoffmann and Stroobant 2007), although it was initially regarded as an 
ionisation source solely for protein analysis (de Hoffmann and Stroobant 2007). In 
ESI MS, gas phase ions are produced directly from the liquid phase, eliminating the 
need for analytes to be volatile and thermo stable (Kebarle 2000; Ho et al. 2003; 
Suizdak 2006; Watson and Sparkman 2007).  
In the ESI process, a fine spray of highly charged droplets is generated in the 
presence of a strong electric field applied at atmospheric pressure to a liquid 
(analyte) passing through a capillary tube at low flow rate of about 1 – 10 µl min-1. 
The electric field results from applying a potential difference (3 – 6 kV) between the 
spraying capillary and a counter electrode separated by a distance of 0.3 – 2 cm, this 
generates electric fields of about 10
6
 V m
-1
 in strength. The field causes 
accumulation of charges at the surface of the liquid present at the end of the capillary 
which will break up into highly charged droplets. Subsequently, the droplets will 
pass through either heated inert gas (usually nitrogen) or a heated capillary to remove 
any remaining solvent molecules (Wait 1993; Williams and Fleming 1996; Kebarle 
2000; Ho et al. 2003; Suizdak 2006; de Hoffmann and Stroobant 2007). The polarity 
bias of the spraying capillary will result in the electrosprayed droplets having an 
excess of positive or negative charges (Williams and Fleming 1996; Ho et al. 2003). 
Evaporation of the solvent from the droplets leads to the droplets shrinking and an 
increase in their charge per unit volume (Suizdak 1994; Ho et al. 2003; Suizdak 
2006; de Hoffmann and Stroobant 2007).  
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The reduction in droplet size also leads to an increase in the forces of repulsion 
between the excess charges in the droplets such that the mutual “Coulombic 
repulsion” between the particles exceeds the surface tension and the ions are ejected 
through what is called a “Taylor cone” (Suizdak 2006; de Hoffmann and Stroobant 
2007; Watson and Sparkman 2007).  
Although ESI favours the formation of singly charged molecular ions of small 
molecules, the generation of multiply charged species from larger molecules is a 
widely recognised feature of this ionisation source. Such multiply charged ions are 
produced with large molecules that possess a number of ionisable sites. For instance, 
proteins would usually bear approximately one charge per thousand daltons, the 
number of charges may be less if very few basic amino acids are present in the 
molecule. The generation of multiply charged ions provide the advantage of 
improved sensitivity at the detector and permits the analysis of high molecular 
weight compounds using analysers with a relatively small mass range (Wait 1993; 
Suizdak 1994; Suizdak 2006; de Hoffmann and Stroobant 2007; Watson and 
Sparkman 2007).  
ESI is recognised as a “soft” ionisation technique which permits accurate mass 
determination for small molecules and ionisation of macromolecules without 
disrupting covalent bonds. Also, ESI is particularly suited for the study of biological 
complexes because it maintains weak non-covalent interaction of macromolecules 
like proteins (Loo 2000; Watson and Sparkman 2007). 
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4.5.1.3.1.1.2.2 Tandem MS  
Tandem MS, abbreviated as and often referred to as MS/MS, generically describes 
MS involving at least two stages of mass analysis (de Hoffmann and Stroobant 
2007). The term MS/MS (for mass spectrometry/mass spectrometry) was invented by 
William F. Haddon in 1978 to describe the method of inducing the decomposition of 
a stable ion by forcing it to collide with neutral gas atoms or molecules (Watson and 
Sparkman 2007). 
Frequently in MS/MS experiments, a precursor ion is first isolated using a first 
analyser, this ion then undergoes fragmentation either spontaneously or by activation 
to yield product ions and neutral fragments. The product ions are then analysed in a 
second analyser (Ho et al. 2003; de Hoffmann and Stroobant 2007; Watson and 
Sparkman 2007). This is commonly achieved by positioning a collision cell between 
the first and second (MS1 and MS2 respectively) mass analysers (Ho et al. 2003; 
Watson and Sparkman 2007). However, the number of steps can be increased 
depending on the required application (MSn). Thus for a three step experiment, ions 
of a first mass would be selected, followed by selection of ions of a second mass 
(from the previously generated fragments), the fragments from the last selected ions 
are then analysed. Such an experiment would thus be an MS/MS/MS or MS3 
experiment (de Hoffmann and Stroobant 2007).  
MS/MS is a widely recognised method for determination of protein sequences mostly 
due to the great level of structural diversity of peptides and the limitations of other 
conventional methods (Gross 1990). Also, MS/MS allows more structural 
information to be obtained from ionic species of interest (de Hoffmann and Stroobant 
2007). MS/MS is generally applicable for determination of the amino acid sequence 
of peptides.  
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For instance, cleavage of the same bond such as the CO – NH of consecutive peptide 
linkages (with retention of the positive charge on the CO – group) would generate a 
series of ions of increasing mass. Thus, the identities of consecutive amino acids in 
the peptide sequence would be revealed by the mass difference between consecutive 
pairs (Biemann 1990). 
4.5.1.3.2 Nuclear magnetic resonance (NMR) spectroscopy 
NMR is a phenomenon that was first observed in 1946 (Williams and Fleming 1996; 
Stepišnik 2006) separately by Felix Bloch and Edward Mills Purcell (Nobel Prize in 
Physics 1952) (Smith and Blandford 1995; Stepišnik 2006) and has found routine 
application in organic chemistry as far back as 1960. The influence and adaptability 
of NMR has continued to increase from then onwards and notably since the 
introduction of Fourier Transform (FT) NMR spectroscopy in the late 1970s 
(Williams and Fleming 1996). NMR has the unique advantage over most other 
spectroscopic techniques in the capability to acquire structural and dynamic 
information at atomic resolution (Barber et al. 1993). 
NMR alludes to the absorption and release of radio frequency energy by a nucleus in 
a magnetic field (Smith and Blandford 1995). NMR spectroscopy is based on the 
possession of nuclear spin (I) by some atomic nuclei which confers on them 
behaviour similar to that of bar magnets. These nuclei can orient themselves in 2I + 1 
ways when placed in a magnetic field (Günther 1995; Smith and Blandford 1995; 
Williams and Fleming 1996; Guthrie 1997). The applied external magnetic field 
causes a polarisation in the spin of the constituent protons and neutrons of such 
atomic nuclei which can be aligned (Jones and Mulloy 1993; Stepišnik 2006) parallel 
or antiparallel to the applied field.  
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The spin alignment thus causes the quantum mechanically allowed energy levels of 
such nucleus to split and the nucleus can absorb electromagnetic radiation at a 
frequency corresponding exactly to the difference between the energy levels 
(Stepišnik 2006).   
In practical applications of NMR, the most important nuclei are 
1
H and 
13
C 
(Williams and Fleming 1996), with 
1
H being the most commonly studied (Williams 
and Fleming 1996; Guthrie 1997).  Both 
1
H and 
13
C have a spin of ½, so they can 
only present one of two orientations (from 2I + 1). Thus, they either have a low 
energy orientation aligned with the applied field or a high energy orientation opposed 
to the applied field (Williams and Fleming 1996). The difference in energy is given 
by the equation: 
ΔE = hyB0/2π      Equation 4-1 
where: h is Planck’s constant; y is the magnetogyric ratio (a proportionality constant 
(differs for each nucleus) which essentially measures the strength of the nuclear 
magnets; B0 is the strength of the applied magnetic field (Williams and Fleming 
1996).       
The difference in the number of nuclei in the low energy state (Nα) and the high 
energy state (Nβ) is determined by the Boltzmann distribution, represented in the 
equation: 
Nβ/Nα = exp (– ΔE/kT)   Equation 4-2  
where k is the Boltzmann constant; T is the temperature in Kelvin. 
The distribution changes when an applied radio frequency signal matches the 
frequency at which the nuclear magnets naturally precess in the magnetic field B0 
such that some Nα nuclei are promoted from the low energy state to the high energy 
state, leading to an increase in Nβ (Williams and Fleming 1996).  
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The frequency [in Hertz (Hz)], known as the resonance frequency is given by the 
equation: 
ν = yB0/2π     Equation 4-3 
where ν is the frequency 
The resonance frequency therefore depends on both the strength of the applied field 
and the nature of the nucleus under consideration (Williams and Fleming 1996; 
Hinds and Norton 1997). 
The difference between the Nα and Nβ is usually very small (of the order of 1 in 10
5
 
protons in a 200 MHz instrument), making NMR a relatively insensitive technique 
compared to techniques such as ultraviolet (UV) and infrared (IR) spectroscopy, thus 
NMR requires very sensitive electronics. The difference between the Nα and Nβ 
increases with increasing field strength B0 (equations 2.1 and 2.2), this implies that 
high-field (200 – 500 MHz) instruments are intrinsically more sensitive than the 
older (60 – 100 MHz) instruments (Günther 1995; Smith and Blandford 1995; 
Williams and Fleming 1996). 
4.5.1.3.2.1 Measurement of NMR Spectrum 
To acquire an NMR spectrum, a radio frequency pulse is applied to the sample to be 
analysed. Subsequently, the NMR signal (free induction decay or FID) is changed 
from an analog to a digital signal by an analog to digital converter and stored in a 
computer. After this, the magnetisation of the sample is allowed to relax before the 
next scan starts. The signal-to-noise ratio of a spectrum is directly proportional to the 
square root of the number of scans acquired. This is of great importance in when 
handling small samples as reducing concentration significantly increases the length 
of time needed to generate a spectrum with the same signal-to-noise ratio (Hinds and 
Norton 1997).  
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The NMR spectrum is measured using one of two methods namely: continuous wave 
(CW) NMR or Fourier transform (FT) NMR (Jones and Mulloy 1993; Günther 
1995).  
In conventional CW method, some of the Nα nuclei are promoted to the higher 
energy state by absorbing a small portion of the applied signal and the response is 
detected in a receiving coil. The range of frequency being considered is scanned 
steadily from one extreme end to the other by varying either the frequency of the 
transmitter or the magnetic field. The spectrum acquired is then plotted directly (as it 
is generated) to show the absorption (upwards) versus frequency (increasing to the 
left, as found in UV and IR spectroscopy) (Günther 1995; Williams and Fleming 
1996).  
In the FT method, the radio frequency signal is applied to the sample as a single 
powerful pulse lasting for a period of time (tP) usually a few microseconds. This 
pulse which effectively covers the whole frequency range generates an oscillating 
magnetic field (B1) along the x axis, at right angles to the applied magnetic field (B0), 
which is defined along the z axis (Jones and Mulloy 1993; Günther 1995; Williams 
and Fleming 1996).  
Due to the small difference between Nα and Nβ, the sample to be analysed has a net 
magnetisation (M), initially aligned in the direction of the magnetic field. The 
magnetisation is tipped by the applied pulse through an angle given by the equation: 
θ = yB1tP    Equation 4-4 
The time (tP) is usually chosen such that θ is 90
o 
and these kinds of pulses are termed 
π
/2 pulses (Williams and Fleming 1996). 
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The magnetisation thus disturbed from its orientation along the z axis precesses in 
the xy plane and the magnetisation orientated along the y axis is detected in a 
receiver coil (Günther 1995; Williams and Fleming 1996). Hence, after the 
application of the pulse, the signal detected starts as a positive signal in the + y axis, 
precesses to the x axis (zero signal) and then to the – y axis (negative signal). 
Usually, the signal is detected for times in the order of one second. The frequency of 
oscillation detected is the difference between the excitation frequency and the NMR 
resonance frequency (Williams and Fleming 1996). 
In FT NMR, emissions are recorded and stored in a computer as the nuclei relax and 
go back to the ground state. The data recorded is then converted from the time 
domain (FID) to the frequency domain (spectrum) by mathematical manipulation 
which is the Fourier transformation (Günther 1995; Guthrie 1997; Hinds and Norton 
1997). FT NMR possesses an important advantage over CW NMR which derives 
from the acquisition of the spectrum by the excitation of all the resonances 
simultaneously using a single pulse for a few seconds. This allows the collation of 
data obtained from many acquisitions which gives in turn greatly enhances the 
signal-to-noise ratio, making FT NMR much more sensitive than CW NMR (Jones 
and Mulloy 1993; Williams and Fleming 1996; Guthrie 1997). This is particularly 
important for the study of relatively insensitive nuclei such as 
13
C (also with a low 
occurrence; 1 in 100 carbon atoms) in biological samples, which would have 
otherwise been practically impossible (Williams and Fleming 1996; Guthrie 1997).  
Currently, CW spectra are seldom used except to obtain the first spectrum of a 
product from a reaction mixture, typically for 
1H spectra on samples ≥ 50 mg. On the 
other hand FT NMR is used to acquire all 
13
C spectra and for small samples 
quantities. FT NMR is also employed when accurate and well resolved spectra are 
required. For a typical 
13
C, a sample of about 50 – 100 mg is required while for FT 
1
H spectrum, a sample of 1 – 10 mg would normally suffice (Williams and Fleming 
1996).  
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For acquisition of an NMR spectrum, the sample to be analysed is usually dissolved 
in a solvent which would not give rise to additional signals in the spectrum. For this 
purpose, deuterated (in which most of the 
1
H have been replaced with 
2
H, that is 
deuterium) solvents are employed with the choice of solvent determined by the 
solubility of the sample to be analysed (Williams and Fleming 1996; Guthrie 1997). 
4.5.1.3.2.2 Chemical Shift 
The exact frequency at which an atom will experience resonance is determined by 
both the applied field (B0) and the very small differences in the magnetic 
environment experienced by each nucleus (Günther 1995; Williams and Fleming 
1996; Guthrie 1997). Such differences are a result of the variation in electron density 
surrounding each nucleus so that each chemically different atom (
1
H or 
13
C) in the 
structure under investigation would come into resonance at a frequency slightly 
different from the other nuclei (Williams and Fleming 1996). For each atomic 
nucleus in a magnetic field surrounded by other atoms, the electron clouds from the 
surrounding atomic nuclei will exert a small but significant effect which will create a 
“shielding effect” on the reference atom. The extent of the shielding effect will 
determine the precessional frequency of the reference atomic nucleus, such that the 
greater the shielding effect on the atomic nucleus (more dense electric cloud) the 
lower the precessional frequency and vice versa (Smith and Blandford 1995; Guthrie 
1997). In practise, it is rather cumbersome to characterise individual peaks by 
assigning a specific frequency to each of them, which would all be very close to the 
resonance frequency. The practicable alternative is to measure the difference in the 
frequency (νs) of the peak from that of a chosen internal standard (both in Hz). This 
difference is then divided by the operating frequency (in MHz) to get a field 
independent number in a convenient range.  
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More often than not tetramethylsilane (TMS) is used as internal standard in spectra 
acquisition. The chemical shift is defined by the equation: 
δ = [ν sample – ν reference] / operating frequency   Equation 4-5 
This yields a dimensionless quantity and is expressed in parts per million (ppm) 
(Jones and Mulloy 1993; Günther 1995; Smith and Blandford 1995; Williams and 
Fleming 1996; Guthrie 1997). 
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4.6 Materials and methods 
 Materials 4.6.1
4.6.1.1 List of materials 
S/n Material Supplier 
1 Fmoc- Phe- OH Novabiochem; Merck Schuchardt,  
OHG, Hohenbrunn, Germany 
2 Fmoc- Gly- OH Novabiochem 
3 Fmoc- Leu- OH Novabiochem 
4 Fmoc- Tyr- OH Novabiochem 
5 Fmoc- Arg(Pbf)- OH Novabiochem 
6 Fmoc- Tyr (2- ClTrt)- OH Novabiochem 
7 Fmoc- Leu- Wang resin [(0.64 
mmole/g); (100- 200 mesh)]  
Novabiochem 
8 Fmoc- Phe- Wang resin 
[(0.65mmole/g); (100- 200 
mesh)]  
Novabiochem 
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S/n Material Supplier 
9 Fmoc- Met- Wang resin  
[(0.70 mmole/g); (100 – 200 mesh)] 
Novabiochem 
10 2-(1 H- Benzotriazole- 1- yl)- 1,1,3,3- 
tetramethyluronium 
hexafluorophosphate (HBTU) 
Novabiochem 
11 N,N- Dimethylformamide (DMF) Rathburn Chemicals Ltd, 
Walkerburn, Scotland 
12 Dichloromethane (DCM) GPR Rectapur; VWR Chemicals, 
Fontenay-sous-Bois, France 
13 Dry DCM Sigma-Aldrich  
14 N,N-Diisopropylethylamine (DIEA) Sigma-Aldrich  
15 Trifluoroacetic acid (TFA) Sigma-Aldrich  
16 Triethylamine Sigma 
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S/n Material Supplier 
17 Palmitic acid N- hydroxysuccinimide 
ester 
Sigma 
18 Piperidine Sigma-Aldrich  
19 Triisopropylsilane (TIS) Sigma-Aldrich  
20 Methyl sulfoxide- d6 Sigma-Aldrich  
21 Acetonitrile (MeCN; HPLC grade) Sigma-Aldrich  
22 Water (H2O; HPLC grade) Sigma-Aldrich  
23 Diethyl ether Sigma-Aldrich  
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 Methods 4.6.2
4.6.2.1 Synthesis of PAs 
Three PAs (Peptides A, B and C) were synthesized manually by Fmoc SPPS 
protocols. Peptides A and B comprised essentially the same amino acid residues and 
differed only in the sequence and position of the acyl chain. Peptide A (O-Palm-Y-
G-G-L-R-F) possessed a terminal acyl substituent while peptide B (G-G-Y- (O-
Palm)-F-R-L) possessed a mid-chain acyl substituent. Peptide C is a novel analogue 
of the natural neuropeptide methionine enkephalin modified at the N- terminus with 
an acyl chain attached to the hydroxyl (OH) side chain of the tyrosyl residue (O-
Palm-Y-G-G-F-M). Peptide assembly for the three PAs was done on Wang resin pre- 
coupled with the C- terminal amino acid.  
For the synthesis of O-Palm-Y-G-G-L-R-F (0.5 mmole), Fmoc- Phe-Wang resin 
(770mg, 0.65 mmole/g substitution) was weighed in a glass weighing boat and 
transferred to a glass reaction vessel (sealable sintered glass funnel) and allowed to 
swell in DMF (10 mL) for 1 hour. The DMF was then drained off and the resin was 
washed with 2 further portions of DMF and drained (left wet). The Fmoc protecting 
group of the resin was removed by reacting the resin with piperidine in DMF (20 % 
v
/v) for 20 (2 X 10) minutes. Successful deprotection of the N-terminus was 
confirmed by performing the ninhydrin (Kaiser’s) test. A few resin beads were 
transferred from the reaction mixture unto a small sintered glass funnel and washed 
with a DCM and methanol (1 : 1) mixture and dried under vacuum. The resin beads 
were then transferred into a glass test tube to which was added 2 drops of Solution A 
(80 % 
w
/v phenol in ethanol); 4 drops of Solution B (2 % 
v
/v potassium cyanide in 
1mM pyridine) and 2 drops of Solution C (5 % 
w
/v ninhydrin in ethanol).  
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The test tube was then transferred to a heating block that had been pre- heated to 
120
o
 C for 3 – 5 minutes. Dark blue colouration of the resin beads indicates the 
presence of free primary amines on the resin, hence successful deprotection (Chan 
and White 2000). The deprotected resin was then washed thoroughly with copious 
amounts of DMF to ensure complete removal of piperidine and drained till just wet 
with minimum DMF. 
To the deprotected resin, N,N-diisopropylethylamine [(DIEA); 425 µL, 5 mmol)] 
was added, followed by Fmoc- Arg(Pbf)-OH (811 mg, 2.5 mmol) and 2-(1 H- 
benzotriazole- 1- yl)- 1,1,3,3- tetramethyluronium hexafluorophosphate [(HBTU); 
474 mg, 2.5 mmol)] dissolved in DMF (7 mL). The reaction vessel was capped and 
the reaction was left to proceed with constant agitation for 45 – 60 minutes. The 
reaction mixture was then washed off and the coupling process was repeated to 
ensure complete coupling of the amino acid. The ninhydrin test was performed to 
check the success of the coupling reaction. Production of a yellow to orange 
colouration of the resin beads indicates that coupling has been successful and a dark 
blue colour indicates unsuccessful coupling in which case coupling was repeated. 
Coupling of the other amino acids proceeded as described with the N
α
 protected 
Fmoc- amino acids [5 (2 X 2.5) molar equivalents] and HBTU [5 (2 X 2.5) molar 
equivalents] dissolved in DMF and DIEA (5 molar equivalents at each coupling), for 
30 minutes until the sequence was complete (Figure 4-3). Coupling and deprotection 
reactions were qualitatively monitored with the ninhydrin test.  
When peptide assembly was completed, the peptidyl-resin was washed thoroughly 
with DMF and drained, then with DCM and finally with a DCM and methanol (1 : 1) 
mixture and dried under vacuum. The resin was then transferred into a pre- weighed 
glass vial with the cap perforated and left in a dessicator (in vacuo) overnight.  
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Figure 4-3: Reaction scheme for peptide synthesis 
Key:  
I: Deprotection [piperidine/DMF (10 % 
v
/v); followed by washing (DMF); II: Coupling [HBTU 
(2.5 mmol) + N
α
- protected amino acid (2.5 mmol) + DIEA (5 mmol)] X 2; followed by washing 
(DMF) 
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Acylation of the peptides was achieved by coupling a palmitoyl (C16- alkyl) chain to 
the hydroxyl (OH) side chain of the tyrosyl residue of the peptides.  
For acylation of O-Palm-Y-G-G-L-R-F (0.2 mmol), the required peptidyl- resin 
(511.73 mg) was weighed and transferred into a the glass reaction vessel and swelled 
in DMF (10 mL) for 45 – 60 minutes; triethylamine (1.4 mL; 5 mmol) was added and 
to this mixture, palmitic acid N-hdroxysuccinimide ester (565.62 mg, 0.8 mmol) 
dissolved in DMF was added in a drop wise manner. The vessel was capped, and the 
reaction was left to proceed for 18 – 24 hours with constant agitation. Subsequently, 
the resin was filtered and washed thoroughly with DMF and deprotection of the N
α
 
group was carried out using piperidine in DMF (20 % 
v
/v) for 20 (2 X 10 minutes. 
The acylated peptidyl- resin was then washed thoroughly with DMF, drained and 
then washed with DCM followed by washing with a DCM and methanol (1 : 1) 
mixture, dried under vacuum and transferred into a pre-weighed glass vial (cap 
perforated) and left overnight in a dessicator (in vacuo) [Figure 4-4]. 
Synthesis of G-G-Y-(O-Palm)-F-R-L and O-Palm-Y-G-G-F-M were carried out as 
described above.  
However, to achieve acylation of G-G-Y-(O-Palm)-F-R-L, containing a side chain 
protected tyrosyl residue [Tyr (2- ClTrt)- OH], the protecting group had to be 
removed to make the OH group of the tyrosyl (side chain) residue available for the 
acylation reaction. Selective deprotection of the tyrosyl residue was achieved by 
weighing and transferring the required amount of the peptidyl resin (534 mg, 0.2 
mmole) into the glass reaction vessel. The resin was swelled in dry DCM (10 mL) 
for 45 – 60 minutes. The resin was then drained and a mixture of TFA/TIS/DCM 
(1/5/94 % 
v
/v; 5 mL) was added, the vessel was capped and the resin was agitated for 
2 minutes.  
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Figure 4-4: Reaction scheme for palmitoylation and final cleave to yield target PA 
Key:  
III: Palmitoylation reaction [N
α
-protected peptide (0.2 mmol) + triethylamine (5 mmol) + 
palmitic acid N-hdroxysuccinimide ester (0.8 mmol)]; followed by washing; I: Deprotection 
[piperidine/DMF (10 % 
v
/v); followed by washing (DMF); IV: Cleavage reaction: TFA/TIS/water 
(95/2.5/2.5 % 
v
/v) 
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A bright yellow colouration was observed, indicating the liberation of the 2- ClTrt 
group which is in turn scavenged by the TIS component of the cleavage mixture. The 
resin was drained and washed with dry DCM and the reaction was repeated until 
complete disappearance of the yellow colouration and then one more time to ensure 
complete removal of the Trt group. Subsequently, the resin was washed thoroughly 
with DCM and drained, then with DMF after which it was left to swell in DMF (10 
mL) for 30 minutes before proceeding with the acylation reaction as described above. 
In the case of O-Palm-Y-G-G-L-R-F and G-G-Y-(O-Palm)-F-R-L, acylated peptide 
was liberated from the resin using a high concentration TFA cleavage mixture 
consisting of TFA/TIS/H2O (95/2.5/2.5 % 
v
/v). Dry peptidyl resin was placed in a dry 
round bottom flask and the required amount of cleavage mixture (1mL per 0.1g of 
resin) was added, the flask was capped, and left to stand at room temperature with 
occasional swirling for 2.5 hours. The resin was then filtered and washed with further 
portions of TFA and the filtrate collected in a round bottom flask.  The cleavage 
mixture was then evaporated off under reduced pressure using a rotary evaporator 
(IKA
®
 HB 10 Digital, IKA®-Werke GmbH & Co. KG, Staufen, Germany) until an 
oily residue was left in the flask. The crude peptide was precipitated by drop wise 
addition of ice-cold ether using a glass pipette. The first layer of ether (containing 
residual cleavage mixture) was carefully removed with a glass pipette. The peptide 
was then washed with two further portions of ether. The ether was removed using a 
glass pipette and the peptide was dispersed in a mixture of acetonitrile and water (80 
: 20) and lyophilised. 
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In the case of O-Palm-Y-G-G-F-M, a cleavage mixture consisting of 
TFA/ethanedithiol/thianisole/anisole (90/3/5/2 % 
v
/v) was added to the dry peptidyl 
resin (1 mL per 0.1g of resin) in a dry glass vial, the vial was capped, sealed with 
parafilm and placed in a water bath (25
o
 C; 120 rpm) for 2 hours.  The resin was then 
filtered and washed with further portions of TFA and the filtrate collected in a round 
bottom flask.  The cleavage mixture was then evaporated off under reduced pressure 
(rotary evaporator; IKA
®
 HB 10 Digital, IKA
®
-Werke GmbH & Co. KG, Staufen, 
Germany) until an oily residue was left and the crude peptide was precipitated out by 
drop wise addition of cold double deionised (Millipore) water with a glass pipette 
and left in the fridge overnight. Cold ethanol was added to this and placed in the 
water bath (35
o
 C) for 45 minutes and a further portion of cold water (double 
deionised) was added to complete precipitation. 
The peptide was obtained by centrifugation (4
o
 C; 5000 rpm) for 30 minutes with 
careful removal of the supernatant (with a glass pipette), this was repeated 3 times 
and the peptide washed with fresh portions of cold water after the second 
centrifugation. The peptide was recovered by dissolving the sediment in a mixture of 
acetonitrile and water (80 : 20) and then lyophilised.  
4.6.2.2 Purification of synthesised PAs 
The crude PAs were purified by preparative RP HPLC on a C18 derivatised silica gel 
based column (Atlantis, USA: 10 µm; 19 mm X 250 mm) in a Waters HPLC system 
consisting of a Waters 2487 Dual λ Absorbance Detector, Waters 600 Controller and 
Waters Delta 600 pump. The peptides were injected at a concentration of 
approximately 5 mg mL
-1
 and eluted using the gradient method of elution with the 
mobile phase comprising two solvent systems: 0.02% TFA/H2O (Line A) and 90% 
MeCN /0.016% TFA/ H2O (Line B).  
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For O-Palm-Y-G-G-L-R-F and G-G-Y-(O-Palm)-F-R-L, the peptides were first 
dissolved in Line B (and 90% MeCN /0.016% TFA/ H2O) at low concentration (1 
mg mL
-1
), followed by centrifugation (30 minutes; 2000 rpm). The supernatant was 
carefully collected and then concentrated using a rotary evaporator (IKA
®
 HB 10 
Digital, IKA®-Werke GmbH & Co. KG, Staufen, Germany) to give a final 
concentration of approximately 5 mg mL
-1
. The peptides were then purified using a 
gradient elution method in which the concentration of the organic phase (Line B) of 
the solvent system was increased over a period of 52 minutes (55 % - 100 %), at a 
flow rate of 15 mL min
-1
 (Appendix IV). 
For O-Palm-Y-G-G-F-M on the other hand, the peptide was dissolved by first adding 
DMSO (100µL/ 20 mg sample) to the peptide and vortexing vigorously for about 30 
seconds. Subsequently, MeOH was added to give a final peptide concentration of     
5 mg mL
-1
. The gradient elution was carried out by increasing the concentration of 
the organic phase (Line B) over a period of 40 minutes (55 % - 100 %) at a flow rate 
of 20.4 mL min
-1 
(Appendix V).  
The eluent peaks (absorbance ≥ 0.2) at different retention times were collected in 
glass tubes and subjected to mass spectrometry analysis to identify the peak 
corresponding to the desired peptide mass. The fraction identified as the peptide peak 
was then freeze- dried and stored in the freezer (-20
o
C). 
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4.6.2.2.1 Determination of purity 
The level of purity for the purified PAs was determined by analytical RP HPLC 
using an analytical C18 derivatised silica gel based (Onyx Monolithic: 5 μm; 100 x 
4.6 mm; Phenomenex UK) column using an Agilent Technologies 1200 Series 
HPLC system. The PAs were eluted using a gradient method comprising solvent 
systems: 0.02% TFA/H2O (Line A) and 90% MeCN /0.016% TFA/ H2O (Line B), by 
increasing the concentration of the organic phase (Line B) over a period of 20 
minutes (0 – 100%) at a flow rate of 1.2 mL min-1 (Appendix VI). The 
chromatograms were acquired with the column temperature set at 40
o
 C and 
wavelength of detection was set at 214 nm. Following acquisition of chromatograms, 
all peaks were integrated and the percentage area under the curve (AUC) for the 
peptide peak was taken as the percentage purity for the peptide. 
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4.6.2.3 Characterisation of PAs 
The PAs were characterised by mass spectrometry (MS), nuclear magnetic resonance 
(NMR), and self-assembly was studied by electron microscopy. 
4.6.2.3.1 Mass Spectrometry (MS) 
The eluent peptide peak (from prep RP HPLC) was submitted (1 mL) for MS 
analysis by ESI MS and tandem MS/MS. The samples were analysed by a direct 
infusion ESI-MS
n
 using an LTQ (Thermo Scientific, Hemel Hempstead, UK) linear 
ion trap mass spectrometer. The direct infusion was performed through a 250 µL 
Hamilton syringe at 15 µLmin
-1
 flow rate. The LTQ was operated so that the MS
2 
event was performed after the MS scan. MS
2
 was performed on [M+H]
 +
 ions. The 
scan time was 200 ms with 3 microscans. The collision energy was set to 35 (35 % of 
the output) for the MS
2
 experiments.  
4.6.2.3.2 Nuclear Magnetic Resonance (NMR) 
The PAs were subjected to NMR analysis. The peptides (8mg) were dissolved in 
deuterated DMSO (0.7mL), bath sonicated and transferred into the NMR tubes. The 
NMR spectra were acquired on a Bruker AMX Ultrashield
TM
 400 MHz 
Spectrometer. 
4.6.2.3.3 Self-assembly 
The self-assembly of the PAs was studied by TEM imaging using a Philips (FEI) CM 
120 Bio Twin Transmission Electron Microscope (Philips, Eindhoven, The 
Netherlands)  and scanning electron microscopy (SEM) using a FEI QUANTA 200 F 
microscope (Eindhoven, The Netherlands). Also, molecular dynamics (MD) 
simulations was carried out on O-Palm-Y-G-G-L-R-F and G-G-Y- (O-Palm)-F-R-L. 
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4.6.2.3.3.1 TEM 
 PAs nanofibres were prepared by vortexing for 30 seconds and then probe 
sonication (QSonica sonicator, Connecticut, USA) of the aqueous peptide (1mgmL
-1 
in double deionised water) dispersions on ice at amplitude of 15. The PAs were 
probe sonicated for a total time of 5 minutes and 15 minutes for each PA to assess 
the ease with which they self-assemble into nanofibers. For TEM imaging, a drop of 
the peptide dispersion was placed on a formvar/ carbon coated grid and excess 
sample was blotted off on a filter paper (Whatman No 1). The samples were then 
negatively stained (uranyl acetate 1 % 
w
/v) and left for 1 – 2 minutes to air dry. 
Subsequently, images were captured on the TE microscope using an AMT digital 
camera (5 mega pixels; AMT Deben, UK Ltd).  
4.6.2.3.3.2 SEM 
For SEM imaging, the PA dispersions were prepared as described above and then 
diluted (1 in 10) with double deionised water to avoid excessive clumping. A thin 
layer of the dispersion for each PA was then applied unto a microscope stub and left 
in a desiccator (in vacuo) to dry. The resulting film on the stub was subsequently 
coated with a layer of gold (10 nm) using a sputter coater prior to imaging. SEM 
micrographs were subsequently acquired on the SE microscope.  
4.6.2.3.3.3 Molecular dynamics (MD) simulations of PA self-assembly 
MD simulations was employed to study the molecular organisation of O-Palm-Y-G-
G-L-R-F and G-G-Y- (O-Palm)-F-R-L into nanofibres. To be able to assess the 
microsecond timescales required for observation of self-assembly, the MARTINI 2.1 
coarse-grained (CG) potential for lipids (Marrink et al. 2007) and proteins 
(Monticelli et al. 2008) were employed, with slight refinement which made it 
possible to capture the chemistry of the PAs more accurately.  
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4.6.2.3.3.3.1 Atomistic MD simulation 
To refine the CG model, 50 ns of atomistic MD simulation of O-Palm-Y-G-G-L-R-F 
(linear PA) and G-G-Y- (O-Palm)-F-R-L (“T”-PA) were initially performed in 
TIP3P (Jorgensen et al. 1983) water using the CHARMM all atom force field 
(Brooks et al. 1983). The partial charges on the modified tyrosyl residues were 
defined based on parameters obtained for a related PA, palmitoyl dalargin (Mazza et 
al. 2013). A timestep of 2 fs was used for the simulations and the temperature was 
coupled to 300 K using the Nose-Hoover thermostat (Nose 1984; Hoover 1985) 
while the pressure was coupled to 1 bar using the Parrinello-Rahman barostat (Nose 
1983; Parrinello and Rahman 1981). Lennard-Jones interactions were cut off at 1.0 
nm and electrostatic interactions were calculated using the particle-mesh Ewald 
approach with a real-space cut off of 1.0 nm. Following the simulations, the bond 
angle distributions were calculated from the trajectory and used as target data for 
refinement of the CG models (Appendix VII).  
4.6.2.3.3.3.2 CG MD simulation 
CG linear and “T”-PAs were built using a mapping scheme (Figure 4-5). Essentially 
this follows the standard mapping for amino acid residues in the MARTINI 2.1 
protein force field (Brooks et al. 1983) except for the modified TYR residue which 
was represented by three hydrophobic particles (aromatic ring), one polar particle 
(ester group) and four additional hydrophobic particles (hydrocarbon tail) [Figure 
4-5]. As the MARTINI protein force field requires secondary structure information 
as an input parameter, the peptide backbone was initially assumed to adopt an 
extended β-sheet structure. The bond angle distributions from the atomistic 
simulations were then used to refine the equilibrium bond angles in the CG models.  
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To achieve this, simulations of a single CG peptide in water were carried out and the 
bond angle parameters (equilibrium bond angle and force constant) were iteratively 
modified until optimal agreement with the bond angle distributions from the 
atomistic simulations was achieved. The final set of bond angle parameters 
(Appendix VII), bond (length) parameters, bond constraints and improper dihedrals 
on the aromatic rings were unchanged from the native MARTINI force field. This 
optimal set of parameters was used in all subsequent simulations of PA self-
assembly.  
 
 
 
 
  
 
 
Figure 4-5: Coarse-grained mapping scheme for A: O-Palm-Y-G-G-L-R-F (Linear PA) and B: 
G-G-Y- (O-Palm) - F-R-L (“T”-PA) 
Key: Blue beads: Palmitoyl-Tyrosine residue; orange beads: Glycine residues; pink beads: 
Leucine residue; purple beads: Arginine residue; green beads: Phenylalanine residue.  
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4.6.2.3.3.3.3 Initial configurations 
Initial configurations for the self-assembly simulations were generated by randomly 
inserting 512 PAs into a cubic box and then solvating with 25600 CG water particles 
(each CG water particle represents four real water molecules) and 512 chloride 
counterions. Three different random configurations were generated for each of the 
PAs.  
To reveal the structure of the ends of the nanofibres we performed two additional 
simulations (one each of the linear and “T”-PA) of a more dilute solution of 512 PAs 
in 51200 CG water particles and 512 chloride counterions. Enlarging the simulation 
box in this way prevented the growing nanofibre from spanning the boundaries of the 
periodic simulation cell and thus it was possible to simulate the assembly of an 
isolated nanofibre and observe the arrangements of the peptide amphiphiles at the 
ends of the nanofibres. 
4.6.2.3.3.3.4 CG simulation parameters 
Simulations were carried out in the isothermal – isobaric (Gibbs) ensemble (NPT) in 
which the temperature and pressure are constrained, that is, they have specified 
average values (Hünenberger 2005). The temperature of the system was maintained 
at 300 K and isotropic pressure coupling was applied to maintain a pressure of 1 bar 
using the Berendsen thermostat and barostat (Berendsen et al. 1984). Electrostatic 
and Lennard-Jones interactions were shifted to zero between 0.9 nm and the cut-off 
distance, which was 1.2 nm. Coordinates were saved every 5000 steps for analysis. 
To equilibrate the solvent around the peptides, MD simulations were carried out for 
900 ns, with position restraints of 1000 kJ mol
-1
 on all peptide particles, followed by 
600 ns, with position restraints of 10 kJ mol
-1
 on all peptide particles. Over this time 
the volume of the simulation cell shrank from 20.0 nm
3
 to 17.3 nm
3
. The time step 
for all the CG simulations was 30 fs. Following equilibration, MD simulations of 
self-assembly was carried out for at least 5 μs for each PA.  
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 Results 4.6.3
The three peptides: O-Palm-Y-G-G-L-R-F, G-G-Y- (O-Palm)-F-R-L, and Palm- Y-
G-G-F-M were successfully synthesized. Characterisation data confirmed synthesis 
and the ability of the PAs to assemble into nanofibers in aqueous medium was 
revealed by TEM and SEM micrographs. 
4.6.3.1 Mass spectrometry  
Mass spectrometry revealed the expected mass for the compounds: electrospray 
ionization m/z calculated for C50H79N9O9 = 950.22; found 950.75 (M+H)
+ 
for O-
Palm-Y-G-G-L-R-F (Figure 4-6) and 950.87 (M+H)
+ 
for G-G-Y- (O-Palm)-F-R-L 
(Figure 4-9) and m/z calculated for C43H65O8S = 812.07; found 834.62 (M+Na)
+ 
for 
O-Palm-Y-G-G-F-M (Figure 4-12). Also, MS/MS spectra showed correct amino acid 
sequence for the three peptides (Figure 4-7; Figure 4-10; Figure 4-13) as deduced 
from the resulting fragment peaks (Table 4-1; Table 4-2; Table 4-3).  
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Figure 4-6: ESI MS spectra for O-Palm-Y-G-G-L-R-F 
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Figure 4-7: MS/MS spectra for O-Palm-Y-G-G-L-R-F 
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m/z Corresponding fragment ion 
915.47 (M + H) – 2H20  
785.44 (M + H) – F  
516.13 [(M + H) – F] – R- L  
459.16 {[(M + H) – F] – R- L} – G  
402.16 {[(M + H) – F] – R- L} – G – G = 
Y-(O- palmitoyl) 
385.23 Y-(O- palmitoyl) – OH  
 
Table 4-1: MS/MS peak assignment for O-Palm-Y-G-G-L-R-F 
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Figure 4-8: Major MS/MS fragment ions for O-Palm-Y-G-G-L-R-F 
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Figure 4-9: ESI MS spectra for G-G-Y- (O-Palm) - F-R-L 
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Figure 4-10: MS/MS spectra for G-G-Y- (O-Palm) - F-R-L 
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m/z Corresponding fragment ion 
819.55 (M + H) – L – H2O 
795.54 [(M + H) – L – H2O] – CN + 2H
+
 
759.54 {[(M + H) – L – H2O] – CN + 2H
+
} – 
2(H2O) 
542.38 {[(M + H) – L – H2O] – CN + 2H
+
} – 
2(H2O) – R – CNO – H2O – H
+
 
525.35 {[(M + H) – L – H2O] – CN + 2H
+
} – 
2(H2O) – R – CNO – H2O – H
+ – OH    
516.18 [(M + H) – L – H2O] – R – F 
488.23 {[(M + H) – L – H2O] – R – F} – CO 
468.32 {[(M + H) – L – H2O] – R – F} – CO – H2O 
– 2H+  
305.21 {[(M + H) – L – H2O] – R – F} – (O-
Palmitoyl) + (CHO) 
= G-G-Y + CHO  
 
Table 4-2: MS/MS peak assignment for G-G-Y- (O-Palm) - F-R-L 
 
  
 227 
 
Nanoparticle based strategies for the treatment of Glioblastoma 
 
 
Figure 4-11: Major MS/MS fragment ions for G-G-Y- (O-Palm) - F-R-L 
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Figure 4-12: ESI spectra for O- Palm-Y-G-G-F-M 
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Figure 4-13: MS/MS spectra for O- Palm-Y-G-G-F-M 
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m/z Corresponding fragment ion 
811.64 M – H  
794.36 M – H2O 
663.22 (M- H2O) – M
5
  
635.31 [(M- H2O) – M
5
] – CO  
618.37 {[(M- H2O) – M
5
] – CO} – OH 
516.24 (M- H2O) – M
5
 – F  
459.19 {(M- H2O) – M
5
 – F] – G  
411.18 [(M- H2O) – M
5
 – F] – G – C – 
2H2O 
374.41 {[(M- H2O) – M5 – F] – G – C – 
2H2O – G} + H2O + 2H 
= Y-(O- palmitoyl) – CO 
 
Table 4-3: MS/MS peak assignment O- Palm-Y-G-G-F-M 
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Figure 4-14: Major MS/MS fragment ions for O- Palm-Y-G-G-F-M 
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4.6.3.2 Nuclear magnetic resonance (NMR) 
The 
1
HNMR spectra [interpreted with the aid of COSY (fixed) spectra] acquired for 
the peptides revealed the relevant proton peaks in the synthesised PAs (Figure 4-15; 
Figure 4-16; Figure 4-17; Appendix IX A – C).  
 
Figure 4-15: 
1
HNMR spectra for O-Palm-Y-G-G-L-R-F 
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Figure 4-16: 
1
HNMR spectra for G-G-Y- (O-Palm) - F-R-L 
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Figure 4-17: 
1
HNMR spectra for O- Palm-Y-G-G-F-M 
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4.6.3.3 Determination of purity 
Analytical RP HPLC of the purified PAs showed that a purity level higher than 90 % 
was achieved for the three PAs following preparative RP HPLC purification (Figure 
4-18; Figure 4-19; Figure 4-20) 
 
 
 
 
 
 
 
 
 
Figure 4-18: Analytical RP HPLC chromatogram for O-Palm-Y-G-G-L-R-F 
Linear gradient 0 – 100 % organic phase (90 % MeCN/0.016 % TFA/H2O) over 20 minutes.  
 
 
 
 
Solvent peak 
O-Palm-Y-G-G-L-R-F 
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The HPLC chromatograph showed that the purity level achieved for O-Palm-Y-G-G-
L-R-F was 95 %, with a retention time of 16.315 minutes using the gradient system 
employed (Figure 4-18). 
For G-G-Y- (O-Palm) - F-R-L, analytical HPLC revealed a purity of 91 % with a 
retention time of 16.893 minutes (Figure 4-19). 
 
Figure 4-19: Analytical RP HPLC chromatogram for G-G-Y- (O-Palm) - F-R-L 
Linear gradient 0 – 100 % organic phase (90 % MeCN/0.016 % TFA/H2O) over 20 minutes. 
 
 
 
 
 
G-G-Y- (O-Palm) - F-R-L 
Solvent peak 
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Analytical RP HPLC for O-Palm-Y-G-G-F-M also showed the purity to be 94 % 
with a retention time of 18.241 minutes (Figure 4-20). 
 
Figure 4-20: Analytical RP HPLC chromatogram for O-Palm-Y-G-G-F-M. 
Linear gradient 0 – 100 % organic phase (90 % MeCN/0.016 % TFA/H2O) over 20 minutes. 
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O-Palm-Y-G-G-F-M 
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4.6.3.4 Self-assembly 
4.6.3.4.1 TEM  
TEM micrographs have shown that all three PAs synthesised can self-assemble into 
nanofibres in aqueous medium (Figure 4-21; Figure 4-22; Figure 4-23), irrespective 
of the position of the acyl chain.  
 
Figure 4-21: TEM micrographs for O-Palm-Y-G-G-L-R-F (1 mg mL
-1
) 
O-Palm-Y-G-G-L-R-F (1 mg mL
-1
) in double deionised water, vortexed for 30 seconds then 
probe sonicated (QSonica sonicator, Connecticut, USA) on ice for 5 minutes (left) or 15 minutes 
(right) at amplitude of 15. 
The TEM micrographs show formation of nanofibres measuring 10 – 12 nm in 
diameter with variable length up to 1 µm. The nanofibres are formed mostly as 
individual fibres with straight needle-like morphology [Figure 4-21; Appendix X 
(A)].  
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Figure 4-22: TEM micrographs for G-G-Y- (O-Palm) - F-R-L (1 mg mL
-1
) 
G-G-Y- (O-Palm) - F-R-L (1 mg mL
-1
) in double deionised water, vortexed for 30 seconds then 
probe sonicated (QSonica sonicator, Connecticut, USA) on ice for 5 minutes (left) or 15 minutes 
(right) at amplitude of 15. 
 
The TEM micrographs reveal formation of nanofibres approximately 10 nm in 
diameter while the length varies up to almost 1.5 µm. The nanofibres show an 
extensive network of fibres which are well formed even from the short sonication 
time of 5 minutes [Figure 4-22; Appendix X (B)].  
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Although both O-Palm-Y-G-G-L-R-F (linear PA) and G-G-Y- (O-Palm) - F-R-L 
(“T”-PA) have been shown to self-assemble into nanofibres, the resulting assemblies 
from the two PAs possess distinct morphologies as seen in the TEM micrographs 
(Figure 4-21; Figure 4-22). While O-Palm-Y-G-G-L-R-F self-assemble to form 
mostly straight individual fibres in aqueous medium, G-G-Y- (O-Palm) - F-R-L 
forms thinner, slightly curved and longer fibres which are joined to each other 
appearing to form a network of fibres (Figure 4-22). This might be the result of the 
difference in the molecular architecture of the two PAs. Although they comprise the 
same amino acids and so would be expected to possess more or less the same 
properties, O-Palm-Y-G-G-L-R-F has a linear arrangement while G-G-Y- (O-Palm) - 
F-R-L is shaped like a “T”. The mid-chain location of the acyl chain in the “T”-PA 
may lead to enhanced hydrophobic as well as π – π interactions of the tyrosyl and 
phenylalanyl side chains, leading to the formation of extensive fibre networks at a 
concentration as low as 1 mg mL
-1 
(0.1 % 
w
/v) in aqueous medium. This might be 
indicative of the possibility for gel formation at an even lower concentration than the 
concentrations (0.25 – 0.5 % w/v) that had been previously reported in literature.  
At these relatively low concentrations (0.25 – 0.5 % w/v),  ionic PAs had been shown 
to self-assemble into nanofibres which can then entangle into networks to form self-
supporting gels as a result of lowering the pH or addition of metal ions (Beniash et 
al. 2005; Stendahl et al. 2006). The induction of gelation in the PAs as a result of 
lowering the pH or addition of metal ions implies that their self-assembly is initiated 
by the screening of their charges by counterions in the medium, leading to a 
reduction in the double layer repulsive forces. Subsequently, other non-covalent 
attractive forces such as such as van der Waals and hydrophobic forces, ionic 
bridging, coordination and hydrogen bonding promote close association of the 
amphiphilic molecules to form the nanofibres (Stendahl et al. 2006).  
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Therefore, apart from metal ions, self-assembly and stability of nanofibre gels 
formed by the PAs are also greatly influenced by the interplay of factors related to 
the chemistry of each individual PA such as hydrophobic interactions including 
attraction between hydrophobic tails, intermolecular interaction of the side chains of 
hydrophobic amino acid residues, hydrophilic repulsion, hydrogen bonding in the 
peptide region, and the molecular geometry in relation to amphiphilic packing 
(Beniash et al. 2005; Stendahl et al. 2006). In these PAs, the formation of 
supramolecular nanofibres which impede the thermal motion of the solution and 
resist external shear stress, lead to the transition from the liquid state to a self-
supporting gel (Stendahl et al. 2006). 
Thus, in contrast to a linear PA comprising the same amino acids (O-Palm-Y-G-G-L-
R-F), the “T”-PA [G-G-Y- (O-Palm) - F-R-L] demonstrated the ability to form 
extensive nanofibre networks in aqueous medium (double deionized water) at a 
concentration as low as 0.1 % 
w
/v, which may be attributed to the unique molecular 
architecture (“T”-shape) of G-G-Y- (O-Palm) - F-R-L.  
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The TEM micrographs for O-Palm-Y-G-G-F-M reveal the formation of short, 
slightly twisted nanofibres approximately 10 nm – 20 nm in diameter and less than 
500 nm in length. The nanofibres tend to occur with two or three fibres close 
together and they also lie across each other to form short nanofibre networks [Figure 
4-23; Appendix X (C)]. 
 
Figure 4-23: TEM micrographs for O-Palm-Y-G-G-F-M (1 mg mL
-1
) 
O-Palm-Y-G-G-F-M (1 mg mL
-1
) in double deionised water, vortexed for 30 seconds then probe 
sonicated (QSonica sonicator, Connecticut, USA) on ice for 5 minutes (left) or 15 minutes (right) 
at amplitude of 15. 
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4.6.3.5 SEM 
SEM micrographs also show that all the three PAs synthesized self-assemble into 
nanofibers (Figure 4-24; Figure 4-25; Figure 4-26). 
 
 
Figure 4-24: SEM micrograph for O-Palm-Y-G-G-L-R-F (1 mg mL
-1
) 
O-Palm-Y-G-G-L-R-F (1 mg mL
-1
) in double deionised water, vortexed for 30 seconds then 
probe sonicated (QSonica sonicator, Connecticut, USA) on ice for 15 minutes at amplitude of 15; 
diluted 1 in 10 before preparation for imaging.  
The SEM micrograph shows nanofibers of the PA as well as clumps of the PA on the 
stub surface (Figure 4-24). 
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Figure 4-25: SEM micrograph for G-G-Y- (O-Palm) - F-R-L (1mg mL
-1
) 
G-G-Y- (O-Palm) - F-R-L (1 mg mL
-1
) in double deionised water, vortexed for 30 seconds then 
probe sonicated (QSonica sonicator, Connecticut, USA) on ice for 15 minutes at amplitude of 15, 
diluted 1 in 10 before preparation for imaging. 
 
The SEM micrograph show nanofibers of the PA as well as some clumps of dried PA 
on the stub surface (Figure 4-25). 
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Figure 4-26: SEM micrographs for O-Palm-Y-G-G-F-M (1 mg mL
-1
) 
O-Palm-Y-G-G-F-M (1 mg mL
-1
) in double deionised water, vortexed for 30 seconds then probe 
sonicated (QSonica sonicator, Connecticut, USA) on ice for 15 minutes at amplitude of 15, 
diluted 1 in 10 before preparation for imaging 
 
The SEM micrographs show nanofibers of the PA as well as a few clumps from 
aggregates in the sample (Figure 4-26). 
The SEM micrographs for O-Palm-Y-G-G-F-M reveal the formation of short 
networks of twisted PA nanofibres. Although O-Palm-Y-G-G-F-M is also able to 
form fibre networks in aqueous medium (double deionized water) at low 
concentration (0.1 % w/v), the fibre networks observed in the case of O-Palm-Y-G-
G-F-M are short and are not continuous (Figure 4 26) as the networks observed for 
G-G-Y- (O-Palm) - F-R-L (Figure 4 25). 
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4.6.3.6 Molecular Dynamics (MD) modelling 
4.6.3.6.1 Coarse-grain MD modelling simulations 
MD modelling using coarse-grained (CG) models was successfully applied to model 
the self-assembly of O-Palm-Y-G-G-L-R-F: terminal acyl chain and G-G-Y- (O-
Palm) - F-R-L: mid-chain located acyl chain. 
The CG MD simulations data showed nanofibre formation for both the linear PA (O-
Palm-Y-G-G-L-R-F) with terminal acyl chain (Figure 4-27) and the “T”-PA [G-G-Y- 
(O-Palm) - F-R-L] with mid-chain located acyl chain (Figure 4-28). 
 
    
 
Figure 4-27: Snapshots of the simulations of nanofibre formed through self-assembly of O-
Palm-Y-G-G-L-R-F (Linear PA) 
Key: Orange spheres: Peptide backbone; blue lines: acyl chain. Side chain particles, water and 
ions are removed for clarity. 
 
 
 
Time = 5.2 µs Time = 5.2 µs _ rotated (90
o
) 
A B 
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Figure 4-28: Snapshots of the simulations of nanofibre formed through self-assembly of G-G-Y- 
(O-Palm) - F-R-L (“T”-PA) 
Key: Orange spheres: Peptide backbone; blue lines: acyl chain. Side chain particles, water and 
ions are removed for clarity. 
 
In the self-assembly process, the “T”-PA seemed to have a tendency to aggregate 
more quickly and to a greater extent, with the final assembled fibre showing the 
formation of multiple inter-chain contacts (networks). Also, the fibres appear to 
exhibit what looks like a branch to varying extents in the final assembly, which was 
observed in three independent simulation runs for the peptide (Figure 4-29; 
Appendix XI). The linear PA on the other hand exhibited somewhat slower 
aggregation with lower degree of inter-chain contacts (Figure 4-30). Branching was 
observed in one out of three simulation runs for the linear PA (Appendix XII). The 
branching and networks observed in the “T”-PA may be the result of the architecture 
of this PA.  
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B 
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Figure 4-29: Snapshots of the simulation of the self-assembly process for G-G-Y-(O-Palm) - F-
R-L at different time intervals during the simulation  
Key: Orange spheres: Peptide backbone; blue lines: acyl chain. Side chain particles, water and 
ions are removed for clarity. 
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Figure 4-30: Snapshots of the simulation of the self-assembly process for O-Palm-Y-G-G-L-R-F  
Key: Orange spheres: Peptide backbone; blue lines: acyl chain. Side chain particles, water and 
ions are removed for clarity. 
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In the “T”-PA, the acyl chain-modified tyrosyl residue is located in the mid-region 
rather than at the end of the molecule and is next to the phenylalanyl residue which 
also has a phenyl side chain. Thus, in the “T”-PA, the bulky groups are located in the 
middle of the PA while there is no bulky group at the end of the molecule. 
Intermolecular contact of the hydrophobic side chains of amino acid residues of PA 
may enhance the driving force for the self-assembly of PAs (Beniash et al. 2005). 
The location of the phenyl side chains for both the tyrosyl and phenyalaninyl 
residues in the mid-region will also result in the π – π interactions of the phenyl rings 
which also contribute to the self-assembly (Reches and Gazit 2003; Paramonov et al. 
2006; Yan et al. 2008) to be concentrated in the mid-region. Thus in the “T”-PA, the 
multiple inter-chain contacts observed may be the result of the localization of the 
hydrophobic as well as π – π interactions in the mid-region of the PA molecule 
which fostered multiple inter-chain bonding of the PA molecules. This resulted in the 
formation of the extensive fibre networks and branching observed for the “T”-PA. In 
the linear PA on the other hand, the acyl chain-modified tyrosyl residue and the 
phenylalanyl residue are located far apart in the PA molecule thus resulting in the 
reduced inter-chain contacts observed in this PA. 
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4.6.3.6.2 Radial distribution function (RDF) 
The RDFs for O-Palm-Y-G-G-L-R-F and G-G-Y- (O-Palm) - F-R-L suggest the 
formation of antiparallel β- sheets by the two peptides (Figure 4-31; Figure 4-32). 
RDFs serve as a means of determining the probability of finding a particular atom 
type within a specified distance of another atom chosen as the reference. The peaks 
generated reveal the extent of the interaction between the two atoms such that a big 
and sharp peak is indicative of a strong interaction (Langham et al. 2007). 
 
Figure 4-31: Radial distribution function for O-Palm-Y-G-G-L-R-F 
Key: r is the distance in nm; g(r) is the probability of finding an atom within the distance tested 
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Figure 4-32: Radial distribution function for G-G-Y- (O-Palm) - F-R-L 
Key: r is the distance in nm; g(r) is the probability of finding an atom within the distance tested 
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The RDFs for both O-Palm-Y-G-G-L-R-F and G-G-Y- (O-Palm) - F-R-L showed 
similar peak patterns for the termini tested. (Figure 4-31; Figure 4-32).  
The RDFs reveal a sharp peak for C- terminus and N- terminus atoms for both 
peptides. However, there are some differences in the heights of the peaks for the 
other termini interactions. For O-Palm-Y-G-G-L-R-F, there was a slightly higher 
peak for the C- terminus and C- terminus atoms whereas for G-G-Y- (O-Palm) - F-R-
L, the peak for N- terminus and N- terminus atoms was higher than that for O-Palm-
Y-G-G-L-R-F (Figure 4-31; Figure 4-32). 
The RDFs suggest antiparallel β-sheet formation for both O-Palm-Y-G-G-L-R-F and 
G-G-Y- (O-Palm) - F-R-L as the peak obtained for the interaction of the C- terminus 
and the N- terminus is sharp indicating that there is a strong interaction as would be 
expected for atoms in close proximity (Langham et al. 2007). The differences 
obtained for the peak of the interaction for the other termini may be as a result of the 
differences in their molecular architecture. 
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 Discussion and conclusions 4.6.4
The PAs synthesized were successfully purified to relatively high purity levels 
(Figure 4-18; Figure 4-19; Figure 4-20). The PAs (O-Palm-Y-G-G-L-R-F and G-G-
Y- (O-Palm) - F-R-L) which comprise essentially the same amino acids but with 
modifications in the sequence and architecture of the molecules show some 
differences in hydrophobicity as shown in their retention times in RP HPLC. O-
Palm-Y-G-G-L-R-F showed a retention time of 16.315 minutes (Figure 4-18) while 
G-G-Y- (O-Palm) - F-R-L showed a retention time of 16.893 minutes (Figure 4-19). 
This suggests that O-Palm-Y-G-G-L-R-F is somewhat more hydrophobic than G-G-
Y- (O-Palm) - F-R-L. Also, TEM micrographs of the PAs negatively stained with 
uranyl acetate (1 % ) show that O-Palm-Y-G-G-L-R-F (Figure 4-21) was more 
stained than G-G-Y- (O-Palm) - F-R-L (Figure 4-22), also indicating that G-G-Y- 
(O-Palm) - F-R-L being less stained with uranyl acetate is more hydrophobic than O-
Palm-Y-G-G-L-R-F (Beniash et al. 2005). 
Furthermore, the novel methionine
5
- enkephalin analogue, O-Palm-Y-G-G-F-M 
showed a retention time of 18.241 minutes (Figure 4-23) and less staining on TEM 
micrographs (Figure 4-23), implying that this PA is even more hydrophobic than O-
Palm-Y-G-G-L-R-F and G-G-Y- (O-Palm) - F-R-L. 
PAs comprising a short hydrophobic portion, usually an alkyl chain bonded to a short 
peptide sequence (hydrophilic in comparison to the alkyl chain), have been shown to 
self- assemble into high- aspect- ratio nanofibres under defined solution conditions, 
such as pH, temperature and ionic strength (Hartgerink et al. 2001; Hartgerink et al. 
2002; Cui et al. 2010).  
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These PAs are usually designed to possess a β-sheet forming peptide region which 
facilitates intermolecular hydrogen bonding and which causes the PAs to assemble 
into high aspect ratio nanofibres (cylindrical or twisted), a hydrophobic region 
usually an alkyl chain, a region of charged amino acids to facilitate water solubility 
and pH or salt – induced self-assembly (optional) and another region which may be 
used for the display of bioactive epitopes on the surface of the nanostructure 
(Webber et al. 2009). Thus, these PAs invariably incorporate the β-sheet forming 
peptide region and the active epitope as separate portions of the PA molecule. 
More recently, work by Mazza and co – workers demonstrated the self-assembly of a 
PA comprising only of a β- sheet forming peptide region and an alkyl chain, the  β-
sheet forming peptide region also being the active epitope. Their work demonstrated 
that the PA, palmitoyl dalargin (pDal), a novel analogue of the hexapeptide dalargin, 
an opioid receptor agonist was transported into the brain. Their data showed that 
dalargin was not detected in tissue samples (plasma, liver or brain) following 
intravenous administration of either dalargin or pDal, and what could be detected in 
plasma was the main metabolite of dalargin (D- Ala
2
 –Leu5- enkephalin). On the 
contrary, pDal was detected in all the tissue samples and most importantly in the 
brain up to 4 hours following intravenous administration of pDal nanofibres (Mazza 
et al. 2013). Thus, PAs combining the β- sheet forming peptide and the active 
epitope into one region may be used to facilitate the transport and delivery of active 
peptides as therapeutics for treatment of CNS pathologies. PAs designed in this 
manner are expected to yield the active peptide following cleavage of the ester bond 
linking the peptide to the alkyl chain by endogenous esterases as reported by Lalatsa 
and co – workers for a similarly modified peptide (palmitoyl leucine5-enkephalin; 
TPLENK) which was shown to yield the active peptide, leucine
5
-enkephalin 
following administration of TPLENK (Lalatsa et al. 2012a).  
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The molecular design of these PA nanofibers is essentially like that of pro drugs 
which dissociate to release the active moiety at the desired site of action. These PA 
nanofibers consist of a peptide molecule covalently linked to the alkyl chain 
(palmitic acid tail) through an ester bond. Following transport and localisation at the 
site of action, the ester linkage between the alkyl chain and peptide would be cleaved 
by endogenous carboxylesterases. These enzymes catalyze the hydrolysis of a variety 
of ester containing xenobiotics and endogenous compounds to yield the free acids. 
They therefore limit distribution of potentially toxic substances and facilitate their 
elimination by converting them into polar molecules. This process of bioconversion 
is exploited in the design of pro drugs for the release of the active drug at the desired 
site of action (Sogorb and Vilanova 2002; Satoh and Hosokawa 1998). 
 For the synthesized PAs therefore, hydrolysis of the ester bond by the 
carboxylesterase will lead to dissociation of the nanofibers yielding free palmitic acid 
and the peptide molecule as separate entities. 
From the foregoing, the PAs synthesized in this present study may be employed in 
the delivery of non-BBB penetrating drugs to the brain by aiding their transport 
across the BBB. Thus, O-Palm-Y-G-G-L-R-F and G-G-Y- (O-Palm) - F-R-L could 
be employed in the transport and delivery of therapeutics to the brain for the 
treatment of glioblastoma and other intracranial tumours.  
On the other hand, this PA design will enable the transport of methionine
5
-
enkephalin to the brain using the self-assembling PA analogue, O-Palm-Y-G-G-F-M. 
Methionine
5
-enkephalin has been reported in previous studies to possess inhibitory 
activities against different cancers including neuroblastoma (Zagon and McLaughlin 
1989), pancreatic cancer (Zagon et al. 1997); ovarian cancer (Donahue et al. 2011) 
and human squamous cell carcinoma of the head and neck (McLaughlin et al. 2003).  
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Thus, the synthesized analogue (O-Palm-Y-G-G-F-M) would facilitate the transport 
and delivery of methionine
5
- enkephalin to the brain for the treatment of intracranial 
tumours as shown for dalargin (Mazza et al. 2013).  
Furthermore, the present study has shown that a PA possessing a mid-chain located 
acyl chain rather than the conventional terminal acyl chain is also able to self-
assemble into nanofibres. This “T”-PA [G-G-Y- (O-Palm) - F-R-L] showed the 
formation of extensive nanofibre networks at low aqueous PA concentration (0.1 % 
w
/v) after a short sonication time of 5 minutes as revealed in TEM and SEM 
micrographs  (Figure 4-22; Figure 4-25). Such extensive network was not observed 
in the linear PA (O-Palm-Y-G-G-L-R-F) comprising the same amino acids but 
possessing the conventional terminally located acyl chain (Figure 4-21; Figure 4-24). 
Also, CG MD modelling data further supported the tendency for the “T”-PA (Figure 
4-29) to self-assemble into nanofibre networks. The MD modeling data revealed that 
the “T”-PA had a greater tendency to form multiple inter-chain contacts in the 
assembled fibres. This is in agreement with the formation of fibre networks observed 
in TEM and SEM micrographs for this the “T”-PA (Figure 4-22; Figure 4-25). The 
linear PA on the other hand showed less tendency for inter-chain contacts in the MD 
modelling (Figure 4-30; Appendix XII) and this also correlated with the formation of 
individual (not joined) fibres revealed in the TEM and SEM micrographs (Figure 
4-21; Figure 4-24). This suggests that the unique molecular architecture of the “T”-
PA may provide additional advantages for the application of similarly designed PAs 
in drug delivery as they may provide more drug loading efficiency than the 
conventional PAs comprising terminally located acyl substituents.  
 
 
 
 
 258 
 
Nanoparticle based strategies for the treatment of Glioblastoma 
Therefore, the data reported in this present study indicates that in the PAs 
synthesised, the hydrophobic interactions of the alkyl chains, the intermolecular 
hydrogen bonding of the peptide segments as well as stacking of the aromatic side 
chains (of phenylalanine and tyrosine residues) by π – π interactions necessary for 
formation of fibres (Reches and Gazit 2003; Paramonov et al. 2006; Yan et al. 2008) 
were not disrupted by changing the position of the acyl chain as in the case of G-G-
Y-(O-Palm)-F-R-L (“T”-PA) which possessed a mid-chain acyl substituent. 
 Thus, this current work has demonstrated the ability of a PA possessing a mid-chain 
acyl substituent (“T”-PA) to self-assemble into nanofibres which has not been 
previously reported in literature. PAs possessing such molecular architecture could 
represent a unique drug delivery construct for delivery of therapeutics to the brain. 
The position (mid-chain location) of the acyl chain may confer an added advantage 
for the formation of slightly different supramolecular structure from what would be 
obtained from the conventional linear (terminal acyl chain) PAs. Moreover, there is 
indication that PAs possessing mid-chain located acyl substituents may be more 
hydrophobic and they form more extensive networks than their linear counterparts. 
This may also be advantageous in the delivery of hydrophobic drugs which may be 
better solubilised using PAs with this unique (“T”) architecture.  
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Chapter 5 Conclusion and Future work 
5.1 Conclusion 
Glioblastoma still remains a largely incurable disease in spite of tremendous research 
and resultant advances in the treatment strategies employed in the management of the 
disease (Stupp et al. 2009; Chamberlain 2010; Grossman et al. 2010). This calls for 
urgent development of novel strategies for the effective management of the disease 
to yield better treatment outcomes (Chamberlain 2010; Raizer 2011; Malmström et 
al. 2012). 
Chemotherapy induced dose-limiting myelosuppression is a major limitation in the 
successful management of glioblastoma using clinically employed cytotoxic agents 
(Newlands et al. 1992; Peters et al. 1993; Carey 2003; Stupp et al. 2005; 
Chamberlain 2010). This imposes a limitation on the extent of potentially beneficial 
dose intensification (Boesen et al. 1994; Tolcher et al. 2003; Crawford et al. 2004; Su 
et al. 2005; Tosoni et al. 2006; Gerber et al. 2007) with currently used therapeutic 
agents. The incidence of myelosuppression frequently necessitates dose delays or 
reductions and in some cases the need for outright disruption of drug treatment. This 
compromises the effectiveness of the therapeutic agents as there are indications that 
continuous exposure of tumour cells to cytotoxic therapy may improve treatment 
outcomes by improving chemosensitivity of tumour cells (Dolan et al. 1990; Brandes 
et al. 2006; Wick et al. 2007). Moreover, dose interruptions have been shown to 
compromise tumour response to therapy (Hitron 2011). 
In this study, lomustine an alkylating nitrosourea that has been clinically employed in 
glioblastoma chemotherapy was selected as the model drug. Lomustine like other 
nitrosoureas produces dose limiting myelosuppression manifesting as neutropenia 
and thrombocytopenia. This necessitates the observance of “treatment holidays” in 
clinical practice.  
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Thus, patients receive an initial dose of lomustine (100 – 130 mg m-2) with a rest 
period of 6 – 8 weeks and repeat doses are administered only if haematologic 
parameters are recovered at the end of this rest period (Cianfriglia et al. 1980; van 
den Bent et al. 1998; van den Bent et al. 2006; Jakacki et al. 1998). 
Lomustine is soluble in organic solvents but practically insoluble in water (Ph Eur 
2014). This solubility profile of lomustine poses a challenge in the aqueous 
formulation of the drug. The self-assembling amphiphilic GCPQ nanoparticles 
employed in this study had been previously shown to facilitate the encapsulation of 
the hydrophobic intravenous anaesthetic, propofol at a higher level than is obtained 
with triblock copolymers.  The polymer formulation increased the brain activity of 
propofol by producing sleep times that were up to 10 times those obtained with 
commercial formulations of the drug. This demonstrates the efficiency of GCPQ 
nanoparticles in aqueous formulation of hydrophobic drugs (Qu et al. 2006).  
In this study, formulation of lomustine using the GCPQ nanoparticles enabled the 
administration of a higher dose (10 times; 13 mg kg
-1
) of the drug, while the 
ethanolic formulation of the drug could only be administered at a dose of 1.2 mg kg
-1
 
due to the limited aqueous solubility of the drug.  Evaluation of the antitumour 
activities of the nanoparticle based formulation of lomustine in tumour bearing mice 
demonstrated significantly (p < 0.05) increased survival outcomes compared to the 
low dose ethanolic formulation. Mice that were treated with the high dose 
nanomedicine (Q-LOM) formulation had a mean survival time of 33.2 days, the mice 
treated with the low dose ethanolic formulation had a mean survival time of 22.5 
days and untreated control mice had a mean survival time of 21.3 days. Also, weight 
measurements of treated and untreated mice did not show any difference in the 
weight of mice treated with the Q-LOM formulation compared to mice that received 
the low dose ethanolic formulation and untreated controls.  
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Thus, administration of the Q-LOM formulation did not lead to additional gross toxic 
effects in the mice that received this formulation as this would have been reflected as 
weight loss in the treated mice (van den Bent et al. 2003; Hofland et al. 2005). 
Therefore, the GCPQ nanoparticle based formulation permitted the administration of 
a high dose of lomustine in a dose intense manner by intravenous administration 
once daily for 10 consecutive days. This resulted in markedly improved survival 
outcome in Q-LOM treated mice which had a survival time 1.5 times longer than 
mice treated with the low dose ethanolic formulation without leading to additional 
toxicity. 
Furthermore, assessment of the toxicity of the Q-LOM formulation on haematologic 
parameters revealed that there was no effect of this formulation as well as the low 
dose ethanolic formulation on the white blood cells of treated animals compared to 
the untreated controls. This indicates that the Q-LOM formulation did not produce 
neutropenia in the treated animals after the 10 consecutive daily doses administered. 
However, there was a transient drop in the red blood cell counts of the Q-LOM 
treated mice with recovery by Day 7. Also, there was a drop in the platelet counts for 
both groups of treated animals at Day 7 following completion of the dosing regimen. 
Although the Q-LOM treatment group had a lower nadir value than the low dose 
ethanolic formulation treatment group, there was no significant difference between 
the platelet counts for both groups. The platelet counts for the low dose ethanolic 
formulation treatment group were recovered by day 14, while for the Q-LOM group, 
the counts were recovered by day 21. This indicates that the occurrence of 
thrombocytopenia resulting from lomustine therapy (van den Bent et al. 2006; Intile 
et al. 2009) could still potentially occur with the nanoparticle based formulation. 
Nevertheless, there was no indication of delayed or cumulative myelosuppression 
with the Q-LOM formulation as weight measurements and blood counts of animals 
showed recovery from the effects of the drug with time after dosing had been 
completed.  
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Lomustine, like other nitrosoureas is known to produce delayed and cumulative 
myelosuppression (Jakacki et al. 1998; Smaaland et al. 2002). Therefore, the 
alteration in the pattern of myelosuppressive effects of lomustine produced by the Q-
LOM formulation could be clinically important as this may result in quicker recovery 
of haematologic parameters with Q-LOM formulation. Moreover, flow cytometry 
analysis of blood samples showed that there was no effect of either formulation on 
leucocytes and erythrocytes of the both groups of treated mice, and a quicker 
recovery of platelet counts. The transient drop in platelet counts of both Q-LOM and 
the low dose formulation treated groups of animals which was observed on Day 1 
was recovered by Day 7 after dosing had been completed for both groups of animals.  
Although there is therapeutic benefit derivable from the nanoparticle formulation, 
there is still the need for even safer therapies for the effective management of 
glioblastoma. Thus, the optimal strategy for effective treatment of glioblastoma still 
remains an enigma and the question still remains “is ordo ad chaos” possible at all 
(Olar and Aldape 2014). 
Therefore, this study has shown that the nanoparticle based formulation of lomustine 
enabled the administration of a higher dose of the drug which resulted in 
significantly (p <0.05) prolonged survival without commensurate toxicity. 
Furthermore, three self-assembling PAs, O-Palm-Y-G-G-L-R-F, G-G-Y- (O-Palm) - 
F-R-L and O-Palm-Y-G-G-F-M, a novel analogue of the naturally occurring 
neuropeptide methionine
5
- enkephalin were synthesised and characterised.  
O-Palm-Y-G-G-L-R-F and G-G-Y- (O-Palm) - F-R-L were synthesised as potential 
carriers for the delivery of materials to the brain. The two PAs comprised essentially 
the same amino acid residues but differ in their molecular architecture. O-Palm-Y-G-
G-L-R-F has the molecular architecture of conventional PAs, with a terminal acyl 
chain (linear PA), while G-G-Y- (O-Palm) - F-R-L on the other hand possessed a 
mid-chain located acyl chain, thus shaped into a “T” (“T”-PA).  
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Both PAs were shown to self-assemble into nanofibres in aqueous medium at 
relatively low concentration (0.1 % 
w
/v). However, the resulting assemblies showed 
different morphologies as revealed by the electron micrographs for the aqueous 
dispersions of the PAs. The “T”-PA showed the formation of slightly curved 
nanofibres which are joined together to form extensive nanofibre networks after 
probe sonication for a short period of 5 minutes and this network formation was 
maintained with 15 minutes sonication time. The linear PA on the other hand showed 
formation of individual nanofibres with straight needle-like morphology after probe 
sonication for 5 minutes and 15 minutes. Previous reports in literature showed the 
self-assembly of PAs into nanofibres which further entangle into self-supporting gels 
at low PA concentration (0.25 – 0.5 % w/v). The self-assembly of these PAs are 
usually triggered by the addition of metal ions or lowering of pH of solution 
(Beniash et al. 2005; Stendahl et al. 2006). Also, CG MD data revealed that the “T”-
PA had a tendency to aggregate faster and to a greater extent than the linear PA. The 
final assemblies for the “T”-PA showed branching and the formation of nanofibre 
networks through multiple inter-chain contacts. Aggregation of the linear PA 
appeared to proceed more slowly than the “T”-PA. Also, the formation of nanofibre 
network was less frequent in the linear PA and was observed in only one out of three 
simulation runs for the PA. This correlates to the morphologies revealed in the 
electron micrographs of the PAs.  
Therefore, these data demonstrate that changing the position of the acyl chain from 
the terminal end of the molecule does not disrupt the molecular interactions required 
for self-assembly of the PAs into nanofibres. On the other hand, the “T”-PA 
demonstrated quicker self-assembly and the formation of nanofibre networks than 
the conventional linear PA. This suggests that the unique structure of the “T”-PA 
may be a platform for more efficient encapsulation and delivery of materials to the 
brain using this and similarly designed PAs.  
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Moreover, the “T”-PA appears to be more hydrophobic than the linear PA, 
suggesting that the “T”-PA might afford better solubilisation and loading of 
hydrophobic molecules. To the best of my knowledge, this is the first report of the 
synthesis, characterisation and demonstration of the self-assembly of PAs with this 
unique (“T” shape) molecular architecture. 
The novel methionine
5
- enkephalin analogue synthesised, O-Palm-Y-G-G-F-M also 
self-assembled into nanofibres at low PA concentration (0.1 %
w
/v) in aqueous 
medium. The parent peptide methionine
5
- enkephalin was modified by the 
attachment of a palmitoyl group to the OH side chain of the tyrosyl residue of the 
peptide. It has been previously shown that similarly designed PAs are delivered 
across the BBB to the brain (Lalatsa et al. 2012; Mazza et al. 2013). Methionine
5
- 
enkephalin has been studied for its antiproliferative activities against a number of 
cancers (Zagon and McLaughlin 1989; Zagon et al. 1997; McLaughlin et al. 2003; 
McLaughlin et al. 2003 Donahue et al. 2011). Therefore, O-Palm-Y-G-G-F-M has 
the potential for application in the treatment of intracranial tumours as the attachment 
of the palmitoyl group would enhance brain transport and delivery of methionine
5
- 
enkephalin to the tumours.   
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5.2 Future work 
In order to derive maximal benefit from the nanoparticle based strategy for 
glioblastoma treatment, experiments need to be carried out to determine the optimal 
dose of the formulation required to yield the desired therapeutic benefit but with 
minimal side effects. This would involve variations in the actual dose of formulation 
administered, the duration of treatment (that is the number of doses given) and the 
frequency of administration of doses. 
 Also, studies should be carried out to measure the direct effect of the drug 
formulations on the tumours by assessing tumour volumes and biological changes in 
tumour characteristics due to the effect of the treatment. This study may lead to the 
generation of information that would inform the design of an optimal dosing regimen 
that would deliver maximum therapeutic outcomes of the drug treatment.  
Also, evaluation of the toxic effects of the formulation on the blood parameters by 
flow cytometry analysis also needs to be optimised. Such analysis would inherently 
be more sensitive and specific than the clinical (human) haemocytometer since 
mouse (or the particular animal type) specific antibodies would be employed for flow 
cytometry analysis.  
In addition, targeting ligands could be attached to the GCPQ nanoparticles for 
specific tumour targeting. The efficacy of such targeted delivery system in further 
improving the survival outcomes with the GCPQ nanoparticle based formulations 
would be assessed. Also, the capability of such targeted nanoparticle delivery system 
to lead to even better toxicity profiles, especially in reducing the effects of the drug 
formulation on the platelets would also be evaluated. 
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Furthermore, the potential for the use of the PAs synthesised for the brain delivery of 
therapeutic agents should be investigated. This would also reveal the potential 
advantages that may be derived from the increased hydrophobicity of the “T”-PA. 
The studies should include comparison between the two PAs [O-Palm-Y-G-G-L-R-F 
(linear PA) and G-G-Y- (O-Palm) - F-R-L (“T”-PA)] to determine whether there is 
an advantage in varying the molecular architecture in terms of drug encapsulation 
and stability of resulting composites. The studies would show whether the formation 
of nanofibre networks by the “T”-PA would afford higher loading efficiency and 
controllable release of loaded molecules.  
Further studies should also be carried out to elucidate the observed differences in the 
self-assembly profile of the two PAs, with the aim to understand fully the molecular 
basis for the differences. This would help in understanding the molecular basis for 
the higher tendency for the formation of nanofibre networks by the “T”-PA. Such 
studies should also assess the formation and stability of higher order structures 
obtainable from the two PAs. 
Also, other “T”-PAs should be studied and compared with their linear counterparts to 
determine if the differences observed between the two PAs in this study would be 
universally manifested.  
Investigation of the in vitro and in vivo antiproliferative activities of the novel 
methionine
5
- enkephalin (O-Palm-Y-G-G-F-M) analogue should be carried out. This 
would be a potential bio-therapeutic agent for application in the treatment of 
intracranial tumours. This is inherently advantageous because such a peptide-based 
therapeutic agent could provide a safer alternative to currently used cytotoxic agents 
which produce myelosuppressive effects.   
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Weight measurement for animals culled for analysis of blood samples by percentage of their 
initial body weight, A: Day 1; B: Day 7; C: Day 14; D: Day 21 and E: Day 30 after completion of 
10 consecutive daily doses of lomustine formulations 
Key: Blue arrow: Treatment start date; Red Arrow: Treatment end date. Weights were recorded 
from commencement of dosing until mice were culled for collection of blood samples for 
analysis. Days 1, 7, 14, 21 and 30 correspond to number of days following completion of 10 
consecutive daily doses of lomustine formulations 
: Significantly different (p < 0.05) from CONTROL and Lom-ETOH (One-way ANOVA with 
Tukey post hoc test) 
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Appendix II 
 
 
Semi-quantitative assessment of fluoresc ence intensity of confocal images for A: GCPQ NR and 
B: Liposome NR treated J774A.1 cells 
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Appendix III 
 
Confocal microcopy images showing uptake of GCPQ NR by J774A.1 over time (Time lapse 
experiment) 
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Confocal microcopy images showing uptake of Liposome NR by J774A.1 over time (Time lapse 
experiment) 
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Appendix IV  
Time Flow rate  
(mL min
-1
) 
% A 
0.02 % TFA/ H2O 
% B 
90 % MeCN/ 0.016 % 
TFA/ H2O 
0 15 45 55 
52 15 0 100 
57 15 0 100 
60 15 45 55 
61 0 45 55 
 
Gradient table for preparative RP HPLC purification of O-Palm-Y-G-G-L-R-F and G-G-Y- (O-
Palm) - F-R-L 
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Appendix V  
Time Flow rate  
(mL min
-1
) 
% A 
0.02 % TFA/ H2O 
% B 
90 % MeCN/ 0.016 
% TFA/ H2O 
0 20.4 45 55 
40 20.4 0 100 
45 20.4 0 100 
52 20.4 45 55 
 
Gradient table for preparative RP HPLC purification of O-Palm-Y-G-G-F-M 
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Appendix VI 
Time Flow rate  
(mL min
-1
) 
% A 
0.02 % TFA/ H2O 
% B 
90 % MeCN/ 0.016 
% TFA/ H2O 
0 1.2 100 0 
20 1.2 0 100 
25 1.2 0 100 
32 1.2 100 0 
 
Gradient table for analytical RP HPLC determination of purity of synthesised PAs 
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Appendix VII 
Extended T-shaped 
i j k θeq kθ /kJ mol
-1 
rad
-2
 
i j k θeq kθ /kJ mol
-1
 
rad
-2
 
1 10 11 132.00 50 1 2 3 129.00 200 
10 11 12 137.00 50 2 3 12 125.00 100 
11 12 14 134.00 100 3 12 16 118.00 200 
12 14 17 150.00 200 12 16 19 149.00 200 
10 1 2 97.00 50 2 3 4 100.00 50 
11 12 13 101.00 50 3 12 13 92.00 100 
12 14 15 106.00 50 12 16 17 97.00 100 
14 17 18 82.00 200 16 19 20 91.00 100 
1 2 3 114.00 100 3 4 5 117.00 200 
1 2 4 140.00 200 3 4 6 140.00 200 
14 15 16 143.00 100 12 13 14 145.00 200 
17 18 19 140.00 200 12 13 15 120.00 200 
17 18 20 122.00 100 16 17 18 144.00 100 
3 5 6 144.00 50 5 7 8 143.00 100 
4 5 6 143.00 50 6 7 8 138.00 100 
5 6 7 140.00 25 7 8 9 120.00 100 
6 7 8 180.00 25 8 9 10 180.00 100 
7 8 9 180.00 25 9 10 11 180.00 50 
 
 Bond angle parameters for the linear and “T”-PAs 
Key: i, j and k refer to atom indices following the numbering used for the CG 
mapping scheme,  θeq is the equilibrium bond angle between particles i, j and k and 
kθ is the force constant. 
 
 
 
 
 
 310 
 
Nanoparticle based strategies for the treatment of Glioblastoma 
Appendix VIII 
Atom 
Number 
Extended T-shaped 
Residue MARTINI 
particle 
type 
Charge Residue MARTINI 
particle 
type 
Charge 
1 palm-TYR Qd +1 GLY Qd +1 
2 palm-TYR SC4 0 GLY Nda 0 
3 palm-TYR SC4 0 palm-TYR Nda 0 
4 palm-TYR SC4 0 palm-TYR SC4 0 
5 palm-TYR Na 0 palm-TYR SC4 0 
6 palm-TYR C1 0 palm-TYR SC4 0 
7 palm-TYR C1 0 palm-TYR Na 0 
8 palm-TYR C1 0 palm-TYR C1 0 
9 palm-TYR C1 0 palm-TYR C1 0 
10 GLY Nda 0 palm-TYR C1 0 
11 GLY Nda 0 palm-TYR C1 0 
12 LEU Nda 0 PHE Nda 0 
13 LEU AC1 0 PHE SC4 0 
14 ARG Nda 0 PHE SC4 0 
15 ARG N0 0 PHE SC4 0 
16 ARG Qd +1 ARG Nda 0 
17 PHE Qa -1 ARG N0 0 
18 PHE SC4 0 ARG Qd +1 
19 PHE SC4 0 LEU Qa -1 
20 PHE SC4 0 LEU AC1 0 
 
 MARTINI particle types chosen to model the linear and “T”-PAs. The atom number for each 
particle corresponds to that used for the CG mapping scheme 
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Appendix IX 
 
COSY (fixed) spectra for O-Palm-Y-G-G-L-R-F 
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COSY (fixed) spectra for G-G-Y- (O-Palm)-F-R-L 
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COSY (fixed) spectra for O-Palm-Y-G-G-F-M 
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Appendix X 
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TEM micrographs for PAs with measurements: (A): O-Palm-Y-G-G-L-R-F; (B): G-G-Y- (O-
Palm) - F-R-L; (C): O-Palm-Y-G-G-F-M. Measurements are as generated by the AMT digital 
camera software. 
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Appendix XI 
  
 
Snapshots of the simulations of nanofibre formed through self-assembly of G-G-Y- (O-Palm) - 
F-R-L (“T”-PA) 
Key: Orange spheres: Peptide backbone; blue lines: acyl chain. Side chain particles, water and 
ions are removed for clarity. 
Run 1 Run 2 
Run 3 
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Appendix XII 
   
 
 Snapshots of the simulations of nanofibre formed through self-assembly of O-Palm-Y-G-G-L-
R-F (Linear PA) 
Key: Orange spheres: Peptide backbone; blue lines: acyl chain. Side chain particles, water and 
ions are removed for clarity. 
Run 1 Run 2 
Run 3 
